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Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease of elusive origin 
and characterised by polyclonal B cell hyperactivity and the production of pathogenic 
antibodies targeting self DNA and nucleoproteins. Clinical manifestations of SLE are 
highly heterogeneous and include multisystem inflammation of connective tissue and 
vasculitis of the central nervous system (CNS). SLE is known to have genetic associations, 
and is widely acknowledged to involve a profound breakdown in immune tolerance. The 
aim of this project was to identify whether defects in early B cell development that affect 
the expressed repertoire of immunoglobulin light chains could be observed and to ask 
whether receptor editing contributes to disease pathogenesis. 
 
Chapter 3 describes a high-throughput sequencing analysis of the human immunoglobulin 
kappa light chain gene repertoire in healthy and SLE mature naive peripheral B cells. We 
observed that involvement of gene segments as the repertoire develops is equivalent in 
health and SLE and that a previously described bias towards usage of the gene segment 
IGKV4-1 in SLE is only observed in the expressed repertoire analysed.  
 
Chapter 4 describes an inefficient function of the kappa deleting element (KDE) in SLE, 
which manifests as reduced frequency of KDE rearrangement status in populations of 
CD19+ B cells and a failure to inactivate alleles of IGK allowing them to accumulate 
somatic hypermutations within non-productive IGK rearrangements. 
 
Chapter 5 identifies a potential biological outcome of a failure to inactivate rearranged 
alleles of IGK in SLE; cell surface expression of both kappa and lambda light chains were 
observed by flow cytometry analyses. Efforts to disprove this were unsuccessful and 
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detection of both light chain transcripts was confirmed through single cell PCR 
amplification of cDNA. 
 
The data in this thesis suggest that the failure of the KDE to inactivate alleles of IGK 
efficiently in SLE permits the expression of IGK light chains that have been selected against 
resulting in allelic inclusion. This mechanism may account for the broader and less 
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PAMP Pathogen-associated molecular pattern 
PBMC Peripheral blood mononuclear cell 
PC Plasma cell 
PCR Polymerase chain reaction 
pDC Plasmacytoid dendritic cell 
PE Phycoerythrin 
PerCP-Cy5.5 Peridinin-chlorophyll-protein complex (PerCP) conjugated with cyanine dye 5.5 
Pred Prednisolone 
PRR Pattern recognition receptor 
PTPN22 Protein tyrosine phosphatase, non-receptor 22  
qRT-PCR Quantitative real-time polymerase chain reaction 
RA Rheumatoid arthritis 
RAG 1/2 Recombination activating genes 1 and 2 
RNA Ribonucleic acid 
RNA-FISH RNA-fluorescent in situ hybridisation 
RNP Ribonucleoprotein 
ROR-t RAR-related orphan receptor gamma t 
RSS Recombination signal sequence 
RTX Rituximab 
RUNX1 Runt-related transcription factor 1  
S region Switch region 
SHM Somatic hypermutation 
SLE Systemic lupus erythematosus 
SLEDAI Systemic Lupus Erythematosus Disease Activity Index 
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SLyRT Sort-Lysis Reverse Transcription buffer 
Sm Smith antigen 
SNP Single nucleotide polymorphism 
ssDNA Single stranded DNA 
STAT Signal transducer and activator of transduction 
Syk Spleen tyrosine kinase 
T nucleotide Thymidine 
T1 B Transitional 1 B cell 
T1D Type 1 diabetes 
T2 B Transitional 2 B cell 
T3 B Transitional 3 B cell 
TACI 
Transmembrane activator-1 and calcium modulator 
and cyclophilin ligand-interactor 
TCR T cell receptor 
TD Thymus-dependent 
TdT Terminal deoxynucleotidyl transferase 
TFH T follicular helper cells 
Tg Transgenic 
TGF Tumour necrosis factor beta 
Th1 Type 1 T helper cells 
Th17 Type 17 T helper cells 
Th2 Type 2 T helper cells 
TI Thymus-independent 
TLR Toll-like receptor 
TNF Tumour necrosis factor alpha 
TNFAIP3 Tumor necrosis factor, alpha-induced protein 3 
TNFR Tumour necrosis factor receptor 
U nucleotide Uracil 
UNG Uracil-DNA glycosylase 










































1.    The human immune system 
 
A central feature of the mammalian immune system is the ability to recognise and respond 
specifically to foreign antigen whilst maintaining tolerance to self.  The innate immune 
system achieves this by expression of pattern recognition receptors (PRRs) that recognise 
pathogen-associated molecular patterns (PAMPs) not shared by mammalian cells. In 
contrast, specific antigen recognition in the adaptive immune system is mediated by cell-
unique antigen receptors expressed by T cells and B cells. The mechanisms generating the 
antigen receptors of the adaptive immune response include some random genetic events 
that maximise the potential for receptor diversity.  However, unlike the innate immune 
system that is focused on exogenously derived antigens, the receptors of the adaptive 
immune system comprise a diverse repertoire of cell surface expressed T cell receptors 
(TCR) and immunoglobulin (Ig), some of which have the potential to recognise self.  The 
various mechanisms that regulate recognition of self by the adaptive immune system are 
therefore important and failure can lead to disease. Experiments in this thesis investigate 
regulation of expression of immunoglobulin light chains by human B cells and how this 
system might fail in the autoimmune disease systemic lupus erythematosus (SLE).  
The introduction to this thesis will be separated into two sections; the first will describe 
how the nascent human B cell pool is established and the different fates met by B cells 
during different stages of their development. The mechanisms that serve to regulate human 
B cell development, maintain monoclonal expression of antigen receptors and counter-
select newly produced B cells expressing unwanted specificities will also be discussed. The 
second section will describe the role of B cells in human biological states where self-




1.1   The development of a human immunoglobulin 
 
Developing B cell subsets are defined by the sequential stages of immunoglobulin gene 
rearrangement.  Therefore, the description of B cells will start by analysis of the 
immunoglobulin loci.   
 
1.1.1   The human immunoglobulin loci 
 
Tonegawa’s pioneering studies of the 1980s described that the Ig genes were encoded by 
discrete, non-functional gene segments that assemble by somatic recombination to form 
functional receptors capable of recognising cognate antigen, known as V(D)J 
recombination (Tonegawa, 1983). This in the first instance accounts for the extreme 
repertoire diversity required by Ig B cell repertoires for a robust immune response. The 
human Ig gene loci are located on different chromosomes, each possessing unique 
organisation. The human Ig heavy chain (IGH) gene locus is encoded on chromosome 
14q32.33 over four regions, where the variable (VH), diversity (DH), joining (JH) and 
constant (CH) gene segments are located in sequential clusters (Lefranc, 2001a). In the 
human, there are approximately 40 VH segments, 25 DH segments, 6 JH regions and a large 
cluster of 10 CH segments, though only nine of the latter segments are functional due to the 
presence of a CH pseudogene (Murphy. K, 2008). This differs from mice, where the IGH 
locus consists of approximately 150 VH segments, 12 DH segments, 4 JH segments and 8 
functional CH regions (Corcoran, 2005). The genetic organisation of the human IGH locus 







Figure 1.1    Locus representation of the human IGH locus. Figure reference: IMGT, the 
international ImMunoGeneTics information system. 
 
The genes encoding the human kappa (IGK) and lambda (IGL) light chain loci, that will be 
referred to as Ig and Ig when describing the protein Ig molecule, are located on 
chromosomes 2p11.2 and 22q11.2 respectively, and differ from the IGH genes in that they 
do not possess D gene segments. The genetic organisation of the two light chain gene loci 
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also differs; IGK gene segments are ordered similarly to the heavy chain genes, V-J-C 
where all J segments lie 5’ of the one C region (Lefranc, 2001b). The human IGK locus 
consists of 40 functional V gene segments, 5 J segments and a single C region (Murphy. 
K, 2008). The mouse IGK locus consists of ~140 V gene segments, 5 J segments and one 
C gene segment (Corcoran, 2005). The human IGL locus is comprised of 30 functional V 
gene segments, and 4 pairs of functional Jgene segments and C genes (Murphy. K, 2008). 
Gene clusters at the IGL loci have a nested arrangement, where a cluster of Vλ gene 
segments is followed by Jλ segments which are associated with their own Cλ segment 
(Lefranc, 2001c). The genetic organisation of the human IGK and IGL loci are depicted 















Figure 1.2    Locus representation of the human IGK light chain locus. Figure reference: 















Figure 1.3    Locus representation of the human IGL light chain locus. Figure reference: 
IMGT, the international ImMunoGeneTics information system 
 
 
1.1.2   Recombination signal sequences 
 
Each functional V, D and J gene segment at both the heavy and light chain loci is associated 
with a recombination signal sequence (RSS), which is used by the cell’s recombination 
machinery to direct the rearrangement process. RSSs consist of a heptamer sequence 
(typically CACAGTG) and nonamer sequence (typically ACAAAAACC) separated by a 
less conserved spacer sequence of either 12 or 23 nucleotides, considered to reflect one or 
two turns of the DNA double helix (Sakano et al., 1979; Schatz and Ji, 2011). The 12/23 
rule is a mechanism that controls rearrangement, since a gene segment flanked by a 12 
nucleotide spacer may only recombine to an RSS with a 23 nucleotide spacer, and vice 
versa (Eastman et al., 1996). Following successful recombination of a heavy and light 
chain, the immunoglobulin is assembled by linkage of two heavy chains (50-70 kDa) with 
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two light chains (approximately 23 kDa) by inter-chain disulphide bonds and other non-
covalent interactions. Intra-disulphide bonds and similar non-covalent associations are 
present within each heavy and light chain, maintaining the structure of the Ig (Murphy. K, 
2008). A schematic outlining the production of an Ig molecule is depicted in Figure 1.4. 
The enzymes and mechanisms that catalyse and regulate V(D)J recombination will be 


















Figure 1.4 Immunoglobulin gene rearrangement at the heavy and light chain gene loci.  
Somatic recombination of the gDNA encoding the Ig chains takes place initially between the DH and 
JH gene segments at the heavy chain loci and the VL and JL segments at the light chain loci. DHJH 
rearrangement takes place on both heavy chain alleles simultaneously, whereas VLJL recombination 
takes place asynchronously at the light chain loci. The first allele on which DHJH segments have 
rearranged then recombines with a VH gene segment to complete rearrangement of the IGH variable 
region. V gene segments at both the heavy and light chain loci are preceded by a leader (ldr) 
sequence which is responsible for directing the newly rearranged polypeptide into the cells secretory 
pathways but is later cleaved following translation of the complete polypeptide. To complete 
rearrangement at the heavy chain locus CH regions are spliced to the VHDHJH region. Completion of 
light chain gene rearrangement involves the splicing of RNA to remove the ldr-VL and JL-CL intronic 









1.1.3   The structure of human immunoglobulin 
 
The antigen binding portion of an immunoglobulin is known as the variable (V) region and 
is located in the Fab fragment (fragment antigen binding) of the Ig molecule. It is 
comprised of the rearranged VHDHJH segments of the heavy chain, known as the variable 
(VH) region, and rearranged VLJL of the either the IGK and IGL light chain loci, referred to 
as VL region (Murphy. K, 2008). Variable regions are unique to each immunoglobulin, 
conferring individual specificity to each molecule predominantly through variations in their 
complementarity determining regions (CDRs); each immunoglobulin carries three CDRs 
on each heavy and light chain. CDR3 regions are separated by more conserved stretches of 
DNA known as framework regions (FW) which play a role in stabilisation of antigen 
binding.  
The constant (C) regions of the heavy chains make up the Fc (Fragment crystallisable) 
portion of the Ig molecule, and are formed of discrete domains, CH2, CH3 and in some cases 
a CH4 domain (CH1 is a component domain of the Fab fragment) where conserved 
sequences within these domains determine the isotype of the immunoglobulin. The isotype 
ultimately determines the effector function of the secreted Ig. The genetic organisation of 
the IGH constant regions generally relates to the expression of Ig classes during B cell 
development. The C regions of immunoglobulin molecules are known to be the 
predominant sites that harbour N-glycosylated oligosaccharides (Dunn-Walters et al., 
2000). The consensus sequence for N-glycosylation sites typically involve a Asn-X-
Ser/Thr/Cys motif, where X may reflect any amino acid except a proline (Medzihradszky, 
2008). A role of glycosylation in the maintenance of Ig structure and effector function was 
elucidated by a study involving removal of an attachment residue, Asn-297, located 
between the CH2 domain of chimeric mouse-human IgG (Tao and Morrison, 1989). This 
study demonstrated that although the Ig lacking Asn-297 are assembled and secreted 
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normally, they are more sensitive to protease degradation than wild-type (WT) Ig and 
cannot bind FcRI. It has also been identified that somatic hypermutation can affect N-
glycosylation sites in IGVH genes used by mucosal plasma cells secreting IgM, IgA and 
IgG, where increased frequencies of hypermutation were found to be associated with the 
loss of germline encoded glycosylation sites (Dunn-Walters et al., 2000). Variable Ig 
regions have also been found to undergo glycosylation and is a subject of great interest due 
to the influence these modifications may have on antigen selection. Potential novel sites of 
N-glycosylation located at VH CDR3 regions of B cells were identified in 79% of patients 
with follicular lymphoma (FL) compared to 9% in healthy controls following analysis of 
similar VH CDR3 regions in control memory B and plasma cells carrying similar levels of 
mutation. This glycosylation was found to be introduced following somatic mutation in the 
germinal centre (GC), and it was proposed that the addition of carbohydrate at these sites 
supported tumour development by influencing antigen selection  (Zhu et al., 2002). 
 
A functional cell surface B cell receptor (BCR) exists in a complex through non-covalent 
association with the transmembrane Ig-/Ig-heterodimeralso referred to as 
CD79a/CD79b complex. This association is critical for mediating signal transduction to 
intracellular signalling molecules downstream of the BCR since the cytoplasmic tails of 
each CH region of membrane-bound Ig molecules are short; mIgM and mIgD molecules 
contain only three amino acid residues, and the cytoplasmic tails of mIgA, mIgM and mIgE 
are 14, 28 and 28 residues respectively (Kindt, 2007; Reth, 1992). The Ig/Ig-molecules 
have long cytoplasmic tails of 61 and 48 amino acids respectively and contain 
immunoreceptor tyrosine-based activation motifs (ITAMs) that contain two repeats of the 
consensus sequence Tyr-X-X-Leu/Ile (Isakov, 1997). BCR engagement by antigen induces 
rapid phosphorylation of tyrosine residues within the ITAMs that consequently provide 
docking sites for cytoplasmic effector molecules, predominantly Src family kinases, which 
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mediate the downstream signalling pathways that ultimately shape the gene expression 
profile of the activated B cell.  
 
1.1.4   V(D)J recombination 
 
The initiation of V(D)J recombination in the developing B cell is dependent on the 
introduction of chromosomal double-stranded DNA (dsDNA) breaks at RSS junctions of 
each V, D and J gene segment; an inherently harmful genetic reorganisation that is tightly 
controlled in a temporal, cell-lineage specific and stage-specific manner (Corcoran, 2005). 
V(D)J recombination is mediated by the protein products of the recombination activating 
genes (RAGs) which together are referred to as the V(D)J recombinase. Expression of 
V(D)J recombinase is restricted to cells of the lymphocyte lineage at specific stages in their 
development and associate with several other DNA binding a repair proteins, known 
collectively as high-mobility group proteins B1 and B2 (HMPB1/2) (Oettinger et al., 1990; 
Schatz and Ji, 2011).  
 
The products of the RAG genes, RAG1 and RAG2, are nuclear proteins that mediate site-
specific recombination of Ig gene segments preferentially between 12RSS and 23RSS 
signals. RAG1 and RAG2 have differing roles in Ig gene recombination. RAG1 has been 
demonstrated to activate V(D)J recombination in NIH 3T3 fibroblasts in vitro (Schatz et 
al., 1989), and co-transfection of RAG1 and RAG2 expression constructs was shown to be 
sufficient to activate recombination in many non-lymphoid cell types (Stanhope-Baker et 
al., 1996). The recognition of RSSs is considered to be mediated predominantly by RAG1, 
which carries an RSS nonamer-binding domain which anchors the RAG proteins to the 
DNA and an active site for the breakage of DNA. RAG1 is expressed throughout the cell 
cycle (Schatz and Ji, 2011). The central region of RAG1 interacts with the heptamer 
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sequence of the RSS and RAG2, and co-transfection of RAG2 into a fibroblast cell line 
already expressing RAG1 has been shown to confer a 1000-fold increase in the frequency 
of V(D)J recombination events (Oettinger et al., 1990). Thus, RAG2 is thought to enhance 
DNA cleavage by increasing the affinity and specificity of the RAG complex for RSSs, 
though it has negligible binding activity alone and is only expressed at stages G0 and G1 
of the cell cycle. The C-terminus of RAG2 is also known to interact with histone proteins, 
where the introduction of mutations in RAG2 was demonstrated to severely inhibit the 
efficiency of VH-DHJH joining (West et al., 2005). Additional studies suggested that the 
RAG1/RAG2 complex in addition to other DNA binding proteins binds one RSS initially 
and ‘captures’ an unbound, complementary (dissimilar) RSS forming a synapse during 
recombination (Jones and Gellert, 2002).  
 
Double stranded DNA cleavage involves sequential single strand nicking between the 
heptamer and Ig coding gene segment by hydrolysis of a phosphodiester bond of the DNA 
backbone (Stanhope-Baker et al., 1996). This generates a free 3’ hydroxyl (OH-) group 
which then attacks the remaining un-nicked DNA strand forming a hairpin loop. Two 
broken-ended DNA intermediates are produced; a signal end, blunt and 5’ phosphorylated, 
and a coding end which is sealed in a hairpin structure and subsequently processed to form 
open-ended molecules (Roth et al., 1992; Roth et al., 1993). Signal ends and coding ends 
are subsequently joined to generate heterogeneous coding joints and precise signal joints 
by slightly different mechanisms (Stanhope-Baker et al., 1996). The coding joint is 
produced following association of essential proteins with the hairpin structures of V and 
J segments; the heterodimer Ku70:Ku80, DNA-dependent protein kinase (DNA-PK), the 
nuclease Artemis, DNA ligase IV and the DNA repair protein XRCC4 (Murphy. K, 2008). 
The signal joint is the result of association of Ku70:Ku80 and subsequent joining of the 
signal ends by DNA ligase IV and XRCC4.  The imprecise composition of the coding joints 
36 
 
represents an additional layer of diversity embedded within the recombination process. 
This process is illustrated in Figure 1.5.  
 
Further diversity is introduced to the rearranging Ig genes by the action of terminal 
deoxynucleotidyl transferase (TdT) which adds non-templated (N) nucleotides to the 
junctions of the antigen receptor chains. TdT-mediated receptor diversification was initially 
only associated with the IGH genes due to the patterns of TdT expression in the BM, acting 
only at the pro-B cells stage and down-regulated at the developing pre-B cell stage where 
light chain rearrangement is initiated, though evidence has been provided for differential 
TdT activity at both the IGK and IGL loci in CD45(B220)+CD43+ pro-B cells from MT 














Figure 1.5   V(D)J recombination. 1. The composition of the recombination signal sequences 
(RSSs) associated with a V and J gene segment. RSSs contain both a heptamer and nonamer 
sequence, separated by a spacer region of either 12 or 23 base pairs (bp). Recombination typically 
takes place between gene segments that are associated with RSSs of opposing orientation and 
different spacer length. 2. Recombination is initiated by bringing together the RSSs associated with 
the recombining gene segments so they are arranged in the same transcriptional orientation in the 
allele. This results in the looping out of the intervening DNA. 3. Single strand nicking at the gene 
segment:RSS junction by RAG1 and 2 proteins results in the generation of a 3’-hydroxyl group that 
attacks the un-nicked DNA strand forming a hairpin loop. This generates two DNA intermediates. 
The coding joint is produced following association of Ku70:Ku80, DNA-PK and Artemis, DNA 
ligase IV and XRCC4 with the hairpin structures of V and J segments. The signal joint is produced 
following association of Ku70:Ku80 and subsequent joining of the signal ends by DNA ligase IV 
and XRCC4.   
 
 
1.1.5 Allelic exclusion 
 
B and T lymphocytes of healthy individuals are genetically committed to express a single 
antigen receptor with unique specificity. This monoclonal Ig expression is considered to 
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guarantee a high concentration of a single receptor by these cells. This is paradoxical 
considering that the hierarchical nature of Ig receptor development can leave a single 
lymphocyte with the genetic potential to express many simultaneously, and the mammalian 
immune system is required to respond to vast numbers of foreign antigens with a myriad 
specificities. The requirement for allelic exclusion and the mechanisms that serve to 
maintain it will be discussed in the following sections. 
 
1.1.5.1  B cell development and allelic exclusion 
 
Allelic exclusion is achieved by silencing of one of the two homologous lymphocyte 
receptor alleles. Ig gene rearrangements at each of the three Ig loci in the developing human 
B cell takes place temporally and sequentially, starting at the activated IGH loci and 
subsequently rearranging genes at the IGK then IGL light chain loci. Allelic exclusion is 
exhibited at both the IGH and IGL loci, and in addition isotypic exclusion is a feature of 
IGL rearrangements, where either a Ig or Ig light chain will be expressed (Alt et al., 
1981; Alt et al., 1984; Ehlich et al., 1993; Korsmeyer et al., 1981). Several mechanisms 
govern this process, and play a role before and after the recombination events. In order to 
provide context for the requirement and establishment of allelic and isotypic exclusion, an 
overview of primary B cell development will be described and the Ig gene rearrangements 
initiated at each stage of differentiation.  
 
Development of the primary B cell repertoire begins upon differentiation of a non-
committed haemopoietic stem cell (HSC) into an early pro-B cell. This marks the beginning 
of IGH gene rearrangement, where DH-JH joining takes place simultaneously on activated 
IGH alleles (Ghia et al., 1998). The following VH- to DHJH recombination event takes place 
asynchronously on just one allele, where only if the resulting exon produced is non-
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productive is rearrangement continued on the second allele. Non-productive 
rearrangements are those that carry a stop codon, are incompletely rearranged or are in the 
incorrect genetic reading frame and consequently are not able to produce functional protein 
(Vettermann and Schlissel, 2010). At this time, the IGK light chain loci remain genetically 
silent and a VH- to DHJH second rearrangement is attempted on the second allele of the IGH 
locus (Bergman, 1999). 
Successful generation of the pre-BCR after pairing of a productively rearranged VHDHJH 
exon with surrogate light chains VpreB and 5 protein represents a fundamental checkpoint 
for selection in the development of a new B cells (Meffre et al., 2000a), and only successful 
pre-BCR signalling subsequently permits the initiation of light chain rearrangements as 
cells that cannot signal through their pre-BCR are induced to die by apoptosis (Keyna et 
al., 1995; Osmond et al., 1994; Pillai and Baltimore, 1987; ten Boekel et al., 1998). Pre-
BCR surface expression also involves interaction with the signalling chains Ig-/Ig-
(Tsubata and Reth, 1990) and is dependent upon IL-7R signalling. It has been shown in 
mice that disruption of IL-7R signalling prevented expression of the pre-BCR in new large 
pre-B cells. Furthermore, successful expression of a pre-BCR lowered the activation 
threshold of IL-7-induced proliferation, and that there was a positive correlation between 
IL-7-dependent pre-BCR expression and the activation of the ERK/MAP kinase pathway, 
which transduces the activation signal downstream of the pre-BCR (Corcoran et al., 1998; 
Corcoran et al., 1996; Fleming and Paige, 2001).The transition to a small pre-B cell is 
defined by initiation of primary light chain gene rearrangement at the IGK locus (Reth et 
al., 1987). In the pre-B cell, V-J joining is undergone where a productively rearranged 
exon is then paired with the new and productively rearranged IGH protein and expressed 
on the cell surface as a newly rearranged BCR. This allows exposure to endogenous stromal 
ligand of the BM as a large pre-B cell. Failure to productively rearrange both alleles at IGK 
loci results in light chain rearrangement proceeding at the IGL locus (Hieter et al., 1981). 
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Cells that fail to productively rearrange an allele at either the IGH and both IGK and IGL 
light chain loci are removed from the developing B cell pool by apoptosis. Despite the 
stringent selection checkpoints in the BM, the production of B cells expressing polyreactive 
and self-reactive receptors is frequent (Wardemann et al., 2003), so the mechanisms used 
to extinguish these specificities and in many instances rescue the cell from apoptosis will 
be discussed later. Figure 1.6 outlines the hierarchical heavy and light chain Ig gene 





Figure 1.6  B cell gene rearrangements during early B cell development. DH-JH rearrangement 
takes place on both alleles simultaneously in the early pro-B cell. The first IGH allele to complete a 
DH-JH rearrangement then undergoes rearrangement with a VH gene segment as a late pro-B cell. 
Following complete VHDHJH recombination the new heavy chain is required to pair with surrogate 
light chain VpreB and 5 for expression of a pre-BCR on the cell surface as a large pre-B cell. If 
this process is successful and a functional heavy chain has been produced, Ig rearrangement at the 
light chain kappa loci is initiated. At this stage the small pre-B cell undergoes rearrangement 
sequentially on the first kappa allele (V-J) and the second if rearrangement of the first allele is 
non-productive. Only if rearrangement at the IGK locus is unsuccessful is rearrangement of the IGL 
locus initiated. A successful light chain rearrangement results in the pairing of the new light chain 
with the heavy chain and expression as a surface IgM BCR. The new B cell can then enter the 




1.1.5.2   Models of allelic exclusion and regulation of Ig gene 
rearrangements 
 
It is acknowledged that the ordered recombination of Ig genes in both humans and mice is 
not per se required for the establishment of allelic exclusion, since other species such as 
chickens exhibit allelically excluded lymphocytes but rearrange their heavy and light chain 
genes simultaneously (Ratcliffe, 2006). However, it is clear that allelic exclusion is obeyed 
during the development of healthy human B cells, and several models can be used to 
describe its establishment; the asynchronous recombination models, the stochastic model, 
the feedback inhibition model and the allelic communication model.  
 
The asynchronous recombination models explain how the establishment of allelic 
exclusion is a result of the restricted chromatin accessibility to Ig alleles and gene segments 
at a given time during B cell development. Chromatin accessibility and the mechanisms 
governing nuclear re-localisation of Ig genes and the histone modifications involved in this 
process are fundamental features of allelic exclusion so will be discussed independently in 
a later section. There are two variations on the asynchronous recombination model; the 
probalistic and instructive models. The probabilistic model supports the notion that it is the 
restricted access to chromatin that serves to limit the frequency of recombination events on 
one allele. As a consequence of this, the incidence of biallelic recombination events would 
be improbable (Coleclough et al., 1981; Liang et al., 2004). This model is similar to the 
stochastic model that proposes that Ig gene rearrangement is maximally efficient, but the 
probability of productively rearranging more than one Ig allele that encodes a pairing Ig 
chain is statistically low (Coleclough et al., 1981). These two models differ in that they are 




The instructive model attributes asynchronous recombination to the earliest replicating Ig 
allele established during early embryogenesis. This allele is thought to have a higher 
probability of undergoing rearrangement first, where monoallelic epigenetic changes may 
take place even before rearrangement is initiated. This hypothesis suggests that the process 
of allelic exclusion is more similar to X chromosome inactivation than previously 
considered, where only if the first replicating allele rearranges non-productively is the 
second allele activated (Mostoslavsky et al., 2001). 
 
The classical model of allelic exclusion is referred to as the feedback inhibition model and 
postulates that the protein intermediates produced during Ig gene rearrangement serve to 
restrict and shape the subsequent rearrangement decisions made by the developing B cell 
(Alt et al., 1980; Alt et al., 1984; Yancopoulos and Alt, 1986). A primary example of this 
is the contribution of membrane bound IGH in the maintenance of allelic exclusion, where 
membrane bound IGH protein (and not soluble IGH) has been shown to suppress further 
heavy chain gene rearrangement (Nussenzweig et al., 1987; Schatz et al., 1992; Storb et 
al., 1988) and initiates rearrangements at the light chain loci by redirecting the recombinase 
to the IGK locus (Reth et al., 1987; Storb et al., 1988). Targeted disruption of the membrane 
exon of the IGH chain resulted in loss of allelic exclusion, supported by the demonstration 
that mIGH expression is accompanied by decreased transcription through the germline 
VH locus (but not the DJH locus) and decreased levels of RSS breaks associated with DJH 
alleles (Schlissel and Morrow, 1994).  
 
The allelic communication model is a more recent concept since it is now understood that 
homologous alleles physically interact and communicate (Vettermann and Schlissel, 2010). 
It has been demonstrated that Ig alleles pair in a largely RAG-dependent manner, and 
introduction of DNA breaks to one of the Ig alleles resulted in the activation of ATM, 
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which acted in trans to reposition the second, uncleaved allele to pericentromeric 
heterochromatin. It was suggested that this served to prevent biallelic recombination and 
the potential for chromosomal translocations (Hewitt et al., 2009).  
 
1.1.5.3   Chromatin accessibility and allelic exclusion 
 
Of primary importance to the process of Ig gene rearrangement is the accessibility of V(D)J 
recombinase to the RSSs within chromatin, which in turn is reliant upon the architecture 
remodeling, methylation status and histone modifications of the hundreds of gene segments 
at Ig loci in the nucleus at the specific times during of V(D)J recombination (Schatz and Ji, 
2011). The significance of chromatin accessibility to the maintenance of allelic exclusion 
was demonstrated by Yancopoulos et al., 1985, who observed high expression levels of 
unrearranged IGHV genes specifically in early B cells rearranging VH-DHJH segments 
(Yancopoulos and Alt, 1985). Such unrearranged IGHV gene expression was not detected 
in mature Ig-secreting cells. It was subsequently proposed that these findings were the 
consequence of inactivation of a previously transcriptionally active IGH locus – a 
phenomenon termed germline or sterile transcription. This work was supported by several 
reports demonstrating the correlation between chromatin accessibility and rates of V(D)J 
recombination (Schlissel and Baltimore, 1989; Schlissel et al., 1991). It has also been 
demonstrated that accessibility of the IGK locus to V(D)J recombinase and subsequent 
activation of the IGK gene is enhanced by the presence of IGHprotein following analysis 
of isolated nuclei in vitro (Stanhope-Baker et al., 1996). The same study proposed that the 
accessibility and cleavage of RSSs is dependent upon the maturity of the cells the nuclei 
are isolated from, since the VH locus could be cleaved in vitro in the presence of intact pro-
B cell nuclei or purified gDNA from pro- or mature B cells, whereas in the nuclei from 
mature IgD+ B cells, RSSs flanking VH gene segments were not cleaved even in the 
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presence of recombinase. This suggests that chromatin accessibility at the IGH locus at a 
given developmental stage governs heavy chain allelic exclusion (Stanhope-Baker et al., 
1996). 
   
1.1.5.3.1  Non-coding RNAs in Ig gene regulation 
 
In the last decade novel studies have exposed a role for non-coding RNA in the field of 
gene regulation by identifying that a large proportion of the genome is responsible for the 
production of non-coding RNA transcripts. Alongside understanding of sterile 
transcription, the genic and intergenic transcription of antisense DNA throughout the IGHV 
locus has been identified (Bolland et al., 2004). Using RNA fluorescent in situ hybridisation 
(RNA-FISH), it was identified that transcription of non-coding antisense DNA strands was 
strictly regulated and only observed during DHJH to VHDHJH recombination transition, being 
down-regulated on both alleles following productive rearrangement on one of the alleles. 
This led to the hypothesis that this serves as a mechanism to assist in the remodeling of VH 
region chromatin at this developmental stage of the B cell (Bolland et al., 2004).  
 
1.1.5.3.2  Histone modifications in Ig gene regulation 
 
Of further importance to the control of allelic exclusion is the covalent modification of 
histones that mediate chromatin accessibility through methylation and acetylating events. 
Inactive IGK, IGL and IGH C regions are DNA-methylated, and H3K9 methylation has 
been proposed to regulate the silencing of Ig loci before the initiation of recombination 
(Corcoran, 2005; Storb and Arp, 1983). Despite this, it has also been shown that loss of 
methylation of the IGK locus was not sufficient to activate recombination in a 
recombination-active B cell line with Cre-lox mediated loss of Dnmt1, an enzyme that 
plays a key role in the establishment of DNA methylation (Cherry et al., 2000).  
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1.1.6  Isotypic exclusion of Ig light chains  
 
The human immunoglobulin B cell repertoire typically expresses Ig kappa (Ig) and Ig 
lambda (Ig) light chain classes at a ratio of approximately 60% Ig to 40% Ig (Hieter et 
al., 1981; Korsmeyer et al., 1981; Korsmeyer et al., 1982). This differs in mice however, 
where 95% of B cells express Ig light chains and just 5% express Ig  (Bräuninger et al., 
2001) Studies of light chain rearrangements in cases of human leukemia provided some of 
the first evidence showing that IGK rearrangement proceeds on both alleles before 
rearrangement of the IGL light chains. It was observed that only 2 - 3 % of Ig-expressing 
cells harboured a VλJλ rearrangement joint, whereas nearly all Ig-expressing cells 
contained VJ joints (Bräuninger et al., 2001). Exceptions to the ordered rearrangement of 
Ig genes have been described in both mouse and human B cells, where EBV-transformed 
pre-B cells isolated from human fetal bone marrow were found to express Ig light chains 
without detection of functional IGH protein. Of four Ig-producing EBV-transformed 
lines established, cells had either just undergone DH-JH segment rearrangements, or they 
carried IGH alleles in germline configuration. Despite these observations, exceptions to the 
ordered light chain rearrangement process are rare and isotypic exclusion is robust in 
healthy individuals. The observation that single B cells may express more than one Ig light 
chain, known as allelic inclusion, will be described in a later section. 
 
 
1.1.6.1  The kappa deleting element 
 
A fundamental mechanism involved in the maintenance of light chain isotypic exclusion 
involves rearrangements of the kappa deleting element (KDE). The first description of a 
regulatory element mediating the functional silencing of IGK light chain rearrangements in 
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human B cells followed the observation that just one of twenty rearranged IGK alleles 
isolated from ten Ig-producing B cells retained its constant region (Hieter et al., 1981).  
KDE rearrangements were characterised through mapping and sequencing the 5’ 
rearrangements on both kappa alleles of the Nalm-6 cell line, generated from pre-B cells 
isolated from a case of acute lymphoblastic leukemia (Graninger et al., 1988).  The human 
KDE, or recombining sequence (RS) in mice, is located 24-25 Kb downstream of the C 
region (Durdik et al., 1984; Graninger et al., 1988; Siminovitch et al., 1985). 
Rearrangement of the KDE can occur via one of two pathways; in 75% of instances, the 
KDE undergoes RSS-mediated site-specific recombination with the palindromic sequence 
CACAGTG, referred to as the intronic recombination signal sequence (iRSS) located 
between the distal J and C gene segments (Graninger et al., 1988; Klobeck and Zachau, 
1986; Siminovitch et al., 1985). The alternative KDE rearrangement takes place to an 
upstream, unrearranged V gene segment. Both RSS-mediated recombination events result 
in deletion of the C region and the enhancers flanking the KDE itself; iE and 3’E, though 
in the latter instance the V-J joint is also removed (Figure 1.7).  
The reason for the different rearrangement sites of the KDE is unknown, though it was 
initially suggested that RS rearrangement was a pre-requisite for rearrangement at the IGL 
locus (Muller and Reth, 1988; Persiani et al., 1987), where RS rearrangement correlated 
with Igproduction by B cells (Vela et al., 2008). Subsequent studies however 
demonstrated that Ig-expressing B cells still are produced in the absence of KDE 
rearrangement (Zou et al., 1993). Of further interest, when RS rearrangement was 
prohibited in mouse models, the frequency of sequential light chain gene rearrangements 
(receptor editing) were impaired in response to autoantigen exposure and the frequency of 





Figure 1.7 KDE rearrangements. The KDE is located 25 kb downstream of the C gene segments 
and is flanked by two enhancers; iE and 3’E. Recombination of the KDE takes place when a V-
J rearrangement is either non-productive, or generates a self-recognising specificity. The KDE 
rearranges by two different mechanisms – it involves either 1. rearrangement to an intronic RSS 
located between the J and C gene segments deleting C and the enhancers flanking it (green 
ovals), or 2. to an RSS of an upstream and unrearranged V segment deleting the rearranged VJ 
joint in addition to the 3’ C region. 
 
The functional consequences of KDE (RS) rearrangements and the role of the enhancers 
iE and 3’E and the constant region C in mediating IGK locus silencing were elucidated 
using transgenic mice carrying neomycin resistance genes in the place of C or the 
iEStudies have described that mice homozygous for both C and iE inactivation 
produce 7-fold more Ig-expressing B cells (and around 2.3 times fewer total B cells) 
compared to the WT mice. Heterozygous mutants produce different phenotypes; iE 
inactivation completely blocks rearrangement at the IGK locus whereas Cinactivation 
alone permits V-J rearrangement though rearrangements of the RS in these mice are 
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lower in frequency than in WT mice (Zou et al., 1993). Additional studies have shown that 
the 3’E enhancer is required for high levels of IGK gene expression, and it has been 
suggested that this enhancer alone is sufficient for the transcription of IGK genes in mature 
B cells (Meyer and Ireland, 1998; Takeda et al., 1993). Interestingly, double mutant B cells 
for the iE and 3’E enhancers were unable to rearrange their IGK genes, but could 
rearrange and subsequently express IGL light chains (Inlay et al., 2002).  
The enhancers flanking the KDE have also been implicated in conferring the ability to 
acquire mutations within IGK alleles. Analysis of Ig gene rearrangements and somatic 
mutation in monocytoid B cell lymphoma (MBCL) Ig-expressing cells demonstrated that 
VH genes were highly mutated, whereas IGK genes that had rearranged and were KDE 
inactivated were unmutated (Kuppers et al., 1996). Of note, both productive and non-
productively rearranged heavy and light chains can undergo mutation (Kocks and 
Rajewsky, 1989). These data suggested that the deleterious KDE recombination event 
prevented B cells from acquiring somatic mutations in their IGK rearranged genes if the 
cell were to become activated peripherally (Betz et al., 1994). These data are important 
since not only non-productively rearranged IGK alleles are KDE inactivated. An elegant 
study that involved Ig sequence analysis of gDNA isolated from FACS-sorted single naive 
Ig and Ig-producing B cells identified that 30% of all V-J rearrangements isolated 
from Ig-expressing B cells were actually productively rearranged. These findings  
suggested that despite being in the correct genetic reading frame, a molecular decision was 
made to not use these productive rearrangements of IGK and inactivate them by 
rearrangement of the KDE (Bräuninger et al., 2001). 
 
The frequency of KDE rearrangements in populations of B cells has been suggested to 
represent an indicator of light chain rearrangement activity (Panigrahi et al., 2008). KDE 
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rearrangements also take place independently of antigen specifity and do not encode 
functional protein, reinforcing the potential for using KDE rearrangement status as a 
marker of extensive light chain rearrangements (Vela et al., 2008).  
A prominent study by Panigrahi et al., 2008 studied the rearrangement frequency of the 
KDE to the iRSS in health and SLE by isolating the gDNA from FACS-sorted populations 
of both Ig- and Ig-producing CD19+ B cells and performing real-time PCR anaysis for 
quantification of the iRSS-KDE rearranged junction (Panigrahi et al., 2008). They observed 
that KDE rearrangements were significantly decreased in frequency in SLE compared to 
controls. Reduced KDE rearrangement frequency was also observed in Ig-producing 
CD19+ B cells from type I diabetic patients (T1D), though this was not observed in Ig-
producers. In light of this data it was proposed that the silencing of IGK light chain 
rearrangements may be defective in SLE and T1D, interpreted as a defective ability to edit 
light chains; a mechanism of B cell tolerance. Studies of the murine equivalent of the KDE, 
the RS, have also provided evidence for a role for the KDE in secondary gene 
rearrangements, since RS knockout mice produce Igλ-expressing B cells with self-
specificity in the periphery (Vela et al., 2008).  
 
 
1.1.7  B cell tolerance 
 
1.1.7.1 Mechanisms of B cell tolerance 
 
The importance of establishing self-tolerance is critical to mammalian immune 
homeostasis to avoid what is referred to as ‘horror autotoxicus’, a termed coined by Paul 
Ehrlich at the turn of the century and represented the earliest understandings of 
autoimmunity (Steinman and Nussenzweig, 2002). Studies using transgenic mice have 
elucidated roles for three main mechanisms that mediate self-tolerance and the removal of 
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autoreactive specificities in the development of the primary B cell repertoire in the BM; 
clonal deletion, the induction of anergy and receptor editing (Casellas et al., 2001; Radic et 
al., 1993).  
Clonal deletion was first described following isolation of BM cells from transgenic mice 
for Ig rearrangements encoding anti-H-2Kk antibodies and subsequent injection into 
lethally irradiated mice expressing or not expressing the H-2Kk antigen. It was shown that 
transgenic mice expressing the H-2Kk antigen had deleted H-2Kk-specific B cells from the 
spleen and LNs, whereas mice lacking H-2Kk antigen carried an abundance of H-2Kk-
specific B cells in circulation (Nemazee and Buerki, 1989). This mechanism was mediated 
by receptor cross-linking in immature B cells (Nemazee and Weigert, 2000). Strong signals 
via the BCR are thought to induce immature B cell deletion by apoptosis (Meffre and 
Wardemann, 2008). 
Some prominent studies in the late 1980s used transgenic mice exposed to self-antigen and 
observed down-regulation of surface IgM in response to BCR stimulation that exceeded 
the threshold for activation. This appeared to correlate with clonal silencing of self-
responsive B cells and they proposed that a proportion of the circulating peripheral B cell 
repertoire were tolerised by this mechanism (Goodnow et al., 1988; Goodnow et al., 1989; 
Nossal and Pike, 1980). This is known as the induction of anergy. A recent study has 
described the identification of a population of human B cells that are predominantly 
autoreactive, as demonstrated by binding to HEp-2 antigens, but tolerised by functional 
attenuation. These cells were suggested to be fully mature IgD+IgM- B cells, referred to as 
BND cells, and are thought to represent 2.5% of peripheral blood (Duty et al., 2009).  
Receptor editing can rescue a newly rearranged light chain that is self-reactive for 
ubiquitous membrane-bound autoantigens of the BM stroma by a sequential and nested 
rearrangement event on the same allele, altering the specificity in order to eliminate self-
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reactivity (Halverson et al., 2004). The anti-DNA antibodies spontaneously produced in 
MRL/lpr mice aided in discovery of receptor editing as a mechanism to achieve tolerance. 
B cells of adult transgenic mice bearing both the IGH and IGL chain of anti-DNA 
antibodies only expressed the transgenic IGH paired with endogenous light chains using a 
restricted repertoire of V segments. That was the case despite detection of transcription 
of the transgenic, dsDNA-specific light chain. These observations suggested that 
autoreactive transgenic B cells may alter their light chains to enhance the likelihood of 
producing a non-self reactive receptor and consequently escape deletion (Gay et al., 1993). 
Receptor editing takes place at the light chain loci following intermediate levels of BCR 
antigen engagement in the developing B cell (Meffre and Wardemann, 2008). Ig heavy 
chains do not have the capacity to undergo receptor editing, since the process of successful 
V-DHJH rearrangement removes remaining DH gene segments from the repertoire, and 
recombination cannot take place between distal VH and JH segments due to the same 
orientations of their RSSs. It was proposed that receptor editing is the primary mechanism 
used to rescue autoreactive B cells, where clonal deletion only becomes necessary when no 
unrearranged gene segments are available on the same light chain alleles to permit further 
editing (Halverson et al., 2004). Furthermore, a significant shift in J gene segment usage 
between the VJ joints of Ig and Ig-expressing B cells has been observed, indicating 
that Ig-producers undergo sequential VJrearrangements on the same allele before 
undergoing rearrangement at the lambda allele (Bräuninger et al., 2001). 
Sequential rearrangements events of the light chain loci in peripheral lymphoid organs is 
often referred to as receptor revision and is a more contentious concept, though studies 
have demonstrated that secondary rearrangements of Ig light chains are commonly 
undergone by IgA+ plasma cells in a healthy gut (Su et al., 2008). The identification of 
biases in the productive and non-productive repertoires of Ig-expressing B cells, evidence 
of RAG gene and protein expression and identification of rearrangement intermediates 
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support this hypothesis (Su et al., 2004). In addition, T-cell dependent replacement of light 
chains has been described to take place in the germinal centres (GCs) of secondary 
lymphoid tissues to further diversify the Ig repertoire and select for high affinity BCRs and 
eliminate autoreactive receptors generated by somatic hypermutation.  
 
Studies in mouse models have similarly identified products of recombination and the 
protein product of RAG1 and -2 genes in GCs (Hikida et al., 1998). The expression of RAG 
genes is a much-debated subject, with evidence for and against its re-expression in 
peripheral lymphoid tissues. Although RAG1 and RAG2 gene expression is typically 
thought to occur in two waves during B cell development, catalysing IGH chain 
rearrangements followed by recombination at the IGL loci, it has been reported that RAG1 
and -2 are re-expressed in human GC B cells that have lost surface Ig, suggesting the ability 
to undergo a secondary round of Ig gene rearrangement (Giachino et al., 1998).  In addition, 
the detection of RAG has been reported in activated B cells isolated from human tonsil 
(Girschick et al., 2001). Of note, the reactivation of RAG gene expression in mature 
lymphocytes has been suggested to be responsible for aberrant rearrangement events 
involving Ig or TCR loci and proto-oncogene loci (Korsmeyer, 1992). Evidence against the 
re-induction of RAG used mice carrying GFP-tagged RAG gene products and illustrated in 
their hands that RAG gene expression is retained within the transitional B cell compartment 
of peripheral blood, proposing that re-induction of these genes in peripheral tissues does 
not take place (Nagaoka et al., 2000). 
 
1.1.7.2  B cell tolerance checkpoints 
 
As described above, clonal deletion, the induction of anergy and receptor editing exist to 
maintain central tolerance in the BM by negative selection of autoreactive specificities. The 
actual frequencies of self-reactive antibodies generated during the development of B cells 
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had previously not been studied until 2003 when Wardemann et al., 2003 investigated the 
development and silencing of self-reactive B cells in three healthy subjects. Individual 
antibodies from B cells at different stages of development were isolated from peripheral 
blood and BM and their antibodies were expressed in 293A cell lines. A total of 248 
antibody clones were then tested for binding to the HEp-2 cell line extract – a standard 
clinical assay for the detection of true ANAs that may be pathogenic and are hallmark of 
SLE (Leslie et al., 2001; Wardemann et al., 2003).   
 
Enzyme-linked immunosorbent assays (ELISAs) demonstrated that 75.9% antibodies 
cloned from early immature B cells showed high levels of reactivity in this assay, which 
decreased to 43.1% in B cells at the immature stage. HEp-2 reactivity remained at 40.7% 
in newly emigrated B cells in the blood, but an additional drop in reactivity in was observed 
between the new emigrant and naïve B cell compartments (Wardemann et al., 2003). Of 
the 75.9% antibody clones from early immature B cells, 58.6% showed nuclear or 
nuclear/cytoplasmic staining by indirect immunofluorescence assays (IFAs) on fixed HEp-
2 cells. Long IGH CDR3 regions have previously been associated with self-reactive 
antibodies (Aguilera et al., 2001), and this study illustrated that cloned antibodies from 
early progenitor B cells had significantly longer CDR3 regions than the mean CDR3 length 
of IGH antibody chains from peripheral B cells. Positively charged CDR3s were also 
enriched within pre-B and early immature B cell pools. Both these features were selectively 
removed as B cells developed. These data demonstrate in healthy individuals, self-reactive 
antibodies are eliminated from the B cell repertoire at the early immature to immature B 






1.1.7.3  Allelic inclusion – failure of B cell tolerance? 
 
The ability to express more than one rearranged Ig allele has been demonstrated in 
genetically modified mice engineered to develop a B cell repertoire which stably expressed 
two different heavy chains (Sonoda et al., 1997). It has also been suggested that the co-
expression of a non-self-reactive Ig light chain can rescue autoreactive B cells from 
negative selection by ‘diluting’ the self-reactive receptor, and essentially ‘bypassing’ 
central tolerance (Gerdes and Wabl, 2004; Li et al., 2002b; Liu et al., 2005). An 
examination of how tolerance to autoantigen is established involved the K/BxN mouse 
model of spontaneous and inflammatory autoimmune arthritis. Arthritogenic B cells 
expressing antigen-specific B cell receptors (BCRs) with different affinities for the 
autoantigen glucose-6-phosphate isomerase (GPI) were used to generate knock-in mice for 
in which the rearranged IGH and IGL variable gene segments of an anti-GPI hybridoma 
were targeted into the corresponding germ-line J loci. It was observed that sequential light 
chain rearrangements on the same allele, receptor editing, contributed to the removal of 
autoreactive BCRs with a high affinity for GPI. It was also suggested that the expression 
of an additional light chain by some of the GPI-reactive B cells contributed to their ‘escape’ 
from negative selection due to their low affinity for antigen (Huang et al., 2006). 
Interestingly, these findings have led to the proposal that light chain allelic inclusion may 
represent an additional B cell tolerance mechanism (Makdasi and Eilat, 2013). 
 
It is thought that receptor editing compromises allelic exclusion since it sustains ongoing 
recombination events even after production of  a functional Ig receptor (Li et al., 2002b). 
One study used gene targeting to replace the mouse IGKC region with the human 
counterpart allowing for the generation of normal mice heterozygous for the human IGKC 
allele (Igm/h) in the context of a wild-type repertoire. Ten percent of mature B cells were 
found to co-express both alleles of IGK and that these cells participated in immune 
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responses (Casellas et al., 2007). Thirty percent of these dual-light chain expressing B cells 
exhibited autoreactivity in screens for dsDNA or Hep-2 cell binding. They also suggested 
that light chain inclusion by these cells was the result of receptor editing since usage of 
IGKJ5 was significantly enriched within the dual-expressing B cell population (Casellas et 
al., 2007). Furthermore, Igh mice bearing a gene targeted human IGKC allele were crossed 
with the lupus-prone MRL-Faslpr/lpr in a study that demonstrated that B cells expressing two 
Ig light chains were increased in frequency with the age and disease progression of the 
mice. In addition, the dual-Ig -expressing B cells exhibited higher levels of autoreactivity 
than single Igcells and were frequently observed to have undergone antigen activation 
and differentiated into memory and autoantibody-secreting plasmablast populations 
(Fournier et al., 2012). 
 
A very recent study however has provided evidence to contradict this study, finding that 
just 0.5% of anti-DNA-producing hybridomas from knock-in lupus-prone NZB/NZW mice 
appeared to exhibit light chain inclusion, and that those that do express allelically included 
light chains do not express higher proportions of autoreactive BCRs.  Ultimately, whether 
the allelic inclusion of light chains is a protective tolerance mechanism, or the by-product 
of ongoing light chain gene rearrangements, it remains to be a highly interesting area of 
study.  
 
1.1.8  Human B cell subsets 
 
The development of human B cell subsets can largely be defined by the status of their 
immunoglobulin genes, and those that have successfully undergone gene rearrangement 
events on both the IGH and IGL loci in the BM enter the peripheral circulation. The 
peripheral development of B cells can be broadly separated into five sequential stages; 
56 
 
transitional B cells that represent new BM emigrants, mature naïve B cells that are antigen 
inexperienced, germinal centre B cells that are engaged in immune responses to cognate 
antigen, memory B cells that survive for prolonged periods and plasma cells that secrete 
soluble antibodies (Bemark et al., 2012). 
 
1.1.8.1   Differences between mouse and human B cell development 
 
Human B cell development is not equivalent to the development of the murine B cell 
repertoire (Weill et al., 2009). During murine B cell development, immature transitional B 
cells are thought to be comprised of four transitional B cell subclasses; T0, T1, T2 and T3, 
defined by their expression of CD23 and IgM and AA4, a fetal stem cell marker (Allman 
et al., 2001). T2 B cells are thought to be derived from T1 B cells and are located 
predominantly in the spleen, and T3 B cells are considered to represent an anergic B cell 
population (Teague et al., 2007). Upon reaching the spleen murine transitional B cells 
become mature naive B cells existing as either splenic resident marginal zone (MZ) or 
circulating follicular (FO) B cells; these subsets thought to be specialised for taking part in 
T-independent and T-dependent immune responses respectively (Garraud et al., 2012; 
Vossenkamper et al., 2012). Murine B1 cells represent a fetally derived B cell lineage and 
are restricted to the peritoneal and pleural cavities and are a self-renewing population 
(Carey et al., 2008). There is no equivalent B cell subset in humans and the anatomical 
differences between the mouse and human MZ supports the notion that human B cell 
development is unlikely to occur by the same pathway (Mebius and Kraal, 2005).  
 
1.1.8.2   Human transitional B cells 
 
Human transitional B cells comprise approximately 2-3% of human peripheral blood 
(Vossenkamper et al., 2012) and can be phenotypically identified by the high cell surface 
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expression of CD19, CD24, CD38 and CD10 (Palanichamy et al., 2009; Sims et al., 2005). 
Human transitional B cell subsets can be further divided into T1, T2 and T3 populations. 
The T1 population can be sub-divided into CD21lo or CD21+ cells, with T1 CD21lo cells 
considered to be at a more immature developmental stage than the CD21+ T1 population. 
It has been suggested that T1 CD21lo cells may represent an anergic transitional B cell 
population since the down-regulation of CD21 expression following antigen encounter has 
been associated with the induction of anergy (Andrews and Wilson, 2010; Suryani et al., 
2010).  
 
Human transitional B cells may also be identified in populations of CD27-IgM+ B cells 
through the lack of expression of the ATP-binding cassette B1 (ABCB1) transporter, since 
ABCB1 expression is restricted to resting naive B cells (Wirths and Lanzavecchia, 2005). 
These two methods for identifying transitional B cells led to the designation of the T3 
transitional B population that is phenotypically naive, though lacks expression of ABCB1 
(Bemark et al., 2012; Palanichamy et al., 2009).  The differentiation of a human transitional 
B cell and its progression to becoming an MZ B cell is poorly understood, but the recent 
suggestion that transitional B cells enter gut-associated lymphoid tissue (GALT) as part of 
normal human B cell development has contributed to this area of debate (Vossenkamper, 
2013). In this study, T2 cells were demonstrated to be selectively recruited to Peyer’s 
patches of GALT, supported by the highest expression of the 47 integrin by this 
transitional B cell subset. T2 cells were shown to be activated in vivo by detection of 
phosphorylated of BTK, Erk and Syk and approximately 30% of GALT T2 cells had 
acquired somatic mutations in their IGVH genes, indicative of participation in an immune 
response (Vossenkamper, 2013). These findings suggest a novel, previously un-described 
pathway of human B cell development and repertoire development in humans. It is 
58 
 
unknown what the fate of these T2 cells may be; they may die in the gut or may be the 
precursors of either human MZ cells, enigmatic in origin, or intestinal plasma cells. 
 
1.1.8.3  Human naive and memory B cell subsets 
 
The human naive B cell population used to be phenotypically characterised by the 
expression of unmutated IgD or IgM and absence of CD27 expression, since these B cells 
represented a population that had not encountered antigen or undergone subsequent CSR 
to produce either IgG, IgA or IgE (Wu et al., 2011). Naive CD27- B cells comprise 
approximately 60-70% of the total B cell pool (Weill et al., 2009). However, it is now 
understood that a significant population of IgM+IgD+ cells carry V region mutations and 
comprise around 15-20% of the total lymphocytes in the peripheral blood of healthy 
subjects (Dunn-Walters et al., 1995; Klein et al., 1997; Klein et al., 1998; Weill et al., 
2009). Since this IgM+IgD+ subset also expressed CD27, it was proposed that CD27 was 
an appropriate marker for the identification of memory B cell subsets (Klein et al., 1998).  
The origin of this B cell subset remained elusive for some time, though more recent studies 
have demonstrated that IgM+IgD+CD27+ and IgM+IgD-/loCD27+  cells both carry mutations 
in Bcl6, indicative of cells participating in germinal centre responses. In addition, the 
IgM+IgD+CD27+ population were found to be clonally related to  GC-derived IgG+ cells 
that shared V gene mutations (Seifert and Kuppers, 2009). The identification that naive 
cells could be discriminated from memory B cell populations by their expression of 
ABCB1 also aided these studies (Wirths and Lanzavecchia, 2005).  
 
Memory B cells respond more rapidly to antigen encounter than naive B cells with the same 
specificity and use a different repertoire of IGVH gene segments than naive B cells 
(Blanchard-Rohner et al., 2009; Tangye et al., 2003; Wu et al., 2010). The identification of 
memory B cell subsets is complex. The early suggestion that CD27 represents a general 
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marker of all memory B cell subsets (Klein et al., 1998) is being questioned following the 
recent identification that CD27- B cells actually represent a heterogeneous B cell pool. A 
population of IgG+CD27- B cells carried somatically mutated VH genes that indicated 
germinal centre involvement (Fecteau et al., 2006). A recent study has described that the 
detection of the CD45RB epitope using a mAb known as MEM55 (CD45RBMEM55 ) is a 
useful method for identification of all memory B cell subsets independently of CD27 
expression (Koethe et al., 2011).  Splicing of the CD45RB exon was found to be unchanged 
during B cell differentiation, and that its expression is regulated by modifications by O-
linked glycosylation. CD45 is a highly expressed tyrosine phosphatase that is involved in 
the regulation of lymphocyte signalling activation strength during antigen encounter 
(Koethe et al., 2011).  
 
1.1.8.4  Human plasmablasts and plasma cells 
 
The plasmablast B cell pool consists of B cells immediately preceding differentiation into 
plasma cells (Bemark et al., 2012). Plasmablasts can be phenotypically defined as 
CD19loCD20−CD27highCD38highCD138+/− B cells and are predominantly of mucosal origin; 
84% have been described to secrete IgA (Caraux et al., 2010; Mei et al., 2009). Expression 
of CD138, also referred to as syndecan-1, is typically acquired as a marker of both human 
and mouse plasma cells and is thought to mediate adhesion of plasma cells to the BM 
stromal matrix via interactions with type I collagen (Jego et al., 2001; MacLennan et al., 
2003; O'Connell et al., 2004). Plasmablasts that express similar levels of CD27 and CD38 
however are commonly either positive or negative for CD138 expression. This makes 
distinction between circulating  plasmablasts and plasma cells limited (Fink, 2012) and as 
a result, these cells are commonly referred to as antibody-secreting cells (ASCs) 
(Wrammert et al., 2008). Very low numbers of plasma cells (2/μL) are found in peripheral 
blood of healthy subjects (Caraux et al., 2010) though increases in plasmablast and plasma 
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cell number are observed in circulation following vaccination or infection (Wrammert et 
al., 2008). 
 
1.1.8.5  Human regulatory B cells 
 
B cells are typically considered to be positive regulators of immunity, largely due to their 
production of antibodies (Yang et al., 2013). However, the role of B cells with regulatory 
capacity have been of great interest since identification of the broad range of 
immunosuppressive cytokines B cells can secrete, such as IL-10 and TGF. One of the 
earliest descriptions of a suppressive role of B cells was proposed in 1974, where studies 
investigating delayed type hypersensitivity (DTH) skin responses in guinea pigs 
demonstrated that DTH was impaired just prior to the detection of antibody (Katz et al., 
1974; Neta and Salvin, 1974). A regulatory role for B cells in restricting autoimmunity was 
elucidated from studying mouse models of experimental autoimmune encephalomyelitis 
(EAE). Increased disease severity and failure to recover from disease was observed in EAE 
mice deficient in B cell function due to disruption of their IGH chain transmembrane exon 
(Wolf et al., 1996). Similar studies using the EAE mouse model illustrated that B cells 
producing IL-10 following autoantigen recognition were responsible for the recovery from 
disease and resolution of inflammation (Fillatreau et al., 2002). This IL-10-producing 
subset of B cells was also shown to up-regulate cell surface expression of CD1d and 
produced IL-10 which directly played a role in the suppression of IL-1 and STAT3-induced 
pathway of inflammation (Mizoguchi et al., 2002). The following year, a role for B cell 
derived IL-10 in the protection against arthritis development was described (Mauri et al., 
2003). This study used the chronic collagen-induced arthritis (CCIA) model, which 
represents a Th1 driven arthritic disease and develops following immunization of  DBA/1-
TcR--Tg mice with type II bovine collagen (CII) in complete Freund’s adjuvant (CFA) 
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(Mauri et al., 1997). They demonstrated that the activation of arthritogenic splenocytes in 
vitro with agonistic anti-CD40 mAb and CII as the source of antigen induced the 
development of B cell population producing high levels of IL-10 and low levels of IFN-. 
Adoptive transfer of these cells into DBA/1-TcR--Tg mice following immunization with 
CII inhibited Th1 cell differentiation, prevented the development of arthritis in these mice 
and could ameliorate established disease (Mauri et al., 2003).  
It was later suggested that the origin of these regulatory IL-10 producing B cells could be 
attributed to a B cell subset expressing high levels of CD21, CD23 and IgM; transitional 2 
marginal zone precursor (T2-MZP) B cells (Evans et al., 2007). Adoptive transfer of this 
B cell subset into immunized DBA/1 mice during the induction phase of CIA ameliorated 
disease by inhibition of Th1 immune responses via and IL-10 mediated mechanism (Evans 
et al., 2007). Human B cells exhibiting a regulatory capacity have been described as a 
population of cells with the surface phenotype CD19+CD24hiCD38hiIgD+CD1dhi that 
constitute approximately 1% of peripheral blood. Healthy CD19+CD24hiCD38hi cells have 
been shown to inhibit the differentiation of naïve CD4+ T cells into Th1 and Th17 cells 
partially through IL-10 secretion. In addition, CD19+CD24hiCD38hi cells of healthy donors 
converted CD4+CD25- T cells into TREGS (Blair et al., 2010; Flores-Borja et al., 2013). 
CD19+CD24hiCD38hi cell numbers have also been correlated with IL-10 and a state of 
tolerance in renal transplant patients (Newell et al., 2010). The studies involving 
investigating regulatory B cells in SLE will be described in a later section. 
Several modes of activation of regulatory B cells have been described. Regulatory B cell 
function is largely dependent upon interaction with effector T cells, where a body of 
evidence supports the requirement for CD40-CD154 interaction in their activation. EAE 
mice harbouring B cells with a CD40-specific deficiency suffer from more severe disease 
and reduced levels of IL-10 production (Fillatreau et al., 2002). The use of monoclonal 
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antibodies targeting CD40 has demonstrated therapeutic benefit to human subjects 
suffering from arthritis which appears to redirect the Th1 response by provision of IL-10 
(Mauri et al., 2000). TLR stimulation has been described to be the strongest stimulus for B 
cell-mediated T cell suppression through IL-10 production in both mice and humans. TLR2 
and TLR4 are required for regulatory B cell function in mice following LPS activation and 
relieve EAE (Lampropoulou et al., 2008). In humans, optimal stimuli of B cells to induce 
IL-10 production involves activation of TLR9 using CpG-B in combination with BCR 
stimulation using anti-Ig. B cells stimulated in this way partially inhibit the proliferation of 
CD4+CD25- naïve T cell populations in vitro (Bouaziz et al., 2010).  
 
1.1.9  B cell activation and immune homeostasis 
 
Maintenance of B cell homeostasis and the appropriate response following activation 
requires the integration and regulation of a number of intracellular signals delivered from 
multiple surface receptors; predominantly the BCR, Toll-like receptors (TLRs), the B cell 
activating factor (BAFFR) receptor, and CD40, as well as intracellular cues. Failure to 
integrate pathways such as NF-κB signalling can lead to B cell deficiency, aberrant B cell 
activity, or even lymphoma (Tavares et al., 2010). Aberrant B cell tolerance and selection 
can cause production of autoantibodies, formation of immune complexes (ICs) and tissue 
damage and the manifestation of autoimmune disease states (Fairhurst et al., 2006).   
The molecular decisions made following activation of a B cell after antigen encounter 
determines the fate of the B cell and ultimately the generation of a successful adaptive 
immune system. The most basic mode for B cell activation and subsequent survival 
involves the integration of two signals; the binding of cognate antigen to the BCR and the 
subsequent engagement of co-stimulatory molecules in a T-dependent interaction of TNF-
family receptor super-family member CD40 expressed on the B cells with co-stimulatory 
63 
 
molecule CD40L (CD154) on the surface of the cognate T cell. CD40 a member of the 
TNFR family and is also expressed by professional antigen presenting cells (APCs) and 
non-immune cells (Elgueta et al., 2009). The strength, duration and B cell developmental 
stage of CD40 ligation plays a role in shaping whether a mature B cell secretes Ig or 
whether Ig secretion is suppressed (Miyashita et al., 1997). The second signal may also be 
provided via TLR stimulation. B cells may be activated by T-cell dependent and 
independent pathways. 
 
1.1.9.1   T-cell independent B-cell activation 
 
The formation of a germinal centre is dependent upon the function of TH cells, though the 
responses of some B cells occur independently of this cognate interaction. T-independent 
B cell activation can occur through interactions with microbial components, typically large 
lipid or carbohydrate molecules, and induce strong antibody responses in healthy 
individuals. These are known broadly as thymus-independent (TI) antigens which can be 
further classified into TI-1 and TI-2 subgroups depending on the activation mechanism 
triggered by the stimulating antigen, though both stimulate rapid IgM production in the 
absence of cognate T cell help (El Shikh et al., 2009). 
TI-1 antigens are capable of polyclonally activating mature and immature B cell 
populations non-specifically resulting in their proliferation and differentiation, providing 
they are at a high concentration (Murphy. K, 2008). In mice, lipopolysaccharide (LPS) is a 
TI-1 antigen and a potent B cell mitogen expressed on the outer membrane of gram-
negative bacteria where recognition by TLR4 following binding to LPS-binding protein 
and CD14 elicits an immune response. TI-2 antigens tend to consist of multiple repeating 
subunits of bacterial capsular polysaccharides; the most potent TI-2 antigens 
simultaneously cross-link a number of BCRs, and it has been demonstrated that TI-2 
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molecules must consist of a minimum of twenty repeating epitopes that were appropriately 
spaced in order to elicit immunogenicity (Dintzis et al., 1976; Dintzis et al., 1983). TI-2 
antigens contain no intrinsic B cell stimulating activity and can only activate mature B cells 
(Fagarasan and Honjo, 2000; Lesinski and Westerink, 2001). B cell activation by TI-2 
antigens is supported by BAFF, a co-stimulatory molecule provided by DCs, and these 
antigens have also been shown to play a role in triggering activation of the complement 
pathway (Mond et al., 1995). The density of TI-2 antigen is considered to be pivotal to the 
B cell response induced, where excessive cross-linking of B cell receptors by TI-2 antigens 
is considered to render the B cell anergic, and low TI-2 antigen concentrations fail to induce 
its activation (Murphy. K, 2008). 
 
1.1.9.2   T-cell dependent B-cell activation 
 
Following human B cell development in BM, B cells enter the periphery as transitional B 
cells expressing a distinct cell surface molecule phenotype CD19+IgD+CD27-
CD24hiCD38hiCD10hi. These new B cells are thought to migrate via high endothelial 
venules (HEVs) in T cell zones harboring patrolling and unstimulated CXCR5lo and CCR7hi 
to secondary lymphoid organs such as the spleen, Peyer’s patches, lymph nodes (LNs) and 
tonsils where B cells then migrate to B cell follicles if antigen is encountered (Goodnow et 
al., 2010). Transit to the follicle is facilitated by the expression of CXCR5 and CCR7 which 
mediates chemotaxis towards CXCL13-expressing follicular dendritic cells and stromal 
cells producing CCL19 and CCL21 respectively (FDCs).  
B cells that fail to encounter cognate antigen re-enter the peripheral circulation via efferent 
lymph vessels (Okada et al., 2005; Reif et al., 2002). BCR engagement induces higher 
expression of CCR7 within 1-6 hours of antigen receptor binding to facilitate migration to 
the follicle/T cell zone border and expression of CD86 to mediate interaction with CD28 
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on the cognate T cell. At this location, self-reactive B cells undergo cell death as prolonged 
antigen exposure down-regulates CD86 expression whereas non-autoreactive B cells begin 
to proliferate within 1-2 days at this site and reposition themselves to perifollicular areas 
rich in CD11chi DCs that are responsible for production of BAFF and APRIL survival 
signals to the B cell (Steinman et al., 1997). By day 3 molecular decisions determine 
whether a single proliferating B cell becomes a re-circulating early memory B cell, an 
extrafollicular plasma cell or a germinal centre (GC) B cell. B cell clones with the highest 
affinity tend to be selected for extrafollicular plasmablast compartment (Chan et al., 2009) 
and differential expression of chemoattractant receptors shape the fate of the B cell; for 
example, plasma cells lose CXCR5 and express high levels of CXCR4 whereas GC B cells 
retain CXCR5 expression. 
  
1.1.9.2.1   Somatic hypermutation and class-switch recombination 
 
Upon reaching a GC, mature B cells that have encountered cognate antigen migrate towards 
the dark zone of the GC as rapidly proliferating centroblasts and undergo somatic 
hypermutation (SHM) and class switch recombination (CSR) upon entering the light zone; 
both processes occur during antigen-driven differentiation of B lymphocytes and are 
absolutely dependent upon the expression of activation induced cytidine deaminase (AID) 
specifically by activated B lymphocytes (Dunnick et al., 2009; Neuberger et al., 2003). AID 
was identified to be responsible for governing both processes through studies of AID-
deficient mice and humans. Mouse B cells specifically express AID in GCs, and AID-
deficient mice develop hyper-IgM syndrome and are unable to make IgG, IgA or IgE 
antibodies. Human studies have revealed that patients with the autosomal recessive form 
of hyper-IgM syndrome (HIGM2) carry mutations in the human counterpart AID which 
manifests as an inability to class switch Ig, the inability to acquire somatic hypermutations 
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and lymph node hyperplasia, thought to be caused by the presence of very large germinal 
centres (Revy et al., 2000).  
AID deaminates deoxycytidine residues to uracil residues in single stranded DNA. The 
resulting U:G mispairs act as lesions for repair mechanisms and base substitutions 
(Murphy. K, 2008). If cell division proceeds before any repair events, DNA replication can 
reads uracil residues as thymidine residues thus generating a C to T transition. 
Alternatively, the uracil residue produced by the action of AID can become the substrate 
for the base-excision repair enzyme uracil DNA glycosylase (UNG). UNG can excise the 
U residue, and this process generates an abasic site in the DNA that may be replicated over 
by the action of error-prone polymerases (Stavnezer, 2011). These actions promote 
transitions and transversions at C:G pairs. Mutation at A:T pairs are considered to result 
from recognition of the U:G mismatch by MSH2/MSH6 which initiates a mutagenic patch 
repair event also involving error-prone polymerases (Di Noia and Neuberger, 2007).  
Somatic hypermutation involves the introduction of point mutations throughout the 
variable regions of both the heavy and light chains at a high rate but occurs during only a 
narrow window of B cell development. Nucleotide substitutions are made at a frequency 
of approximately 10−3 per base pair per generation (Di Noia and Neuberger, 2007). All four 
bases can be targeted for mutation, C:G pairs and A:T pairs are targeted with approximately 
equal frequency and all four bases can be targeted for the introduction of mutations. 
However, though it is known that mutational hot spots exist, and these are often at C:G 
pairs found within a WRCY consensus (where W =A/T, R =A/G, and Y=C/T) (Di Noia 
and Neuberger, 2007).  
 
In the case of CSR, AID mediates a deletional recombination event of the IGH loci and 
involves the C region only; where replacement of the original C IGH chain with an 
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alternative C region takes place (Dunnick et al., 2009). AID catalyses CSR by deamination 
of several deoxycytidine residues in single stranded DNA switch (S) regions and the 
subsequent UNG-mediated excision of the resulting deoxyuracil residues. (Gatto and 
Brink, 2010; Peled et al., 2008; Stavnezer et al., 2008). Instead of filling the resulting abasic 
residues directly, the action of the apurinic/apyrimidinic endonucleases 1 (APE1 and 
APE2) serves to excise the rest of the residue consequently introducing a single or double 
stranded  nick (the latter if the abasic sites are sufficiently close on opposite strands) in the 
DNA opposite the site of the original cytosine. High densities of single stranded DNA nicks 
in S regions flanking C region genes is suggested to produce the staggered double-stranded 
breaks required for CSR (Murphy. K, 2008; Stavnezer, 2011). 
 
The progeny of the proliferating centroblasts are known as centrocytes that express surface 
Ig and transit to the light zone to be screened and selected for their affinity for antigen in 
part by signalling through their BCR. Here they receive cognate T cell help from a 
specialised subset of CD4+ T cells known as follicular T helper cells (TFH) via 
CD40/CD40L interactions and FDCs. TFH cells produce a variety of cytokines that are 
thought to play role in the initiation of class switch recombination, or isotype switching, by 
directing AID activity to the switch recombination sequences located 5’ of each 
unrearranged CH region; γ, α and ε segments (Murphy. K, 2008).  
 
The GC environment is highly dynamic, where refining of T cell-dependent humoral 
immunity is achieved through the positive selection of high affinity centrocytes for further 
amplification and is simultaneous to the induction of apoptosis in non-selected B cells. 
Maintenance of this environment is mediated by a variety of signals and changes in gene 
expression patterns. The isolation of naive IgD+CD27-CD38lo with unmutated V regions) 
by magnetic cell separation (MACS) and FACS-sorted centroblast (CD38hi CD77+) and 
centrocyte B cell populations (CD38hi CD77-) for microarray analyses allowed for the study 
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of global gene expression changes in human B cells entering a GC reaction, and it was 
demonstrated that the naive to CB transition is accompanied by changes in 457 different 
genes involved in the down-regulation of cell adhesion molecules, the acquisition of a pro-
apoptotic phenotype and up-regulation of genes involved in chromatin remodeling, DNA 
replication and DNA repair (Klein et al., 2003). Expression of Bcl6 protein, product of the 
proto-oncogene BCL6, is restricted to the GC stage of a developing B cell (Basso and Dalla-
Favera, 2012) and is required for the repression of hundreds of transcription factors during 
GC formation and a recent study unveiled a potential role of Bcl6 in regulating AID 
expression and promoting the expression of important GC functions through repression of 
the micro-RNA-155  (miR-155) (Basso et al., 2012). Cell fate decisions are then made as 
to whether the new B cell with a high affinity receptor differentiates into a memory B cell 
or a long lived plasma cell, or alternatively whether to re-enter the dark zone to undergo 
further rounds of receptor diversification by SHM. The dynamics of a human GC are 




















Figure 1.8  The dynamics of a human germinal centre. Antigen-activated B cells enter germinal 
centres where they undergo several rounds of proliferation and random somatic hypermutation in 
the dark zone as centroblasts. Centroblasts then migrate to the light zone, the site of selection and 
class switch recombination, as centrocytes where they meet one of several fates. Centrocytes lacking 
surface Ig or recognising self-antigen undergo apoptosis. Centrocytes expressing high affinity 
antibody receptors for foreign antigen are selected for differentiation into plasmablasts or memory 
B cells before leaving the germinal centre to continue their differentiation. 
  
 
1.2   Systemic Lupus Erythematosus (SLE) 
 
1.2.1   SLE disease outline 
 
SLE is a chronic, incurable autoimmune disease of unknown origin with highly 
heterogeneous and complex clinical manifestations. This is thought to be the result of the 
wide range of genetic and molecular defects that contribute to SLE risk (Dorner et al., 
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2011a). SLE is characterised by chronic B cell hyper-activation and the production of 
autoantibodies that target self-DNA and nucleoproteins (Friou, 1958; Holman and Kunkel, 
1957). This process leads to the formation of pathogenic immune complexes and 
widespread activation of complement; the consequence is multisystem inflammation of 
connective tissue (Dorner et al., 2011a; Kerekov et al., 2011; Munoz et al., 2010). The main 
organs typically involved are the kidneys, manifesting as lupus nephritis, the skin, the eyes, 
the central nervous system (CNS) and the joints (Jordan et al., 2013). 
 
The prevalence of SLE in the UK is approximately 28 per 100,000 individuals with a 
female to male ratio of 9:1 SLE prevalence is more common in certain countries and some 
ethnic groups tend to be more susceptible to SLE development. One study reported than 
the mean age at disease diagnosis was 6 years younger among African-American subjects 
and other minority groups compared with Caucasian patients (Cooper et al., 2002). The 
same study suggested that discoid lupus, proteinuria, anti-Sm and anti-RNP autoantibodies 
were more commonly seen in African-American patients though mucosal ulcers and 
photosensitivity were observed less frequently compared to Caucasian patients. African 
American and Orientals are considered to have more severe disease than SLE patients of 
Caucasian origin (D'Cruz et al., 2007; Lau et al., 2006).  Such differences suggest a role of 
genetic and environmental influences on SLE development. 
 
1.2.2   The pathogenesis of SLE 
 
The pathogenesis of SLE remains incompletely defined, though a body of evidence 
strongly suggests that SLE is a syndrome resulting from aberrant interplay between a 




1.2.2.1  Immune cells in SLE pathogenesis 
 
One of the main cell intrinsic defects thought to contribute to SLE development and 
pathogenesis in some patients is a failure to clear apoptotic cells. This results in the uptake 
of previously intracellular self-constituents by macrophages that can subsequently drive an 
autoimmune phenotype through presentation of these antigens to B and T cells (Munoz et 
al., 2005; Munoz et al., 2010). Such findings have been supported by the identification of 
a neutrophil-specific mechanism that appears to contribute to SLE pathogenesis.  
Neutrophil extracellular traps (NETs) are antimicrobial web-like structures of de-
condensed chromatin and cytosolic antimicrobial proteins secreted neutrophils. Several 
studies have provided evidence to suggest that SLE patients fail to clear NETs, typically 
released upon infection, due to impairment of DNase I function. This may provide a source 
of the self-antigen to initiate and propagate an autoimmune disease state (Hakkim et al., 
2010; Knight et al., 2012). SLE is also associated with the chronic activation of 
plasmacytoid dendritic cells (pDCs), where it has been demonstrated that immunogenic 
complexes from the sera of SLE patients were composed of NET proteins and self-DNA 
that subsequently triggered the activation of innate pDCs via TLR9 (Lande et al., 2011). 
The same study also demonstrated that circulating neutrophils from SLE patients produced 
more NETs than healthy donors. Engagement of both the BCR and TLR9 by DNA-
containing complexes activates autoreactive B cells (Leadbetter et al., 2002). 
The analysis of anti-DNA antibodies and why they should be a hallmark of SLE was 
initially unclear since mammalian DNA itself is poorly immunogenic compared with 
microbial DNA (Hirabayashi et al., 2007). This was elucidated by identification that TLR9 
recognises unmethylated CpG dinucleotide motifs, abundant in microbial DNA fragments. 
There is a low abundance of such motifs in mammalian DNA which are typically highly 
methylated and depleted of CpG di-nucleotides. This study demonstrated a role for CpG 
island-rich (50-80% GC containing DNA stretches) mammalian dsDNA fragments 
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approximately 600bp in length in the activation of autoreactive B cells via TLR9 (Uccellini 
et al., 2008).  
1.2.2.1.1  T cells in SLE pathogenesis 
 
Although this study explored the role of B cell immunoglobulin light chains in SLE 
pathogenesis, it is important to acknowledge the potential consequences of aberrant 
immunoglobulin recognition and the result of self-antigen presentation to the T cell 
repertoire in SLE patients. Following the initial loss of tolerance associated with SLE 
development, the interaction of autoreactive B and T cells in patients with the disease 
perpetuates and amplifies the autoimmune and inflammatory response. The resulting tissue 
injury further contributes to end-organ damage (Crispin et al., 2010). SLE T cells have been 
shown to elicit more rapid and increased early signalling events following stimulation via 
the TCR and CD3 signalling complex, displayed by a rapid increase in intracellular calcium 
concentrations and increased cytoplasmic protein tyrosine phosphorylation in freshly 
isolated T cells from SLE patients compared to healthy donors following anti-CD3 
stimulation (Vassilopoulos et al., 1995). SLE T cells have also been shown to display 
aberrant regulation of apoptosis and necrosis. SLE T cells exhibit enhanced spontaneous 
apoptosis in vitro that correlates with disease activity and increased release of intact 
nucleosomes into the extracellular environment following analysis by ELISA. (Emlen et 
al., 1994). SLE T cells also undergo necrosis in response to oxidising agents instead of 
apoptosis observed in healthy subjects (Gergely et al., 2002). These abnormal processes 
may provide a source of self-nuclear antigen that may contribute to the propagation of 
autoimmunity.  
T cell subsets have also been found to exhibit differences compared to healthy subjects. T 
cells are defined by their thymically-determined expression or absence of co-stimulatory 
molecules CD4 and CD8 (Crispin et al., 2010). SLE patients have increased levels of 
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activated CD8+ T cell populations though they have been shown to be impaired in their 
cytotoxic ability (Stohl et al., 1999).  Double negative (DN) T cells (CD3+CD4-CD8-) have 
also been shown to be expanded in the peripheral blood of SLE patients. Although these 
cells have not directly been linked with SLE pathogenesis, they have been shown to secrete 
significant amounts of inflammatory IL-17 and IFN-, and can expand in response to CD3 
stimulation in vitro (Crispin et al., 2008). IL-17+ DN T cells were also observed in the 
kidneys of nephritis patients, suggesting a contribution to disease pathogenesis. 
Th17 cells were identified on their ability to produce IL-17, and commitment to the Th17 
lineage was demonstrated to be dependent upon expression of STAT3 and retinoic acid 
orphan receptor-(ROR-γt) in the presence of IL-6 and TGF- (Alunno et al., 2012).  The 
serum of patients with SLE has been shown to contain higher IL-17 concentrations, and the 
expansion of T cells producing IL-17 in peripheral blood have been identified. Th17 cell 
infiltration of the kidneys has also been observed in some cases of SLE (Alunno et al., 
2012).  
Regulatory T cell populations (TREGS) constitute approximately 1-2% of peripheral blood 
and are an immunologically-suppressive T cell subset that have the cell surface phenotype 
CD4+CD25+Foxp3+ (Cai et al., 2012). TREGS may be thymically-derived (natural, nTREGS) 
or induced peripherally through the induction of the transcriptional regulator forkhead box 
P3 (FoxP3). These are referred to as inducible TREGS (iTREGS), and it has recently been 
proposed that the cell surface molecule neuropilin-1 (Nrp-1) may distinguish nTREGS that 
express high levels of Nrp-1, from iTREGS (Yadav et al., 2012). It has been reported that 
circulating TREGS are reduced in frequency in active SLE and have a reduced capacity to 
suppress effector T cell populations compared to healthy controls (Bonelli et al., 2008; 
Miyara et al., 2005). The reported imbalance of Th17 and TREG cell subsets in SLE suggest 
that disease pathogenesis may be associated with the homeostatic control of the TREG 
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population, though as described previously, distinguishing between cause and effect of 
cellular and biochemical differences implicated in SLE pathogenesis remains challenging.  
 
1.2.2.2  Cytokines in SLE pathogenesis 
 
Cytokines collectively regulate systemic inflammation, and it is known that several 
contribute to disease pathogenesis in SLE. SLE is associated with a distinctive interferon 
(IFN) signature, where a continuous production of IFN correlates with severe disease in 
SLE patients compared to healthy controls. Type I IFN is produced following infection 
and plays diverse roles and is involved in the innate anti-viral response, stimulating Th1 
differentiation, enhancing signalling through the BCR, regulation of apoptosis and the 
induction of DC maturation (Braun et al., 2002; Le Bon et al., 2006; Moser et al., 2009). 
As previously mentioned an early event implicated in triggering SLE is the chronic 
activation of pDCs. This event induces the production of type I IFN that has been shown 
to be responsible for the unabated differentiation of monocytes into myeloid DCs that can 
subsequently maintain continuous activation of autoreactive B and T cells (Ronnblom and 
Pascual, 2008). Serum IFN from SLE patients has been shown to induce DC 
differentiation from normal monocytes; a phenomenon that correlated with disease activity. 
It was demonstrated that the DCs induced by this method subsequently were able to present 
antigen captured from apoptotic cells to CD4+ T cells (Blanco et al., 2001). Furthermore, 
IFN has been shown to lower the activation threshold of autoreactive B cells (Le Bon et 
al., 2006).   
In both murine and human SLE, serum levels of IL-6 are elevated. IL-6 promotes the 
activation and differentiation of macrophages, neutrophils and both B and T cells (Jacob 
and Stohl, 2011). SLE B cells spontaneously express IL6-R and produce high levels of IL-
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6. It has been reported that autoreactive T cell clones promote the response by B cells and 
the production of autoantibodies in SLE through production of IL-6 (Takeno et al., 1997).  
Tumour necrosis factor alpha (TNF) is a cytokine capable of promoting pro- and anti-
inflammatory responses depending on the environmental conditions. Evidence for a role of 
TNFin human SLE pathogenesis is however contentious, with some studies reporting 
that elevated serum TNF levels in patients with SLE correlates with disease activity 
(Studnicka-Benke et al., 1996), and others demonstrating no correlation between TNF 
plasma concentrations and disease activity. The latter study even suggests a protective role 
for the cytokine since higher TNF plasma concentrations were observed in patients with 
quiescent disease (Gomez et al., 2004).  
Of further importance and subject of ongoing study is the cytokine known as B lymphocyte 
stimulator (BLyS), also known as the B cell–activating factor belonging to the TNF family 
(BAFF) that is essential for the survival of B cells. BLyS binds three different receptors: 
BAFFR (or BR3), B cell maturation protein (BCMA) and transmembrane activator and 
calcium modulator and cyclophilin ligand interactor (TACI). The receptors BCMA and 
TACI also bind the cytokine named a proliferation-inducing ligand (APRIL) which is 
closely related to BLyS (Jacob and Stohl, 2011). Important biological functions are 
mediated by the different interaction of these cytokines with their different receptors. 
Plasma cell survival is dependent upon cell surface expression of TACI and BCMA and 
their ligands BLyS or APRIL, whereas the maintenance of pre-PC populations is solely 
mediated by the abundant expression of BAFFR. Memory B cells are thought to exist 
independently of both BLyS and APRIL (Jacob and Stohl, 2011). Circulating levels of 
BLyS have been reported to be elevated in SLE patients with active disease, and high 
mRNA levels of BLyS and APRIL in B cells and plasma cells have been associated with 
levels of anti-dsDNA antibodies and disease severity (Chu et al., 2009; Petri et al., 2008).  
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1.2.2.3  Complement in SLE pathogenesis 
 
It has long been recognised that the complement system plays a role in SLE. A model of 
SLE pathogenesis involves the activation of complement by autoantigen bound Ig immune 
complexes that can subsequently be deposited as inflammatory lesions in tissues 
(Lachmann et al., 1962; Walport, 2002). There is also an association of lower complement-
mediated immune complex clearance in the sera of SLE patients with active disease 
compared with patients with inactive disease (Sakurai et al., 1982). Furthermore, 
homozygous hereditary deficiencies in several  proteins of the classical pathway of 
complement activation are proposed to be strongly associated with the development of 
SLE, the most severe disease being associated with deficiencies in the C1q complex protein 
components and C4 protein deficiency (Pickering et al., 2000; Walport, 2002). 
 
1.2.2.4  Environmental factors associated with SLE pathogenesis 
 
The fact that SLE is predominantly a female disease means that sexual dimorphism forms 
the basis of much investigation into the origin of the disease. This has provoked a body of 
work investigating the involvement of estrogen in SLE, where roles have been 
demonstrated for estrogen in modulation of lymphoid cell growth, differentiation, 
proliferation, antigen presentation, cytokine production and antibody production 
(McMurray, 2001). There is also evidence to suggest that bacterial, viral and parasitic 
infections may play a role in triggering or the exacerbation of SLE (Bach, 2002). Exposure 
to Epstein-Barr virus (EBV) is highly associated with SLE development, where it has been 
described that some patients with SLE harbour EBV-containing B cells in peripheral 
circulation, and EBV-DNA is frequently detected in oropharyngeal secretions (James et al., 
2001). However, EBV infects activated B cells and it is therefore difficult to discriminate 
between cause and effect. Vaccinations have also been linked with SLE development 
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(Aron-Maor and Shoenfeld, 2001), exemplified by the development of lupus nephritis in a 
female following hepatitis B vaccination (Santoro et al., 2010). Other environmental 
factors considered to possibly play a role in SLE development include the exposure to 
chemicals such as aromatic amines, hydrazines, hair dyes and tobacco smoke (Molina and 
Shoenfeld, 2005).  
 
1.2.3  The genetic basis of SLE 
 
Genetic background can influence the risk of an individual developing SLE, illustrated 
from studies involving monozygotic and dizygotic twins and other siblings which exhibit 
concordance rates of greater of 24% and 2-5% respectively (Deapen et al., 1992). Since 
2008, numerous genome wide association studies (GWAS) have been performed in patients 
with SLE in various ethnic populations and identified and confirmed the association of 40 
genes/risk loci with SLE development (Cui et al., 2013). 
Numerous genetic polymorphisms associated with human SLE that relate to immune cell 
signalling (Budarf et al., 2011). In 2008, Kozyrev and colleagues applied a genome-wide 
scan of 85,042 single nucleotide polymorphisms (SNPs) and identified an SLE-associated 
nonsynonymous substitution (rs10516487, R61H) in the gene encoding the B-cell adaptor 
protein with ankyrin repeats (BANK1) Susceptibility to SLE in European and Asian 
populations has been associated with polymorphisms of the BANK1 gene in both functional 
domains and regulatory sites of the protein (Guo et al., 2009; Kozyrev et al., 2008). BANK1 
consists of 13 tyrosine residues susceptible to phosphorylation. BANK1 is bound by LYN 
and SYK and is required for the optimal induction of Ca2+ mobilisation by LYN-mediated 
phosphorylation of type I and II IP3 receptors. Although BANK1 knock-out mice display 
no autoimmune phenotype, BANK1 has also be shown to interact with BLK, also an SLE 
susceptibility allele encoding a tyrosine kinase, both epistatically and at the protein level 
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(Castillejo-Lopez et al., 2012). BANK1 and BLK bind upon BCR stimulation in vitro, and 
together these data suggest a role for these proteins in a potentially biologically relevant 
cell signalling pathway in a disease where hyper B cell activation is a defining feature. 
Such pathways may have a role in the regulation of gene rearrangements events that ensure 
that IGKV segments with undesirable features are not expressed.  
With respect to T lymphocyte genetic risk loci for SLE, there is much interest in the protein 
tyrosine phosphatase, non-receptor type 22 (PTPN22), where identification of a functional 
R620W SNP in exon 14 of PTPN22 was first described in type I diabetes and later 
identified in SLE and RA (Begovich et al., 2004; Bottini et al., 2004; Chung and Criswell, 
2007; Kyogoku et al., 2004). Exon 14 encodes a lymphoid protein tyrosine phosphatase 
(LYP) and the risk polymorphism R620W results in an arginine to tryptophan substitution. 
The resulting gain-of-function variant cannot interact with the negative regulatory kinase 
CSK resulting in unabated intrinsic phosphatase activity. Ultimately T cell activation 
cannot be suppressed. It has also been described that a loss-of-function variant of PTPN22, 
R263Q, conveys a missense substitution within the catalytic domain of LYP that also alters 
its intrinsic phosphatase activity and is also associated with SLE risk (Orru et al., 2009).  
The programmed cell death 1 gene (PDCD1) encodes the immunoinhibitory receptor PD1 
and intronic SNPs within this gene have also been associated with autoimmunity. A SNP 
located in the fourth intron of the gene has been shown to confer an altered binding site for 
the runt-related transcription factor 1 (encoded by the RUNX1 gen) which is a transcription 
factor involved in HSC differentiation (Prokunina et al., 2002). 
Consistent with the IFN signature associated with SLE, the up-regulation of IFN-
responsive genes has also been observed in gene profiling studies of SLE patients (Baechler 
et al., 2004; Crow and Kirou, 2004). Interferon regulatory factor 5 (IRF5) is also associated 
with SLE susceptibility, with an odds ratio (OR) of greater than 1.5. Three functional 
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variants of IRF5 have been described, each having different effects on interferon signalling 
and conferring distinct levels of risk to SLE (Cunninghame Graham et al., 2007; Graham 
et al., 2007).  
Interleukin-1 receptor-associated kinase (IRAK1) is a serine/threonine kinase involved in 
Toll/IL1R (TIR) signalling and has been implicated as an X-chromosome encoded risk 
factor for SLE. Five SNPs spanning the IRAK1 gene were identified in a study of over 
5,000 SLE patients and healthy controls and demonstrated that these SNPs displayed 
disease association in adult- and childhood-onset SLE and across four different ethnic 
groups (Jacob et al., 2009). 
The signal transducer and activator of transcription 4 gene is located on chromosome 2q 
and encodes the STAT4 transcription factor. STAT4 is typically a latent cytosolic protein 
but is activated by several cytokines including type I IFN, IL-12 and IL-23 that are 
predominantly produced by DCs. STAT4 stimulates the transcription of several genes 
involved in regulation differentiation of Th1 and Th17 cell lineages (Nishikomori et al., 
2002; Remmers et al., 2007; Watford et al., 2004). A SNP haplotype in the third intron of 
STAT4 is associated with susceptibility to SLE and RA (Remmers et al., 2007). These 
observations were confirmed in another study that identified that this SNP haplotype was 
associated with a more severe SLE phenotype where nephritis was prevalent (Taylor et al., 
2008). STAT4 risk variants have now been identified in African-American, European, 
Hispanic-American, Asian and Latin-American populations and interestingly, an additive 
effect has been described between STAT4 and IRF5 for increasing predisposition to SLE 
(Abelson et al., 2009; Namjou et al., 2009).  
An SLE risk haplotype has also been identified in the tumour necrosis factor--induced 
protein 3 (TNFAIP3) gene and studies in the context of several autoimmune diseases have 
demonstrated an association with Crohn’s disease, RA and psoriasis (Moser et al., 2009). 
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TNFAIP3 encodes a ubiquitin-editing and zinc finger protein named A20. This protein 
suppresses pro-inflammatory responses mediated via NFB, downstream stimuli induced 
through TLRs, TNFR and IL1R (Boone et al., 2004). Tnfaip3-/- mice exhibit severe 
spontaneous multisystem inflammation and are hyper-responsive to LPS and TNF and fail 
to inhibit TNF-induced NF-B responses (Lee et al., 2000). A recent study involved the 
generation of chimeric mice by crossing Cd19-Cre knock-in mice with mice carrying loxP 
flanked Tnfaip3 alleles to selectively abolish intrinsic expression of A20 in CD19+ B cells. 
These Tnfaip3fl/fl CD19-Cre mice were largely healthy but exhibited reduced CD40 and 
BCR-triggered NF-κB signals and increased generation of autoantibody producing cells 
(Tavares et al., 2010).  
 
1.3  B cells in SLE 
 
Large bodies of evidence implicate virtually all immune cell types in the pathogenesis of 
SLE. This undoubtedly reflects the complexity of the condition and difficulty in 
understanding if differences in cell phenotype and behaviour are a cause or consequence of 
the disease. What is acknowledged however, is that SLE involves a profound breakdown 
in B cell tolerance accompanied by chronic B cell hyperactivity and the production of 
autoantibodies, where multiple factors thought to be involved in disease pathogenesis and 
are not mutually exclusive and are unique to each patient.  
 
1.3.1  B cell tolerance checkpoints in SLE 
 
Two discrete checkpoints in early B cell tolerance have been shown to be responsible for 
the removal of autoreactive B cells in healthy subjects. These checkpoints were overcome 
in three untreated adolescent patients with SLE (Wardemann et al., 2003; Yurasov et al., 
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2005). This study involved the isolation of single early emigrant B cells 
(CD19+CD10+IgM+CD27-) and mature naive B cells (CD19+CD10-IgM+CD27-) from three 
SLE patients the subsequent production of cDNA libraries. This allowed for the cloning 
and expression of a total of 222 SLE-antibodies and subsequent screening for their 
autoreactivity by HEp-2 cell lysate ELISA. Compared to healthy controls where HEp-2 
reactive antibodies were detected in 40.7% and 20.4% of new emigrant and mature naive 
B cells respectively, SLE HEp-2 reactive antibodies similarly accounted for 40.5-59.4% 
new emigrant B cells, however 41.5-50% of the antibodies produced by mature naive SLE 
B cells bound HEp-2. These data suggest a failure of a checkpoint between early emigrant 
and mature B cells in SLE (Yurasov et al., 2005).  The following year, the same group 
examined the same B cell tolerance checkpoint in six SLE patients in clinical remission 
through the cloning of 278 antibodies from mature naïve B cells and subsequent analysis 
of their HEp-2 cell lysate binding capacity.  Despite individual variability, mature naïve B 
cells from SLE patients in remission retained increased autoreactivity compared to 
controls, though the HEp-2 reactivity observed was lower than that of patients with active 
disease (Yurasov et al., 2006).  
A tolerance checkpoint in late B cell development has also been described. It has been 
shown that the spleen and BM of non-autoimmune, healthy mice carry high frequencies of 
ribonucleoprotein Smith (Sm)-specific pre-plasma cells (pre-PCs). Autoantibodies to Sm 
antigen are commonly detected in human SLE patients and have been associated with a 
higher risk of renal involvement (Alba et al., 2003). These Sm-specific pre-PCs were found 
to be predominantly located at the T/B cell borders and had phenotypic characteristics of 
PC differentiation, though the Sm-specific pre-PCs were not autoantibody secreting and 
had a higher frequency of cell death compared to other non-Sm binding pre-PCs (Culton et 
al., 2006). This apparent regulation of autoimmunity took place prior to detection of B 
lymphocyte-induced maturation protein-1 (Blimp-1) expression, which drives terminal 
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differentiation of B cells into PCs (Shaffer et al., 2002). These findings suggest the 
existence of a tolerance checkpoint before the terminal differentiation of pre-PCs to mature 
PCs. Interestingly, this peripheral checkpoint was found to be deficient in lupus-prone 
MRL/lpr mice (Culton et al., 2006).  
 
1.3.2  B cell phenotypes in SLE 
 
The main characteristics of disturbed B cell homeostasis in SLE is the expansions in 
CD24hiCD38hi transitional, switched-memory and CD27++ plasma cell populations in 
peripheral blood and an immature B cell repertoire that is predominantly self-reactive 
(Dorner et al., 2011b; Jacobi et al., 2008; Jacobi et al., 2009; Odendahl et al., 2000; 
Wardemann et al., 2003).  Features of SLE B cell subsets will be described in greater detail 
in the following sections. 
 
1.3.2.1   Transitional B cells in SLE 
 
Transitional B cells are present at a frequency of approximately 2-3% in healthy peripheral 
blood, though they are increased to approximately 6-7% as a proportion of whole peripheral 
blood in SLE patients (Sims et al., 2005). As described in section 1.1.8.2, human T2 
transitional B cells have been shown to be selectively recruited to GALT where they 
acquire an activated phenotype, potentially representing a novel specificity checkpoint 
(Vossenkamper, 2013). Importantly, since SLE is associated with aberrant tolerance 
checkpoints, this study went on to examine the path of T2 transitional B cells in SLE. They 
illustrated that SLE lymphocytes expressed significantly lower levels of 47, implying 
impaired ability to home to gut tissue, and a failure to up-regulate this integrin on SLE 
blood B cells compared to healthy B cells following in vitro stimulation with CpG and 
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retinoic acid. These findings suggest that a failure to access GALT may represent an 
additional aberrant tolerance checkpoint associated with SLE, though it remains unclear 
how these observations relate to individual disease phenotypes. 
 
1.3.2.2   Naïve, memory and plasmablast subsets in SLE 
 
Patients with SLE tend to have marked B lymphocytopenia that affects the naïve 
CD19+CD27- B cell pool more than the CD19+CD27+ memory B cell populations. This is 
thought to be the source of the increased proportion of CD27+ peripheral B cells observed 
in SLE rather than expansion of the CD27+ subset itself (Odendahl et al., 2000). Despite 
increased frequencies of CD27++ peripheral B cells detected in both active and inactive SLE 
patients compared to healthy donors, the absolute numbers of CD27++ plasma cells 
(CD38+CD19dimsIgloCD20-CD138+) were increased only in the peripheral blood of SLE 
patients with active disease. The CD27++ cell population was rarely observed in the 
peripheral blood of healthy control subjects. In addition, following immunosuppressive 
therapy, it is the CD27++ plasma cells and naïve CD27- B cell pools that become markedly 
decreased in peripheral blood compared to similar patients that were untreated (Odendahl 
et al., 2000). Furthermore, the CD27++ B cell subset significantly correlates with disease 
activity and anti-dsDNA antibody titres (Jacobi et al., 2003) 
 
It has been reported that IgD-CD27- B cells are a heterogeneous memory B cell population 
expressing IgM, IgG or IgA that are associated with increased renal disease, the presence 
of autoantibodies and disease activity in SLE patients (Wei et al., 2007). The nature of these 
IgD-CD27- memory B cells  has been explored in SLE and it has been suggested that CD95 
may help to identify them as a homogenous memory B cell population associated with SLE 
since the IgD-CD27-CD95+ cell surface phenotype excludes CD10+ transitional B cells 
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(Jacobi et al., 2008). They too observe that this memory B cell subset is increased in SLE 
patients with disease flares. 
 
1.3.2.3   Regulatory B cells in SLE 
  
Our increasing understanding for the roles of B cells with regulatory capacity in the control 
of autoimmunity make them highly interesting therapeutic targets, where enrichment of 
these populations or enhancement of their suppressive capacity is a current therapeutic goal 
(Blair et al., 2009). Regulatory B cells have been implicated in the amelioration of several 
autoimmune conditions in both mouse models and human subjects. The T2-MZP B cells 
subset previously mentioned is thought to contain IL-10-producing B regulatory cells, and 
it has been shown the transfer of in vitro anti-CD40 generated T2 B cells (T2-like-Bregs) 
improve renal disease and survival in lupus prone MRL/lpr mice by a mechanism 
dependent on IL-10 (Blair et al., 2009). CIA chimeric mice lacking IL-10-producing B cells 
have also been shown to exhibit exacerbated arthritis compared to WT controls, and 
comparably increased populations of T cells with Th1 and Th17 phenotypes, suggesting 
that the IL-10 producing B cells can play a prominent immunoregulatory role in an 
inflammatory environment (Carter et al., 2012).  
 
Studies using human CD19+CD24hiCD38hi regulatory B cells isolated from SLE patients 
have demonstrate that this subset tend to produce less IL-10, be refractory to CD40 
stimulation and have an impaired suppressive capacity compared to healthy equivalents 
(Blair et al., 2010). Human regulatory B cells from healthy subjects have also been shown 
to hold the capacity to suppress CD4+CD25- T cell proliferation and their secretion of TNF-
 and IFN- by conversion into functionally suppressive TREGS cells, in part due to the 
action of IL-10 (Flores-Borja et al., 2013). The similar CD19+CD24hiCD38hi B cell subset 
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isolated from RA patients failed to generate functional TREGS from CD4+CD25 T cells, 
though this has yet to be demonstrated in SLE.  
 
1.3.3   Immunoglobulin light chains in SLE 
 
Both at the genetic level and level of expression, the human immunoglobulin light chain 
repertoire displays preferential usage of some IGKV and IGKL gene segments. In light of 
this observation, several studies have investigated the contribution of molecular events that 
underlie the expression of protein Ig during B cell repertoire development (Dorner et al., 
1998; Foster et al., 1997). The IGK light chain repertoire of healthy individuals was 
examined during an analysis of more than 350 productive and 250 non-productively 
rearranged IGK gene sequences that were cloned and sequenced from single FACS-sorted 
cells. Non-productive rearrangements of IGK are not transcribed and translated into protein 
so studying them reflects the inherent VJ rearrangements during the development of a B 
cell, and as a result they have no influence over the fate of the B cell (Foster et al., 1997). 
This study observed the preferential usage of six IGKV gene segments; IGKV3-20 (A27), 
IGKV3-15 (L2), IGKV3-11 (L6), IGKV2-30 (A17), IGKV1-5 (L12a) and IGKV1-39/1D-39 
(O12/O2). J1 and J2 usage was also overrepresented and accompanied by an 
underrepresentation of J3 and J5 within non-productive rearrangements, suggestive of a 
molecular decision for this bias. A consistent CDR3 length was observed in both productive 
and non-productive rearrangements of IGK genes (Foster et al., 1997). 23% of productive 
VJ rearrangements carried somatic hypermutations, in contrast to the non-productively 
rearranged VJ sequences where just 7% of these were mutated, reflecting functional 
activation by the KDE (Foster et al., 1997). Several of these observations were also shown 
in a similar study of the same year that  analysed 103 rearranged sequences of IGK  
following cloning from the cDNA isolated from healthy PBMCs where 65% of the 
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sequences involved usage of IGKV3-20 (A27), IGKV3-11 (L6), IGKV3-15 (L2) and 
IGKV2D-28 and/or IGKV2-28  (Juul et al., 1997).  
 
A study investigating the contribution of receptor editing to SLE pathogenesis analysed the 
IGKV gene segments usage by CD19+ B cells isolated from an untreated male SLE patient. 
They observed no difference in either IGKV or IGKJ gene segment usage in rearrangements 
that were non-productive compared to equivalent rearrangements of a healthy adults 
(Dorner et al., 1998). However, over-representation of IGKV1D-16, IGKV1-37/1D37 and 
IGKV4-1 was observed in the productively rearranged IGKV repertoire of this patient 
compared to healthy equivalent rearrangements. Interestingly, over-representation of 
IGKV4-1 was observed at the level of expression only, since this bias was not observed in 
the non-productive IGKV rearrangements, suggesting that the inherent Ig gene 
rearrangement process robust in this SLE patient. Increased usage of the IGKJ5 segment 
compared to healthy controls was also found in the expressed kappa light chain repertoire 
of this patient, suggesting more apparent receptor editing of light chains in this individual 
with SLE.  
 
As described in section 1.3.1, a study of B cell tolerance checkpoints in the context of SLE 
involved the cloning of antibodies from cDNA libraries produced from the single cells 
isolated from three untreated SLE patients. Alongside examination of self-reactivity at 
different stages of B cell development, Ig gene usage was also studied (Yurasov et al., 
2005). As observed previously, an over-representation of the gene segment IGKV4-1 was 
observed in the expressed repertoire of newly emigrated and mature naive B cells from two 
of the three SLE patients. A study the following year examined the frequency of somatic 
mutations in groups of productive and non-productive IGK rearrangements sequenced from 
CD19+ B cells from an SLE patient. Compared to healthy donors, a statistically significant 
increase in mutational load was observed in the non-productively rearranged repertoire 
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(Dörner et al., 1999). This group of sequences theoretically should be unmutated since the 
inactivating rearrangement of the KDE deletes the IGKC segment and the enhancers 
flanking it (Das et al., 2009). Significantly increased frequencies of mutations were also 
observed within the productively rearranged sequences, suggesting that enhanced 
mutational activity may be a feature of this SLE patient’s disease. Interestingly, the 
frequency of mutations within the non-productive IGK rearrangements in this SLE patients 
was greater than those observed in the groups of productive rearrangements (Dörner et al., 
1999).  
 
With respect the human IGL light chain repertoire, single cell PCR studies have described 
the over-expression and under-representation of specific IGL gene segments in groups of 
productively and non-productively rearranged sequences (Farner et al., 1999).  These data 
provide further evidence for the existence of positive and negative selection mechanism 
underlying development of the Ig repertoire. In addition, enhanced mutational activity has 
been observed within productive and non-productively rearranged sequences isolated from 
the CD19+ Ig+ B cells of an SLE patient, suggesting globally aberrant light chain 
mutational activity in SLE (Dorner et al., 2001). 
 
1.3.4  Diagnosis of SLE 
 
There is no single diagnostic test for SLE, though the hallmark of the disease is the presence 
of circulating autoantibodies targeted against an array of intracellular antigens. Examples 
include anti-nuclear antibodies (ANAs), anti-dsDNA, anti-Ro, anti-Sm, anti-RNP, anti-La 
which are frequently detected years prior to the onset of the clinical pathologies associated 
with the disease (Arbuckle et al., 2001). New diagnoses are made based on clinical 
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assessment and fulfillment of just 4 of 11 classification criteria established by the American 
College of Rheumatology (Criswell, 2008; Hochberg, 1997; Tan et al., 1982).  
 
Since no single biomarker adequately marks disease activity. SLE disease activity is 
assessed by a number of clinical indices. Two commonly used disease activity score indices 
used are the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and British 
Isles Lupus Assessment Group (BILAG) index (Yee et al., 2008). These scores have since 
been updated and improved to the (SLEDAI)-2000 index and the (BILAG)-2004 index 
following revisions.  The SLEDAI scoring system of 24 items and is used as a global 
measure of SLE disease activity, 8 of which are represented by laboratory results such as 
blood counts, complement component levels and autoantibody titres. The remaining 16 
include clinical manifestations such as arthritis, mouth sores, muscle weakness and 
neurological disturbances. All scores are assigned based on whether these features are 
present or absent in the previous 10 days prior to consultation (Gladman et al., 2002).  
 
The BILAG index attempts to capture varying degrees of change in severity of different 
organs or systems simultaneously involved (Isenberg, 2007). Clinical features that 
constitute the most active form of disease in an organ or system are designated the A (for 
action) clinical score. Groups of clinical features that reflect ongoing but reduced levels of 
disease activity are assigned a clinical score of B (for Beware); a clinical score of C (for 
Contentment) aims to acknowledge mild disease that requires symptomatic treatment only 
and a clinical score of D (for Discount) marks individual organs and systems that were 
once, but are no longer active. An E (for no Evidence) is assigned to organs or systems that 
have never been a feature of the patients’ disease (Isenberg, 2007). This scoring system 
was designed to provide a testable hypothesis of whether a patient should be treated with 
larger doses of immunosuppressive drugs.  A recent assessment compared the reliability of 
both the SLEDAI-2000 and BILAG-2004 indices to conclude that the BILAG-2004 index 
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was more able to indicate a requirement for increased treatment in patients with active SLE 
(Yee et al., 2008). 
 
1.3.5    B cell targeted therapies in SLE 
 
The range of therapies used to treat SLE are largely immunosuppressive and the 
consequence of the clinician’s judgment of individual patients. Immunosuppressive 
treatments include powerful cytotoxic drugs such as azathioprine, mycophenolate mofetil 
and cyclophosphamide, though these regimes are non-specific and pose significant risk of 
infection (Yong and D'Cruz, 2008). The anti-malarial hydroxychloroquine (HCQ) is also a 
commonly administered SLE treatment. A recent study has demonstrated that early 
treatment of patients with HCQ suffered from less disease-associated damage three years 
after diagnosis (Akhavan et al., 2013). These treatments do not target specific pathways 
relating to SLE pathology. A large focus of study into new therapies for SLE patients 
predominantly aims at targeting B cells due to their wide range of effector functions, being 
not only responsible for the production of autoantibodies, but presenting antigen to other 
immune cells and producing a cocktail of cytokines which are immunoregulatory or 
immunogenic in certain environments (Townsend et al., 2010).   
 
Rituximab (RTX) is a chimeric monoclonal anti-CD20 antibody that has become a 
mainstay in the therapy of a broad variety of B-cell malignancies. Over the last decade it 
has become more frequently administered to patients with a variety of autoimmune 
disorders, including use in the treatment of SLE patients with severe disease who are 
refractory to immunosuppressive therapy. Although the mechanism of B cell depletion by 
RTX is poorly defined, it is thought to induce complement-dependent cytotoxicity 
following recognition of rituximab-coated CD20+ B cells (B cell precursors from the pre-
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B cell stage onwards and mature B cells)(Vossenkamper et al., 2012). Rituximab treatment 
is also thought to initiate antibody-dependent cell-mediated cytotoxicity (ADCC) mediated 
by NK cells (Weiner, 2010).  
 
The effectiveness of Rituximab has been investigated in several open-label prospective and 
retrospective studies.  A review of studies involving 188 rituximab treated SLE patients 
identified that 171 (91%) demonstrated a significant improvement in one or more of their 
SLE clinical manifestations following treatment. However, 46 of these patients relapsed, 
despite 80% of those relapsing having demonstrated a clinical response to the initial 
treatment (Ramos-Casals et al., 2009). Furthermore, Phase III randomised controlled trials, 
the EXPLORER (non-renal SLE) and LUNAR (lupus nephritis SLE) trials did not 
demonstrate superior outcome of rituximab treatment over standard therapies (Merrill et 
al., 2010; Vossenkamper et al., 2012). B cell depletion was however associated with 
statistically significant improvement in several serological markers of disease activity such 
as dsDNA titres and complement C3 levels (Vossenkamper et al., 2012). The re-population 
of peripheral B cells following rituximab treatment has been reported to take place between 
6 and 10 months following depletion and bears similarities with the B cell repopulation 
observed following BM transplantation (Anolik et al., 2007; Bemark et al., 2012). During 
reconstitution of the B cell pool in lymphoma patients following RTX-induced B cell 
depletion, the majority of cells have an immature and transitional phenotype (Abulayha et 
al., 2010; Anolik et al., 2007).  
 
Belimumab, the first new drug to be approved for the treatment of SLE in 50 years, and 
represents the first biological agent to be licensed for the treatment of auto-antibody 
positive adult SLE (Lutalo and D'Cruz, 2012). Belimumab is a fully humanized monoclonal 
antagonist antibody that targets and inhibits the action of the B cell survival factor BLyS, 
or BAFF. BAFF is found in high concentrations in the serum of SLE patients (Liu and 
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Davidson, 2011; Pers et al., 2005). (Vossenkamper et al., 2012).  A study investigating the 
long-term effects of BLyS inhibition monitored 17 patients undergoing Belimumab 
treatment alongside standard treatment regimen. Between days 84 and 168 B cell 
frequencies fell to below baseline levels and flow cytometry analysis revealed that this was 
a result of a decrease in naive and transitional B cells, with CD27+IgD+ memory cells and 
plasmablasts decreasing only after day 532. CD27+ IgD- cells and T cell subsets were found 
to be unchanged during the course of treatment (Jacobi et al., 2010).   
 
1.3.6   Serum free light chains 
 
The clonal overproduction of immunoglobulin light chains is associated with a variety of 
hematological malignancies. These light chains circulate without covalent association to Ig 
heavy chains and can readily be detected in peripheral blood and urine (Davids et al., 2010). 
It is thought that monitoring FLCs is a useful measure of disease activity due to the short 
half-lives of Ig and Iglight chains in blood; 2-4 and 3-6 hours respectively, compared 
with their half-life of approximately 21 days when in intact Ig molecules (Davids et al., 
2010). A recent study compared serum free light chain (FLC) levels in 75 patients with 
SLE and the same number of patients with RA, and also compared these against other 
biomarkers of SLE, such as dsDNA Ab titres. They reported that FLC was higher in SLE 
than RA; both were higher than FLC levels of healthy controls. Total FLC showed 
moderate to strong correlation with SLEDAI, proposing the use of serum FLC analysis as 







1.4   Study aims  
 
This thesis seeks to explore the human immunoglobulin kappa light chain repertoire in 
health and the context of the chronic autoimmune disease SLE.  
Chapter 3 examines the origin of the light chain biases previously observed in SLE by a 
high-throughput sequencing approach. This investigation was designed to assess the 
inherent usage of IGKV and IGKJ gene segments by the mature naïve B cell repertoire of 
three healthy individuals and three SLE patients. These data were gathered from 
amplification of IGK rearrangements from gDNA of sorted B cell populations.  Rearranged 
IGK transcripts were also amplified from the cDNA of populations of sorted B cells in 
order to examine IGKV and IGKJ gene usage within the expressed light chain repertoire 
both in health and SLE.  
Chapter 4 investigates the rearrangement of the kappa deleting element, a mechanism that 
functionally inactivates rearranged kappa light chains that are in the incorrect genetic 
reading frame, or encode unwanted specificities. The frequency of KDE rearrangements in 
health and SLE have been analysed, alongside examination of the nature of KDE 
rearrangement junctions. 
Chapter 5 investigates the cell surface expression of immunoglobulin light chains by 
healthy and SLE CD19+ B cells, and brings together the data presented in chapters 3 and 4 
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2.1   SLE patients and peripheral blood samples 
 
SLE patients attending clinic at the Louise Coote Lupus Unit at St. Thomas’ Hospital were 
invited to participate in the study following written informed consent from the KCL 
Infectious Diseases BioBank working under the authority of the Southampton and South 
West Hampshire Research Ethics Committee (REC Approval: REC09/H0504/39 – The 
Control of Inflammation in Immunity and Autoimmunity; IDB ref JS-1b). All SLE patients 
collected fulfilled the American College of Rheumatology classification criteria, with at 
least four of the 11 criteria are present, serially or simultaneously (Hochberg, 1997). 
Information on organ involvement, auto-antibody titres and disease duration were also 
recorded, alongside any treatments each patient had once been prescribed. The clinical 
information of each patient studied can be found in Appendix 2. All SLE patients studied 
were female. Peripheral blood samples were collected in vacutainers (BD) containing 
K2EDTA. The buffy coats of all healthy subjects studied were purchased from the Blood 
Transfusion Service, Tooting, UK. 
 
2.1.1   PBMC isolation 
 
Fresh blood samples were diluted 1:1 with RPMI medium + 10% FCS prior to layering 
approximately 35 ml over 15 ml Ficoll-Hypaque solution in a 50 ml Falcon tube. Tubes 
were centrifuged for 25 mins at 400g with slow acceleration and without brakes. Peripheral 
blood mononuclear cells (PBMCs) were removed from the Ficoll/plasma interface and 
washed in ~4°C  RPMI medium + 10% FCS for 5 mins at 1200 rpm. The supernatant was 
removed and cell yield was approximated by means of a hemocytometer. Cells not to be 
used immediately were re-suspended in FCS supplemented with 10% DMSO (freezing 
medium) at an appropriate volume for storage in 2 ml cryovials at an approximate 
frequency of 5x106 cells/ml. 
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2.2   Working Solutions 
 
Autoclaved phosphate buffered saline (PBS) solution was used throughout this study at a 
working dilution of 1X, its applications including immunostaining of PBMCs, cell sorting 
and DNA isolation.  
 
10X PBS: 80 g NaCl, 2 g KCl, 14.4 g Na2HPO4 and 2.4 g KH2PO4 (all Sigma, UK) were 
dissolved in 800 ml dH20 and the pH adjusted to 7.4 with concentrated HCl. Before 
autoclaving, the final volume was increased to 1 L with dH20.  
 
2.2.1   Solutions for High-Throughput Sequencing 
 
2.2.1.1 Sort-Lysis RT Buffer (SLyRT) Buffer: 180 l of this buffer was used to re-
suspend B cell populations following cell sorting. For single cells sorting, individual cells 
were sorted into 96-well plates containing 18l SLyRT buffer per well.  
 
Table 2.1 Recipes and concentrations for preparation of SLyRT buffer 













First-Strand RT buffer (Invitrogen) 5X 8 400 1X 
pd(N)6  (QIAGEN)  50 ng/µl 12 600 15 ng/µl 
Triton X-100 (Sigma) 5% 1 50 0.13% (v/v) 
RiboSafe RNase inhibitor (40U/ml, Bioline) 40 U/µl 2.5 125 2.5 U/µl 
DTT ( Invitrogen) 0.1 M 4.5 225 11.25 mM 
dNTP mix (Promega) 10 mM each 2 100 500 µM 







2.2.2   Solutions for Agarose Gel Electrophoresis 
 
2.2.2.1  50X  Tris/Acetate/EDTA (TAE) buffer:  242 g TRIS Base, 57.1 ml glacial 
acetic acid, 100ml 0.5M EDTA (all Sigma, UK) were dissolved in 800 ml of dH20 and 
made up to 1 L following complete dissolution. Final 1X working concentration: 0.04M 
Tris-acetate, 0.001M EDTA.   
 
2.2.2.2  10X Tris/Borate/EDTA (TBE) buffer: 108 g Trizma base, 55 g boric acid and 
8.3 g EDTA (all Sigma, UK) were dissolved in 800 ml of dH20 and made up to 1 L 
following complete dissolution. 10X TBE stock buffer was diluted 1:10 to make up a 1X 
working TBE solution. 
 
2.2.2.3  Ethidium Bromide stock (0.5 l/ml): 10 mg ethidium bromide was dissolved 
in 1 ml dH20 was diluted 1:20 with 1X TBE to make up a working solution of 50 ng/100 
ml. 
 
2.2.2.4   Gel loading buffer: 40 g sucrose, 0.25 g bromphenol blue and 0.25 g xylene 
cyanole were dissolved in 100 ml ddH20. 
 
2.2.3   Solutions for Flow Cytometry and cell culture studies 
 
2.2.3.1 RPMI-1640 medium: RPMI-1640 medium containing 1% L-glutamine (Gibco) 
was supplemented with 1% PenStrep (Sigma), 1% Amphotericin B and 10% heat 
inactivated FCS at 56 °C for 30 minutes. 
 
2.2.3.2  FACS buffer:   2 % Fetal Calf Serum (FCS) (seraLab) in 1X PBS. 
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2.2.3.3  Glycine wash buffer pH 3.0:   0.2M glycine solution was  adjusted to pH3 
with acetic acid 
 
2.2.3.4  RPMI-1640 acidic wash buffer pH 2.5:   1640 medium containing 1 % L-
glutamine (Gibco) was adjusted to pH 2.5 with acetic acid. 
 
2.2.2.5  Phorbol myristate acetate (PMA):  PMA was used to stimulate B cells in co-
culture with allogeneic CD3+CD4+ T cells at a concentration of 50ng/ml. 
 
2.2.4   Solutions for Cloning 
 
2.2.4.1 LB agar: 1g Tryptone (DIFCO), 0.5g Yeast Extract (DIFCO), 0.5g NaCl (Sigma) 
and 1.5g Bacto agar (BD) were dissolved in 100ml dIH20 and the solution autoclaved at 
120°C for 20 minutes to sterilise. The agar was allowed to cool for 15 minutes before 
adding 200 l 0.5 l/ml ampicillin (Sigma), 200 l 0.5 l/ml X-Gal (Promega) and 0.5 ml 
IPTG. The solution was swirled to mix the reagents and subsequently 20 ml was pipetted 
into petri dishes prior to blue/white screening of cloned PCR products. Prior to sending off 
individual clones for sequencing, the same LB agar was produced though only 200 l 0.5 
l/ml ampicillin was added to the autoclaved LB and 200 l added to each well of a 96-
well plate. 
 
2.2.4.2   SOC medium:  2.0g Tryptone (DIFCO), 0.5g Yeast Extract (DIFCO), 1 ml 1M 
NaCl (58.44g/L) and 0.25 ml 1M KCl (74.55g/L) were dissolved in 97 ml dH20 and the 
solution was autoclaved at 120°C for 20 minutes to sterilise before allowing to cool. 1ml 
2M Mg2+ stock   (1M MgCl26H20/1M MgSO47H20, filter-sterilised and 1ml 2M sucrose) 
was added and made up to 100 ml with sterile dIH20.  
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2.2.4.3   Isopropylthio-β-galactoside (IPTG) stock (0.1M): 0.6 g IPTG (Promega) 
was added to 20ml dIH20 and the solution was sterilised by filtering through a 0.22µM 
filter. Aliquots were stored at -20°C. 
 
2.2.4.4 Ampicillin stock (50mg/ml):  1g ampicillin (Sigma) was added to 20ml dIH20 
and the solution was sterilised by filtering through a 0. 22µM filter. Aliquots were stored 
at -20°C. 
2.3   Preparation of high-throughput sequencing (HTS) 
samples 
 
2.3.1   B-cell isolation and cell sorting 
 
Peripheral blood mononuclear cells (PBMCs) were isolated from 3 anonymous healthy 
single donor buffy coats obtained from the blood transfusion service and 3 SLE patients 
using Ficoll-Paque Plus (GE Healthcare). Samples from patients with SLE were collected 
through the King’s College London Infectious Diseases Biobank (IDB) and written consent 
was obtained in accordance with Guy’s Hospital research ethics committee.  The SLE 
patients were females aged 40 (Afro-Caribbean, 12 years history of SLE, ANA+, treated 
with mycophenolate mofetil and hydroxychloroquine), 59 (Caucasian, 4 year history of 
SLE, ANA+, treated with Leflunomide) and 32 (Caucasian, 3 year history of SLE, ANA+, 
treated with prednisolone and hydroxychloroquine).  
 
PBMCs were stained with CD19-PerCP-Cy5.5, Ig light chain-APC-H7 (BD Biosciences 
PharMingen) and Ig light chain-Pacific Blue (Biolegend) and LIVE/DEAD Fixable Aqua 
(Life Technologies) for 15 mins at 4°C before cell sorting on the FACSAria machine (BD 
Biosciences PharMingen.) CD19+, single Ig+ and Ig+ expressing B cells were collected 
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separately into 180 l of Sort-Lysis RT buffer (SLyRT).  Unlike healthy control samples, 
SLE cases did not always show clear segregation of Ig- and Ig-expressing cells due to 
apparent light chain inclusion in some cases (Fraser et al, unpublished).  The cases used in 
this study were those where discrete Ig- and Ig-expressing populations could be isolated. 
 
2.3.2   HTS primer sequences for V-J (gDNA) and V-C (cDNA) 
amplification from sorted B cell populations 
 
HTS PCR amplification of gDNA and cDNA was performed in two rounds, where the same 
primer sequences were used in both reactions, though the second round PCR primers were 
MID-tagged, for subsequent identification of cell subsets and the individuals they were 
derived from. Designation of MID primers is described in detail in Chapter 3. 
 
Table 2.2 Sequences of PCR primers used for first round amplification of IGK 




















Primer sequence (first 10 nucl. MID tag) 
 PCR2 
primer ID 
Primer sequence (first 10 nucl. MID tag) 
 PCR2 
primer ID 
Primer sequence (first 10 nucl. MID tag) 
  
MID1 VK1 acgagtgcgtCATCCAGWTGACCCAGTCTCC  MID4 VK1 agcactgtagCATCCAGWTGACCCAGTCTCC  MID7 VK1 cgtgtctctaCATCCAGWTGACCCAGTCTCC 
MID1 VK2 acgagtgcgtGATATTGTGATGACCCAGWCT  MID4 VK2 agcactgtagGATATTGTGATGACCCAGWCT  MID7 VK2 cgtgtctctaGATATTGTGATGACCCAGWCT 
MID1 VK3 acgagtgcgtGACRCAGTCTCCAGCCACCCTG  MID4 VK3 agcactgtagGACRCAGTCTCCAGCCACCCTG  MID7 VK3 cgtgtctctaGACRCAGTCTCCAGCCACCCTG 
MID1 VK4 acgagtgcgtGACATCGTGATGACCCAGTCT  MID4 VK4 agcactgtagGACATCGTGATGACCCAGTCT  MID7 VK4 cgtgtctctaGACATCGTGATGACCCAGTCT 
MID1 VK5 acgagtgcgtGAAACGACACTCACGCAGTCT  MID4 VK5 agcactgtagGAAACGACACTCACGCAGTCT  MID7 VK5 cgtgtctctaGAAACGACACTCACGCAGTCT 
MID1 VK6 acgagtgcgtGAAATTGTGCTGACTCAGTCT  MID4 VK6 agcactgtagGAAATTGTGCTGACTCAGTCT  MID7 VK6 cgtgtctctaGAAATTGTGCTGACTCAGTCT 
MID1 JK1/4 acgagtgcgtTCCACCTTGGTCCCTYSGCCG  MID4 JK1/4 agcactgtagTCCACCTTGGTCCCTYSGCCG  MID7 JK1/4 cgtgtctctaTCCACCTTGGTCCCTYSGCCG 
MID1 JK2 acgagtgcgtCTCCAGCTTGGTCCCCTGGCCA  MID4 JK2 agcactgtagCTCCAGCTTGGTCCCCTGGCCA  MID7 JK2 cgtgtctctaCTCCAGCTTGGTCCCCTGGCCA 
MID1 JK3 acgagtgcgtATCCACTTTGGTCCCAGGGCCG  MID4 JK3 agcactgtagATCCACTTTGGTCCCAGGGCCG  MID7 JK3 cgtgtctctaATCCACTTTGGTCCCAGGGCCG 
MID1 JK5 acgagtgcgtCTCCAGTCGTGTCCCTTGGCCG  MID4 JK5 agcactgtagCTCCAGTCGTGTCCCTTGGCCG  MID7 JK5 cgtgtctctaCTCCAGTCGTGTCCCTTGGCCG 
MID1 IGKC acgagtgcgtCCTTCCACTGTACTTTGGCCTC  MID4 IGKC agcactgtagCCTTCCACTGTACTTTGGCCTC  MID7 IGKC cgtgtctctaCCTTCCACTGTACTTTGGCCTC 
MID2 VK1 acgctcgacaCATCCAGWTGACCCAGTCTCC  MID5 VK1 atcagacacgCATCCAGWTGACCCAGTCTCC  MID8 VK1 ctcgcgtgtcCATCCAGWTGACCCAGTCTCC 
MID2 VK2 acgctcgacaGATATTGTGATGACCCAGWCT  MID5 VK2 atcagacacgGATATTGTGATGACCCAGWCT  MID8 VK2 ctcgcgtgtcGATATTGTGATGACCCAGWCT 
MID2 VK3 acgctcgacaGACRCAGTCTCCAGCCACCCTG  MID5 VK3 atcagacacgGACRCAGTCTCCAGCCACCCTG  MID8 VK3 ctcgcgtgtcGACRCAGTCTCCAGCCACCCTG 
MID2 VK4 acgctcgacaGACATCGTGATGACCCAGTCT  MID5 VK4 atcagacacgGACATCGTGATGACCCAGTCT  MID8 VK4 ctcgcgtgtcGACATCGTGATGACCCAGTCT 
MID2 VK5 acgctcgacaGAAACGACACTCACGCAGTCT  MID5 VK5 atcagacacgGAAACGACACTCACGCAGTCT  MID8 VK5 ctcgcgtgtcGAAACGACACTCACGCAGTCT 
MID2 VK6 acgctcgacaGAAATTGTGCTGACTCAGTCT  MID5 VK6 atcagacacgGAAATTGTGCTGACTCAGTCT  MID8 VK6 ctcgcgtgtcGAAATTGTGCTGACTCAGTCT 
MID2 JK1/4 acgctcgacaTCCACCTTGGTCCCTYSGCCG  MID5 JK1/4 atcagacacgTCCACCTTGGTCCCTYSGCCG  MID8 JK1/4 ctcgcgtgtcTCCACCTTGGTCCCTYSGCCG 
MID2 JK2 acgctcgacaCTCCAGCTTGGTCCCCTGGCCA  MID5 JK2 atcagacacgCTCCAGCTTGGTCCCCTGGCCA  MID8 JK2 ctcgcgtgtcCTCCAGCTTGGTCCCCTGGCCA 
MID2 JK3 acgctcgacaATCCACTTTGGTCCCAGGGCCG  MID5 JK3 atcagacacgATCCACTTTGGTCCCAGGGCCG  MID8 JK3 ctcgcgtgtcATCCACTTTGGTCCCAGGGCCG 
MID2 JK5 acgctcgacaCTCCAGTCGTGTCCCTTGGCCG  MID5 JK5 atcagacacgCTCCAGTCGTGTCCCTTGGCCG  MID8 JK5 ctcgcgtgtcCTCCAGTCGTGTCCCTTGGCCG 
MID2 IGKC acgctcgacaCCTTCCACTGTACTTTGGCCTC  MID5 IGKC atcagacacgCCTTCCACTGTACTTTGGCCTC  MID8 IGKC ctcgcgtgtcCCTTCCACTGTACTTTGGCCTC 
MID3 VK1 agacgcactcCATCCAGWTGACCCAGTCTCC  MID6 VK1 atatcgcgagCATCCAGWTGACCCAGTCTCC  MID9 VK1 tagtatcagcCATCCAGWTGACCCAGTCTCC 
MID3 VK2 agacgcactcGATATTGTGATGACCCAGWCT  MID6 VK2 atatcgcgagGATATTGTGATGACCCAGWCT  MID9 VK2 tagtatcagcGATATTGTGATGACCCAGWCT 
MID3 VK3 agacgcactcGACRCAGTCTCCAGCCACCCTG  MID6 VK3 atatcgcgagGACRCAGTCTCCAGCCACCCTG  MID9 VK3 tagtatcagcGACRCAGTCTCCAGCCACCCTG 
MID3 VK4 agacgcactcGACATCGTGATGACCCAGTCT  MID6 VK4 atatcgcgagGACATCGTGATGACCCAGTCT  MID9 VK4 tagtatcagcGACATCGTGATGACCCAGTCT 
MID3 VK5 agacgcactcGAAACGACACTCACGCAGTCT  MID6 VK5 atatcgcgagGAAACGACACTCACGCAGTCT  MID9 VK5 tagtatcagcGAAACGACACTCACGCAGTCT 
MID3 VK6 agacgcactcGAAATTGTGCTGACTCAGTCT  MID6 VK6 atatcgcgagGAAATTGTGCTGACTCAGTCT  MID9 VK6 tagtatcagcGAAATTGTGCTGACTCAGTCT 
MID3 JK1/4 agacgcactcTCCACCTTGGTCCCTYSGCCG  MID6 JK1/4 atatcgcgagTCCACCTTGGTCCCTYSGCCG  MID9 JK1/4 tagtatcagcTCCACCTTGGTCCCTYSGCCG 
MID3 JK2 agacgcactcCTCCAGCTTGGTCCCCTGGCCA  MID6 JK2 atatcgcgagCTCCAGCTTGGTCCCCTGGCCA  MID9 JK2 tagtatcagcCTCCAGCTTGGTCCCCTGGCCA 
MID3 JK3 agacgcactcATCCACTTTGGTCCCAGGGCCG  MID6 JK3 atatcgcgagATCCACTTTGGTCCCAGGGCCG  MID9 JK3 tagtatcagcATCCACTTTGGTCCCAGGGCCG 
MID3 JK5 agacgcactcCTCCAGTCGTGTCCCTTGGCCG  MID6 JK5 atatcgcgagCTCCAGTCGTGTCCCTTGGCCG  MID9 JK5 tagtatcagcCTCCAGTCGTGTCCCTTGGCCG 
MID3 IGKC agacgcactcCCTTCCACTGTACTTTGGCCTC  MID6 IGKC atatcgcgagCCTTCCACTGTACTTTGGCCTC  MID9 IGKC tagtatcagcCCTTCCACTGTACTTTGGCCTC 




2.3.3   cDNA synthesis and PCR amplification of gDNA and cDNA 
 
Isolation of genomic DNA from populations of sorted cells is described in Section 2.5 of 
this materials and methods chapter. V-Jamplifications were performed from all gDNA 
samples.  
 
To synthesise cDNA from sorted cell populations, cells were centrifuged at 1200rpm for 5 
minutes and the supernatant removed. Cells were re-suspended in 180l of SLyRT buffer 
in a PCR tubes and gently mixed. 20l of 1:8 500U SuperScript III reverse transcriptase 
(RT; Invitrogen) was then added to the cell/SLyRT suspension. The reverse transcription 
was performed at 42°C (10 minutes), 25°C (10 minutes), 50 °C (60 °C minutes) and 72°C 
(15 minutes). V-J and V-C rearrangements were amplified using semi-nested 
polymerase chain reaction (PCR). In PCR1, a 25L reaction mix contained 6.25L of 
cDNA, 0.625U Phusion DNA polymerase (NEB), 200M each dNTPs, 41.75nM each 
upstream IGKV primers, 250nM downstream IGKC primer in 1× reaction buffer. After a 
hot start at 98 °C (for 30 seconds, hold at 50 °C) Phusion DNA polymerase was added, 
followed by 15 cycles of 98 °C, (10 seconds); 58 °C (15 seconds); 72 °C (30 seconds), and 
1 cycle of 72 °C (5 minutes).  
 
PCR2 was then used to amplify from PCR1 products using primers having 10-base 
multiplex-identifier (MID) tails. MID tags enabled 9 different samples to be pooled into 1 
sequencing sample and individual experimental samples were later separated by sequence 
analysis of the MID tags. Twenty l of PCR2 reaction mix contained 2 l of PCR1 
products, 0.5U Phusion DNA polymerase, 200μM each dNTPs, 41.75nM each upstream 
MID: IGKV1-6 primers, 250nM IGKC downstream primer in 1× reaction buffer. PCR2 
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was performed at: 98 °C for (30 seconds), 20 cycles of 98 °C (10 seconds); 58 °C (15 
seconds); 72 °C (30 seconds), and 1 cycle of 72 °C (5 minutes).  Recipe summaries for 
each PCR reaction are provided in Table 2.4 and Table 2.5.  
 
Table 2.4 Recipes and concentrations for HTS first round PCR reactions (without MID tags) 
 
Reagents Stock conc. µl/reaction Final conc. 
GC buffer 5X 5 1X 
1:40 Phusion DNA polymerase 0.125 U/µl 5 0.625 U 
dNTPs 20 mM each 0.25 200 µM  each 
V1-6 (5’) primer mix 835 nM each 
1.25 
41.75 nM each  
VC (3') primer mix 5 µM each + 250 nM 
PCR H20 - 7.25 - 
cDNA - 6.25 ~200 ng 
Volume - 25   
 
 
Table 2.5  Recipes and concentrations for HTS  second round PCR reactions (with MID tags.) 
 
Reagents Stock conc. µl/reaction Final conc. 
GC buffer 5X 4 1X 
1:20 Phusion DNA polymerase 0.25 U/µl 2 0.5 U 
dNTPs 20 mM each 0.2 200 µM  each 
MID: V1-6 (5’) primer mix 835 nM each + 
1 41.75 nM each   
+ 250 nM MID: VC (3') primer mix 5 µM each 
PCR H20 - 10.8 - 
cDNA - 2 - 










2.3.3  Preparation of MID-tagged PCR products  
 
2.3.3.1   General information 
 
In order to obtain sufficient quantities of PCR product for sequencing, first round PCR 
reactions were performed eight times for each DNA sample, from which second round PCR 
reactions were carried out in duplicate (final volume per DNA sample: 20 µl x 16 = 320 
µl.) Total PCR products from 16 second round PCRs of the same MID tag were pooled and 
heated to 95°C for 5 minutes. 
2.3.3.2   Gel electrophoresis of MID-tagged PCR products and purification 
 
For the running of PCR products for high-throughput sequencing, 1x TAE buffer was used 
to prepare a 1.5% agarose gel consisting of 4.5g 3:1 agarose (Flowgen) dissolved in 300ml 
1x TAE (Recipe section 2.2.2.1).  PCR products were run for 40 minutes at 120V and bands 
of target size were extracted using QIAquick Gel Purification Kit (Qiagen). 
 
After determining the concentration of each pooled DNA sample, equal quantities of 
purified PCR products (in ng) from 9 different MID types for each experimental set (control 
and SLE) were passed through QIAquick spin columns to remove any primer carryover 
and to concentrate samples to 50 ng/µl. A minimum of 5 µg purified DNA was required. 
The sequencing was carried out on the GS FLX System by Dr. Gerald Hyakatura and Dr. 
Annett Helfrich-Kröger at LGC Genomics GmBH.  
 
2.3.4  Sequence analysis 
 
Sequences were assigned to the corresponding samples based on the terminal MID 
sequence. Sequences that contained a second MID sequence that was either different, or 
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located internally, were excluded. A series of stringent quality control criteria were applied 
to exclude biologically implausible sequences. IGKV-C rearrangements amplified from 
cDNA were only accepted as biologically plausible if they were over 415 nucleotides in 
length and V-J rearrangements amplified from the DNA of Ig- or Ig-expressing B 
cells were accepted providing they were over 290 nucleotides in length. Sequences that 
failed to start with a MID tag, IGKV with either IGKJ or IGKC were rejected, as were 
sequences with multiple IGKV gene primer motifs.  Identical sequences were identified by 
sorting based on their CDR3 nucleic acid sequences with IGKV and IGKJ gene use as 
secondary identifiers and only one included in the data.  
 
Comparisons involved analysis of contributions of individual IGKV and IGKJ segments to 
the total pool of rearrangements. Since rearrangements of 30 different IGK segments were 
observed in a single data set, groups of sequences were required to contain 300 different 
rearrangements for a single comparison of IGKV segment usage.  Data from different 
individual donors were therefore pooled to give a larger dataset for accuracy. Where it was 
useful for verification using datasets from individual donors we determined that a single 
donor could be analysed alone provided the set for analysis contained more than 300 
different rearrangements.    
 
Analyses were performed in Excel (Microsoft). Proportions were compared using 2 tests 








2.4   Flow cytometry 
 
2.4.1  Protocol 
 
PBMCs were thawed following liquid N2 storage in 1 ml FCS. Following a 5 minute wash 
in 15ml RPMI-1640 medium cells were counted and immunostained in 100µl 2% FCS 
buffer and the appropriate volumes of antibody (See Table 2.6). Cells were stained on ice 











CD19 PerCp-Cy5.5 5l/mil cells 
< 
10million 
Mouse IgG1  PerCP-Cy5.5 BD Pharm 
IgD PE 6l/mil cells Mouse IgG1  PE BD Pharm 
CD27 PE-Cy7 5l/mil cells Mouse IgG1  PE-Cy7 BD Pharm 
CD10 APC 5l/mil cells Mouse IgG1 k APC BioLegend 
CD38 PE 5l/mil cells Mouse IgG1 k PE eBioscience 
IgA FITC 10l/mil cells Mouse IgG1  FITC Miltenyi Biotech 
Ig APC-H7 5l /mil cells Mouse IgG1  APC-H7 BD Pharm 
Ig Pacific Blue 3l /mil cells Mouse IgG2a  APC-H7 BioLegend 
VpreB 











Fluorescence minus one (FMO) controls and appropriate single and isotype controls were 
also stained alongside the cell samples. Titration experiments had previously been 
performed on antibodies to verify the optimal staining concentrations. Following cell 
surface staining, cells were washed in 2ml 2% FCS buffer for 5 mins at 1200 rpm and 4°C. 
A wash step at the same spin conditions but using 2ml 1x PBS was performed prior to 
viability staining with the Live/Dead cell viability stain. All cells were stained for viability 
on ice in 100ml 1x PBS for 30 minutes in the dark. Following staining, cells were washed 
Table 2.6    Mouse anti-human antibodies used for flow cytometry analysis and sorting 
106 
 
in 2ml 2% FCS and cell pellets were re-suspended in 200ml 2%FCS. Cells for sorting were 
sorted into polypropylene FACS tubes containing 1.5ml of 2% FCS buffer. Upon 
completion of cell sorting, cells were centrifuged for 5 minutes at 300g and the supernatant 
removed. 
2.4.2   Analysis 
 
For flow cytometry analysis without sorting, cells were acquired and recorded using the 
FACSCanto (BD). Cell sorting was performed using the FACSAria-II (BD) with sort 
purities >90%. All flow cytometry experiments could be subsequently analysed on Flow 
Jo (V7.5).  
2.4.2.1   Subset phenotypic characterization 
 
The subsets of B cells studied in this thesis are represented in Table 2.7. In most instances 
the gating of these B cell populations was followed by separation of light chain expression, 
kappa and lambda.  
 
 
B cell subset 
Cell surface antigen 
expression levels 
Total B cells CD19+ 
    
Transitional B cells CD19+ IgD+ CD27- CD10hi 
    
Mature naive B cells CD19+ IgD+ CD27- CD10- 
    
Memory B cells CD19+ IgD- CD27+/- CD10- 
    
IgA plasmablasts CD19+ CD38+ CD27hi sIgA+ 
    
Non-IgA plasmablasts CD19+ CD38+ CD27hi sIgA- 
 
Table 2.7    Human B cell subset phenotypic characterisation 
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2.5   Preparation of DNA, RNA and cDNA samples from 
populations of sorted cells 
 
DNA isolated from FACS-sorted populations of B cells was performed using the DNeasy 
Blood and Tissue Kit (Qiagen) where DNA was eluted in 200l elution buffer before 
storage at -20°C prior to use. Isolated DNA from sorted B cell populations was used for all 
qRT-PCR analyses in this study, presented in Chapter 4, and was similarly performed prior 
to sequence analysis of iRSS-KDE junctional analyses (Chapter 4) and VJ 
rearrangements (Chapter 5).  RNA samples were obtained through isolated of RNA from 
FACS-sorted CD19+ B cells using the miRNeasy Mini Kit (Qiagen). To prevent 
contamination of RNA preps during isolation, all equipment to be used was exposed to UV 
light for 20 minutes in a hood designated to RNA isolation. Newly extracted RNA samples 
were immediately stored at -80°C and were kept on ice during preparation of reverse 
transcription. 
 
2.5.1   Reverse transcription of RNA isolated from sorted B cell 
populations 
 
Reverse transcription of isolated RNA samples to cDNA was performed using Oligo dT 
primer and an M-MLV Reverse Transcriptase kit (both Promega). Each reverse 
transcription contained the following volumes of RT reagents: 7l RNA sample, 3l 
molecular standard PCR H20 and 1l Oligo dT primer. Reagents were mixed gently prior 
to incubation at 70°C for 10 minutes. RT reactions were subsequently removed and allowed 
to cool on ice for 10 minutes before centrifuging for 1 minute to collect any products that 
had condensed around the PCR tubes during incubation. Following this, the addition of a 
4l M-MLV buffer, 0.5l dNTPs, 0.5l RNase inhibitor, 1l M-MLV Reverse 
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Transcriptase (all Promega) and 3 l dH20 were added to give a final volume of 20l. The 
reactions were incubated for a further 1 hour at 42 °C. A final extension period of 15 
minutes at 70°C was applied to the samples and held at 15 °C before use. 
 
2.6   Real time-PCR 
 
2.6.1   General information 
 
Quantitative real-time PCR for the amplification of rearranged iRSS-KDE junctions were 
designed by Applied Biosystems using a Taqman Gene Expression Assay.  iRSS-KDE 
rearrangements were amplified from gDNA with 5’-ATTGATGCTGCCGTAGCC-3’ and 
5’-AGGCTTCCTAGGGAGGTCAG-3’ primers and were detected with the FAM-labelled 
5’-TCTGCAGCTGCATTTTTGCCA-3’ hydrolysis probe (Panigrahi et al., 2008). All 
qRT-PCRs were performed in multiplex, with quantification of iRSS-KDE rearrangements 
standardised to the Taqman Copy Number Reference Assay, RNaseP, detected with a VIC-
labelled probe (Applied Biosystems). Quantitative real-time PCR for the amplification of 
an intronic region 5’ to the J-C intronic RSS were also produced by Applied Biosystems 
using a similar Taqman Gene Expression Assay. This region was amplified with the 
following primers 5’-GGGTCTGATGGCCAGTATTGAC-3’ and 5’-
CCAATACAATATTTGGCAAG-3’ and were detected with a FAM-labelled 5’-
AAAGATTGGTAAATGAGGGCATTTA-3’ hydrolysis probe. This assay was also 






2.6.2   Protocol 
 
Quantitative real-time PCRs were carried out in 384-well plates in a 10l reaction volume. 
4µl of sample gDNA was added to 6µl reaction master mix containing 5µl 2x Gene 
Expression Master Mix (Applied Biosystems); 0.5l iRSS-KDE primer and 0.5l RNaseP 
reference primer. KDE-RSS rearrangements were amplified under the following 
quantitative PCR conditions: denaturation at 95°C for 10 mins, followed by 40 cycles of:  
95°C for 15 secs followed by 60°C for 60 secs. Individual samples were performed in 
triplicate, and the reliability of replicates and calculations performed to quantify iRSS-KDE 
rearrangements will be described in Chapter 4.  
 
2.7   Amplification of Ig gene rearrangements 
 
2.7.1   General information 
 
This study involved the analysis of VJ rearrangements and iRSS-KDE rearrangements 
from the genomic DNA of CD19+ Ig+/Ig+ FACS-sorted B cells. Both VJ and iRSS-
KDE rearrangements were amplified by nested PCR reactions. Each PCR reaction 
contained the following quantities of reagents:  10l 5x PCR buffer, 3l MgCl2, 0.5l each 
5’/3’ primer (20mM), 0.5l 20mM dNTPs, 3l DNA. PCR reactions were amplified in a 
total volume of 50ml, so dH20 was added to the PCR mix depending on the total number 






2.7.2   PCR cycle conditions 
 
 VJ and KDE-JC intronic RSS rearrangements :   
o Round 1:  One cycle of 95°C for 7 min, 56°C for 1 min and 72°C for 1 min 
30s. Followed by 30 cycles of 94°C for 1 min, 56°C for 30 secs and 72°C 
for 1 min 30s. A final extension of 5 mins at 72°C was performed.  
o Round 2 (Nested PCR): 5 ml of each first round PCR product was used. 
One cycle of 95°C for 7 min, 65°C for 1 min and 72°C for 1 min 30s. 
Followed by 30 cycles of 94°C for 1 min, 65°C for 30 secs and 72°C for 1 


















2.7.3   PCR primers 
 
The following table provides the primer sequences used for the amplification of VJ 
rearrangements and iRSS-KDE rearrangements. 
 
Table 2.8  Sequences of oligonucleotide primers for the amplification of VJ rearrangements 
(Foster et al., 1997) 
 
Primer name Sequence 5' to 3' 
External 5' primers   
VI/IIE  GCTCAGCTCCTGGGGCT 
VIIIE  GGAA(AG)CCCCAGC(AGT)CAGC 
VIV/VE  CT(CG)TT(GC)CT(CT)TGGATCTCTG 
VVI/VIIE  CT(GC)CTGCTCTGGG(CT)TCC 
    
External 3' primers   
J2E ACGTTTGATCTCCAGCTTG 
J5E CTTACGTTTAATCTCCAGTC 
    








    








Table 2.9  Sequences of oligonucleotide primers for the amplification of KDE rearrangements to 
the J-C intronic RSS. 
 
Primer name Sequence 5' to 3' 
External 5' primer   
JC intron E CCGCGCTCTTGGGGCAGCCGCC 
    
External 3' primer   
KDE E CAGACAGGTCCTCAGAGGTC 
    
Internal 5' primer   
JC intron I GCCGCTATGCCGTGGCCACCC 
    
Internal 3' primer   
KDE I CAGGTTGTCCTAGGGAGCAGGG 
 
Table 2.10   Sequences of oligonucleotide primers for the amplification of surrogate 
 light chain VpreB. 
 
Primer name Sequence 5' to 3' 
External 5' 
primer   
VpreB E CATGCTGTTTGTCTACTGCACAG 
    
External 3' 
primer   
VpreB 5 TGCAGTGGGTTCCATTTCTTCC 
    
Internal 5' 
primer   
VpreB I GCCGCCGGCCATGTCCTCGGCCC 
    
Internal 3' 
primer   
VpreB I CCTCCTTCTCCGAGCTGCGGGC 
 
 
2.7.3   Separation of PCR products by gel electrophoresis 
 
PCR products from amplifications not involved in the high-throughput sequencing were 
run on a 1.5% agarose gel prepared with 3g of MicroSieve 3:1 agarose (Flowgen) dissolved 
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in 200ml 1x TBE solution by a 4 minute microwave heat on a medium setting. Following 
cooling and prior to pouring into the gel mould, 1 l 50mg/ml ethidium bromide solution 
was swirled into the gel, which was allowed to set for 30 minutes.  6 l of each PCR product 
was then mixed with 2 l of gel loading dye and loaded into a single well. 5 l of ΦX174 
DNA11Hinf1 marker (Promega) was run alongside PCR products for identification of the 
PCR product size following the gel run at 125 V for  45 minutes in 1x TBE.  Finally gels 
were visualized under UV light.  
 
2.7.4   Purification of PCR products 
 
PCR products were purified with the MinElute PCR purification kit (Qiagen) and protocol 
followed to manufacturer’s instructions. Samples were stored at -20°C until use. 
 
2.8   Molecular cloning of PCR products 
 
2.8.1   Ligation 
 
The pGEM-T vector kit (Promega) was used to ligate PCR products on ice. The ligation 
reaction was performed in 10µl; 3µl purified PCR products, 5µl ligation buffer (10X), 1µl 
of T4 DNA ligase (3µ/ml) and 1µl of vector and incubated at RT for 2 hours, or at 4°C 
overnight.  
2.8.2   Transformation 
 
2.5 µl of each ligation reaction and 25µl competent cells (JM109, Promega) were added to 
a 1.5ml sterilised Eppendorf and incubated on ice for 20 minutes. The bacteria were heat 
shocked in a water bath at 42°C for 45 seconds and incubated immediately on ice for 2 
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minutes. 950 µl of cold SOC medium was added to each tube and incubated on a shaker 
(150 rpm) at 37°C for 2 hours. Bacteria were collected by centrifuging at 200 rpm at RT 
for 10 minutes and the supernatant discarded. The bacterial pellet was re-suspended in 
100µl of cold SOC medium, and 100µl was spread on individual plates prepared with LB 
agar containing 0.5% ampicillin. 5% X-Gal (Promega) and 0.05M IPTG. Plates were 
inverted and incubated at 37°C overnight.  
 
2.8.3   Blue/white screening of clones 
 
Bacteria successfully transformed with pGEM-T vector containing the rearranged KDE 
insert grew as white colonies on the plates. Bacteria that failed to be transformed grew as 
blue colonies. Discrete white colonies were picked randomly with sterile pipettes, 
transferred to a griddled plate and allowed to grow overnight at 37°C. Pipette tips used to 
select clones were rinsed into 15µl dIH20 in individual wells of a 96-well plate. The plates 
were covered and placed in a PCR machine to boil for 10 minutes. This releases vectors 
and denatures the DNases present. The plate was centrifuged for 10 minutes at maximum 
speed to pellet the vector and stored at -20°C.  
 
2.8.4   Screening clones by PCR 
 
5µl of the supernatant of screened clones was used as template for a PCR reaction 
containing 1.5mM MgCl2, 0.2M dNTPs, 1x Taq DNA polymerase reaction buffer, 50ng of 
each M13For and M13Rev primers and 0.25 units Taq DNA polymerase in a total volume 
of 10µl. After a hot start for 5 minutes at 95°C, 30 cycles of 95°C for 30 seconds, 45°C for 
30 seconds and 72°C for 90 seconds, were followed by a 5 minute extension phase at 72°C. 
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PCR products were visualised after running on a 1.5% agarose gel (previously described) 
and products of the correct size were identified. 
 
2.8.4.1   PCR cycle conditions for clone screen 
 
Samples were denatured for 5 minutes at 95°C, followed by 30 cycles of: 95°C for 30 secs, 




Primer name Sequence 5' to 3' 
M13 Fwd GTAAAACGACGGCCAGT 
M13 Rev GGAAACAGCTATGACCATG 
 
2.8.5   DNA sequencing 
 
Clones were selected from the griddled plate according to the size of the cloned PCR 
products and transferred to individual wells of a 96-well plate containing LB agar + 
0.1m/ml ampicillin. Plates were incubated at 37°C overnight before sending to Beckman 
and Coulter for sequencing.  
2.9   RNA isolation and reverse transcription from single cells 
 
Cells from dual-light chain-expressing SLE patient Lu-025 were FACS-sorted into 96-well 
plates containing 18l of SLyRT buffer per well. Plates were then immediately covered 
with a plastic sterile lid and spun briefly in the centrifuge and kept on ice.  In a clean PCR 
hood, the lid was gently removed and 2l of 1 in 8 SuperScript III (Invitrogen) was added 
Table 2.11   Sequences of M13 oligonucleotide primers used for the screening of transformed clones 
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to each PCR well before a further brief centrifuge spin to ensure each transcription reaction 
was contained within the bottom of each well. Plates were then reverse transcribed under 
the following conditions; denaturation at 42°C for 10 mins, annealing at 25°C for 10 mins, 
an extension period at 55°C for 60 mins followed by termination of transcription at 72°C 
for 15 mins. Plates could then be stored at -20°C until further use. 
 
2.10   PCR amplification of rearranged IGK (VC) and IGL 
(VC) transcripts from cDNA isolated from single cells. 
 
2.10.1  General information 
 
Semi-nested PCRs were used to detect and amplify V-C transcripts for both IGK and IGL 
light chain gene rearrangements in the cDNA of sorted single cells.  
 
Table 2.12  Recipes and concentrations for first round semi-nested PCR amplification of IGK and 
IGL transcripts from single cells 
 
Reagents Stock conc. µl/reaction 
GC buffer 5X 4 
1:20 Phusion DNA polymerase 0.25 U/µl 2 
dNTPs 20 mM each 0.2 
V1-6 or V1-8(5’) primer mix for PCR 1 835 nM or 1000nM each  
1 
VC or VC (3') primer mix for PCR 1 5 µM each 
PCR H20 - 8.8 
MgCl2 2.0 mM 1 
cDNA - 3 






Table 2.13  Recipes and concentrations for first second round semi-nested PCR amplification of 
VC and VC transcripts from single cells 
 
Reagents Stock conc. µl/reaction 
GC buffer 5X 4 
1:20 Phusion DNA polymerase 0.25 U/µl 2 
dNTPs 20 mM each 0.2 
V1-6 or V1-6(5’) primer mix for PCR 2 835 nM or 1000nM each  
1 
VC or VC (3') primer mix for PCR 2 5 µM each 
PCR H20 - 10.8 
PCR1 product - 2 
Volume - 20 
 
 
2.10.2   PCR cycle conditions 
 
 V-C: 
o Round 1: 98 for 30secs, followed by 50 cycles of 98°C for 10 secs, 58°C 
for 15 secs and 72°C for 40 secs. Final extension at 72°C for 10 mins. 
o Round 2: 98°C for 30secs, followed by 20 cycles of 98°C for 10 secs, 64°C 
for 15 secs and 72°C for 15 secs. Final extension at 72°C for 10 mins. 
 V-C: 
o Round 1: 98 for 30secs, followed by 50 cycles of 98°C for 10 secs, 58°C 
for 15 secs and 72°C for 30 secs. Final extension at 72°C for 10 mins. 
o Round 2: 98°C for 30secs, followed by 20 cycles of 98°C for 10 secs, 62°C 
































IGLC outer CCTTCCAGGCCACTGTCAC 
Table 2.14  Sequences of oligonucleotide primers for the 
first round amplification of VC and VC transcripts 
from single cells 
 
Table 2.15  Sequences of oligonucleotide primers for 
the second round amplification of VC and VC 






































Chapter 3                                                                                                            
High throughput sequencing of the 

















3.1   Introduction 
 
This chapter describes an analysis of the IGK light chain repertoire of mature naive B cells 
in health and SLE. The introduction to this chapter will be divided into background, 
experimental design and experimental aims. 
 
3.1.1   Background 
 
Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown origin, 
characterised by chronic B cell hyper-activation and an autoimmune immunoglobulin 
repertoire that targets DNA and nucleoproteins (Dorner et al., 2011a). The breakage of 
tolerance to self-antigen in SLE is thought to be a consequence of failure of an unknown 
systemic checkpoint that governs the transition of B cells from the early bone marrow 
emigrant to a mature naive stage in development (Yurasov et al., 2005). A relatively large 
proportion of functional immunoglobulin expressed by early emigrant B cells expresses 
varying degrees of polyreactivity and autoreactivity (Mouquet and Nussenzweig, 2012; 
Wardemann et al., 2003). In health, a series of checkpoints serve to counter-select B cells 
with self-reactive immunoglobulins during B cell development. At these checkpoints, B 
cells can be removed from the developing repertoire by several mechanisms; clonal 
deletion, the induction of anergy and receptor editing, which involves secondary VJ 
rearrangement events on the same allele at the light chain loci (Goodnow et al., 1988; 
Halverson et al., 2004; Nemazee and Burki, 1989; Radic et al., 1993; Tiegs et al., 1993).  
In SLE however, studies investigating a role of receptor editing in disease pathogenesis 
have provoked debate. It has been reported that more apparent receptor editing is a feature 
of an individual patient with SLE compared to health by analysis of genomic DNA from 
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single CD19+ B cells (Dorner et al., 1998). Contrastingly, it has been suggested that 
receptor editing is reduced in SLE compared to healthy individuals through study of the 
rearranging activity of the kappa deleting element (Panigrahi et al., 2008). 
Diversity in the immunoglobulin repertoire is generated by a hierarchical series of gene 
rearrangement events initiated during B cell development in the bone marrow (Meffre et 
al., 2000a). After rearrangement of a functional IGH chain, rearrangement on one allele at 
the IGK loci follows (Alt et al., 1984). If the first rearrangement of the first IGK allele is 
successful, the IGK light chain is paired with a heavy chain and subsequently expressed on 
the cell surface. When IGK rearrangements are unsuccessful, replacement rearrangement 
events on the same allele can follow in attempt to produce functional light chains of IGK. 
If unsuccessful, the IGL light chain locus is activated until a functional light chain is 
produced (Panigrahi et al., 2008). The successful pairing of functional heavy and light 
chains on the cell surface initiates the cellular and molecular processes to regulate central 
tolerance in the B cell system. The extreme repertoire diversity is the result of several 
processes in the developing B cell receptor. These involve combinatorial diversity 
introduced through the rearrangement of different V, (D) and J gene segments, junctional 
diversity introduced by TdT and exonuclease activity at the segmental junctions, and 
combinatorial diversity associated with different heavy and light chain pairs (Kawasaki et 
al., 2001; Kawasaki et al., 1997; Weigert et al., 1980). 
 As a result of this activity at the light chain loci, B cells isolated from peripheral blood will 
typically contain several Ig light chain gene rearrangements. These may include 
rearrangement events at one or both IGK alleles and in some B cells, one or two 
rearrangement events at the IGL loci additionally (Bräuninger et al., 2001). Many of these 
rearrangements will be in the incorrect genetic reading frame and therefore not functional 
and not subsequently produced as light chain protein. Other rearrangements will be 
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productive and expressed by the cell. Unwanted light chain rearrangements are typically 
inactivated by the rearranging activity of the KDE to an RSS located in the J-C intron 
(Klobeck and Zachau, 1986). This rearrangement event removes the constant region and 
enhancers flanking it from the rearranged IGK allele rendering it functionally silenced 
(Siminovitch et al., 1985). In this way, the KDE acts alongside other mechanisms 
overseeing central tolerance by preventing the expression of more than one light chain, thus 
maintaining isotypic exclusion. Usage of more than one rearranged IGK light chain, or IGK 
and IGL light chains by B cells has been shown to have a profound effect on maintenance 
and breakage of tolerance in animal models of autoimmunity (Andrews et al., 2013; 
Casellas et al., 2007; Fournier et al., 2012). Skewed usage of IGKV gene segments in SLE 
has previously been reported.  
 
3.1.2 Experimental design 
 
High-throughput sequencing technologies were originally used in 2005 and have now been 
developed to allow rapid and large-scale parallel sequencing; a platform now widely used 
in the field of immunoglobulin repertoire analyses. The Roche FLX Genome Titanium 
Sequencer (Agowa GmBH) system can sequence hundreds of samples in parallel through 
the use of sample-specific multiple identifier (MID) tags. This tool has been applied to 
study the human IGH repertoire of transitional, naive and IgM memory and switched 
memory B cell populations (Wu et al., 2010) and was applied in a study aiming to analyse 
paired human heavy and light chain immunoglobulin repertoires by isolation of mRNA 
from single B cells and performing linkage PCR prior to high-throughput sequencing 




3.1.2.1  FACS sorting procedure 
 
In order to investigate the factors that shape the expressed IGK light chain repertoire in 
health and in the context of SLE, a high-throughput sequencing approach was applied to 
FACS-sorted mature naive B cells (CD19+ IgD+ CD27- Ig+/Ig+) from PBMCs isolated 
from the blood of three SLE patients and three healthy controls. Of note, it became apparent 
during the FACS-sorting of some SLE samples that populations of single Ig+ and Ig+ 
CD19+ B cells were not as clearly defined as the two discrete populations of single light 
chain producers typically observed during analysis of healthy samples stained by the same 
method. To ensure clarity and avoid the interference of an unknown experimental variable, 
SLE samples were selected for this sequencing approach based on the existence of two 
discrete populations of cells expressing either Ig or Ig on their cell surface.  
 
Genomic DNA was isolated from sorted populations of both Ig- and Ig-expressing B 
cells, and RNA was isolated and reverse transcribed from Ig-producers only. Two primer 
combinations were used to amplify rearranged IGK genes in a semi-nested PCR consisting 
of two rounds. IGKV and IGKJ primers were used to amplify VJ junctions from the 
genomic DNA of Ig- and Ig-producing B cells, whereas an IGKC primer was used in 
combination with the same IGKV 5’-end primers to amplify cDNA isolated from Ig-





Figure 3.1   Investigating the IGK light chain repertoire in health and SLE. Outline of the 
experimental setup prior to high-throughput sequencing analysis of IGK rearrangements. CD19+ 
IgD+ CD27- Ig/Ig-expressing B cell populations were FACS-sorted from total PBMCs of three 
healthy donors and three SLE patients and genomic DNA isolated from both Ig- and Ig-expressing 
cells for V-J PCR amplification, and RNA was isolated from just Ig-producers for V-C 
amplification following reverse transcription to cDNA. The red primer ends represent the MID tags 
used in the second nested PCR rounds for sample identification.  
 
3.1.2.2  Preparation of PCR-amplified samples 
 
To produce sufficient quantities of DNA for sequencing while maintaining a small number 
of amplification cycles, multiple sample aliquots were amplified by PCR1 (x8 sample 
aliquots) and PCR2 (x2 sample aliquots from each PCR1 product) for each experimental 
sample. PCR2 amplification of PCR1 products used primers with 10-base multiplex-
identifier (MID) tails which enabled for 9 different sample conditions to be pooled into one 
sequencing sample. Healthy controls and SLE samples were kept separate throughout the 
experiment so MID tags 1-9 could be used for both the 3 controls and 3 SLE patient samples 
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for analysis. PCR primers were removed from pooled PCR products from each 
experimental sample (16 final PCR-amplified aliquots) by gel electrophoresis and using a 
QIAquick Gel Purification Kit. Samples to be sent for sequencing were quantified and 
mixed in equal quantities before concentrating using QIAquick PCR Purification Kit and 
being sequenced on the GS FLX Genome Titanium Sequencer (Agowa GmBH.) Individual 
experimental samples could be recognised after sequencing through identification of their 




Figure 3.2  10-base multiplex-identifier (MID) tags on primers used during the second round PCR 
amplification of first round products. Three MID tags were assigned to each individual studied; 
MIDs 1-9 being used for three healthy donors and MIDs 1-9 used for three SLE donors. This was 
permitted since each group of MIDs 1-9 was analysed on discrete sections of the chip during the 
high-throughput sequencing and could therefore be identified following the analysis. 
 
Prior to analysis, sequences were subject to quality control by eliminating sequences that 
were biologically implausible; this was in collaboration with Dr. Deborah Dunn-Walters 
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and Professor David Kipling at the University of Cardiff who designed the QC algorithm. 
Only sequences with an identifiable V at the 5’ end, followed by either a J or a C at the 
3’ end were accepted. VC sequences amplified from IGK rearranged cDNA were only 
accepted as biologically plausible if they were over 415 nucleotides in length and VJ 
sequences amplified from the DNA of Ig- or Ig-expressing B cells were accepted 
providing they were over 290 nucleotides in length. Sequences that failed to start with a 
MID tag, V, J or C were rejected. 
 
Since the amplification method involved PCR from DNA and cDNA, it is possible that 
some groups of identical sequences arose from either the isolation of multiple cDNA copies 
of an IGK sequence from an individual cell, or amplification of a single sequence from 
DNA or cDNA, rather than actual clones of cells. This was addressed during analysis by 
identifying the CDR3; the region unique to each individual Ig gene rearrangement and 
critical to antigen binding, alongside the IGKV and IGKJ gene segment usage. Replicates 
of the same sequences were excluded so a single sequence from any “clone” was 
represented.  
 
3.1.3  Experimental aims 
 
The following table depicts the experimental conditions that were investigated for each 
sample, and describes the nature of each group of rearranged IGK sequences following the 





















Ig+ cDNA VC Expressed In-frame 
Productive rearrangements 




















Productive and  non-
productive rearrangements 
of IGK  ** 
 
 
**  The groups of IGK rearranged sequences obtained from the Ig+ sorted populations of 
B cells will contain rearrangements that are both in the correct and incorrect genetic reading 
frame, though both are unused by the cell since they are from Igexpressing cells. 
   
Theoretically, whether the IGK rearrangement is genetically productive (in-frame) or non-
productive (out-of-frame) it will have been functionally inactivated and therefore not 
transcribed and translated to protein Ig. In-frame IGK rearrangements from Ig-
expressing cells will be referred to as productively rearranged, relating to the genetic 
status of the allele, and does not refer to whether the rearrangement is produced/expressed 





The overall aim of this high-throughput sequencing analysis was to investigate the factors 
that shape the IGK repertoire of mature naive B cells in health and SLE. With reference to 
Table 3.1, the following questions could be addressed: 
 Is there any difference between health and SLE in the imprint of the inherent light 
chain gene rearrangement mechanism? 
 Is there any difference between health and SLE in the relative frequencies of IGKV 
gene segments in the pool of productively rearranged IGK light chains from 
genomic of from Ig- and Ig-expressing cells? 
 Is there evidence of differences between health and SLE in receptor editing? 
 Is there any difference between health and SLE in the expression of IGK 
rearrangements using different gene segments? 
 Is there any difference between health and SLE in the components of the CDR3 
regions of IGK light chains that are expressed compared to those that are 
productive forbidden and not used? Parameters investigated are stated below: 
o CDR3 length 
o GRAVY index 
o Theoretical isoelectric point (pI) 








3.2  Results 
 
A total of 5736 and 4698 unique IGK sequences were acquired from the pooled healthy 
controls and SLE respectively. These included rearrangements of IGK that at the genetic 
level were both productive and non-productive. Expressed IGK light chain rearrangements 
were those amplified from the cDNA of Ig-producing B cells. These rearrangements were 
compared with IGK rearrangements from DNA isolated from either Ig - or  Ig-expressing 
B cells, which could be further divided into two groups;  those that were in the correct 
genetic reading frame and free from stop codons (productively rearranged), and those that 
were in the incorrect genetic reading frame or carried stop codons (non-productively 
rearranged). Productively rearranged IGK sequences obtained from the DNA of Ig-
expressing B cells are referred to as ‘forbidden productive’. A summary of the frequency 
of IGK rearrangements pooled for each healthy donor and SLE sample obtained is shown 
in Figure 3.3 A. The number of sequences obtained from each individual can be found in 
Appendix 1.  
 
Forbidden productive rearrangements of IGK are in the correct genetic reading frame 
and therefore productive at the genetic level, but since they are present in Ig-
producing cells cell fate decisions must have been made to not express them.  
 
Forbidden productive rearrangements are likely to be the consequence of an aspect of 
functionality relating to the specificity of the heavy/light chain pairing or inability to make 
a functional receptor with the heavy chain. The frequency of forbidden productive 
rearrangements from Ig-expressing mature naive B cells was equivalent in health and SLE 







Figure 3.3 High throughput sequence analysis. (A) Frequencies of unique, QC-passed rearranged 
sequences following high-throughput sequencing of the IGK light chain repertoire. Schematic 
outlines the frequency of IGK rearranged sequences obtained from pooled healthy control and 
pooled SLE FACS-sorted Ig- and Ig-expressing mature naive B cells after high-throughput 
sequencing analysis. (B) Percentage of forbidden productive IGK rearrangements sequenced from 
genomic DNA isolated from Ig-expressing mature naive B cells. Forbidden productive 







Ig+ sorted CD19+ B cells 
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3.2.1 Analysis of IGKV and IGKJ segment rearrangement 
frequencies 
 
Biases in IGKV gene segment usage have been observed in SLE, but their origin and 
significance are unknown. This section investigates the origin of these biases by studying 
the profile of IGKV gene rearrangements in productively and non-productively rearranged 
genomic DNA from Ig- and Ig-expressing mature naive B cells. These IGK 
rearrangement profiles will be compared with the IGKV gene segment rearrangement 
frequency of the expressed IGK repertoire, determined through studying the cDNA of Ig-
expressing cells. 
3.2.1.1 Study of unused IGK rearrangements 
  
Studying unused IGK sequences allows investigation into the processes underlying IGK 
gene segment expression and selection. Unused sequences were analysed from genomic 
DNA and included non-productively rearranged alleles of IGK from Ig- and Ig- 
expressing B cells, and the forbidden productive IGK rearrangements from Ig-expressing 
B cells.  No significant differences were observed in the non-productive rearrangements 
from Ig-expressing cells when rearrangements from healthy donors and patients with SLE 
were compared (Figure 3.4 A). Biases towards rearrangement of two infrequently 
expressed V gene segments IGKV3D-20 (p=4.2x10-7) and IGKV2-24 (p=1.78x10-2) were 
observed in SLE compared to health in the non-productively rearranged IGK sequences 
from Ig-expressing cells. (Figure 3.4 B). Forbidden productive rearrangements of IGK 
appeared to have a different profile to the two sets of non-productively rearranged IGK 
sequences, though the only difference observed between health and SLE was a bias towards 
rearrangement of the gene segment IGKV3D-20 (p=7.33x10-3) in SLE which is rarely 




Figure 3.4 Relative rearrangement frequency of IGKV gene segments in the unused IGK repertoire 
of mature naive B cells in health (n=3) and SLE (n=3). (A) Non-productive IGK rearrangements 
from Ig-expressing B cells. (B) Non-productive IGK rearrangements from Ig-expressing B cells 
where biases towards rearrangement of two IGKV3D-20 and IGKV2-24 were observed in SLE 
compared to health and (C) Forbidden productive IGK repertoire from Ig -expressing cells shows 
an SLE bias towards rearrangement of the gene segment IGKV3D-20. Statistical analysis was 
performed using analyses and adjusted by Bonferroni correction (*).
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This section demonstrates that selection of IGKV gene segments and the inherent biases in 
the gene rearrangement process at the DNA level as the repertoire develops is equivalent 
in health and SLE.  
 
3.2.1.2 Comparison of productive IGK rearrangements in genomic DNA from 
Ig- and Ig-expressing cells 
 
It was considered that any productively rearranged IGKV segments that were present with 
greater frequency in the forbidden productive sequences from Ig-expressing cells than the 
productively rearranged group from Ig-expressing cells had been selected against based 
on an aspect of functionality during B cell development. Significant selection against 
inclusion of the IGKV5-2 (p=1.7x10-15), IGKV1-37 (p=7.69x10-7), IGKV1-16 (p=1.92x10-
7), IGKV3-7 (p=1.44x10-2), and the infrequently rearranged IGKV gene segments IGKV1D-
43 (6.37x10-4), IGKV3D-11 (9.74x10-3) and IGKV1D-16 (p=2.79x10-2) into the rearranged 
IGK repertoire in genomic DNA of Ig-expressing cells was observed in health (in order 
of gene segment frequency) (Figure 3.5 A). Selection against IGKV5-2 (p=3.24x10-10), 
IGKV1-37 (p=1.02x10-3), IGKV2-24 (p=1.1x10-4) and IGKV3D-11 (p=2.46x10-4) was also 
apparent in genomic DNA in SLE (Figure 3.5 B).  
 
In addition, it was considered that any IGKV segments that were present with lower 
frequency in the forbidden productive sequences than in the productively rearranged group 
from Ig-expressing cells had been selected for based on an aspect of functionality during 
B cell development.  Selection for inclusion of IGKV1-39 (p=2.0x10-5), IGKV3-20 
(p=6.7x10-6), IGKV3-11 (1.32x10-9), IGKV1-5 (p=5.2x10-6) and IGKV3-15 (p=4.45x10-2) 
segments into the repertoire in genomic DNA of Ig-expressing cells was observed in 
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health (in order of gene segment frequency) (Figure 3.5 A). With the exception of IGKV1-
5 where selection for this segment was apparent as a trend, all of these V segments were 
also significantly selected for in SLE. Inclusion of IGKV1-39 (p=2.84x10-4), IGKV3-20 
(p=8.15x10-5), IGKV3-11 (9.52x10-4) and IGKV3-15 (p=2.84x10-2) SLE segments was 









Figure 3.5 Comparison of the relative rearrangement frequency of IGKV gene segments in the 
productive IGK rearranged repertoires of mature naive B cells from the genomic DNA of Ig- and 
Ig -expressing cells in (A) healthy controls (n=3) and (B) SLE (n=3). Evidence of significant IGKV 
segment selection for and against expression was observed and were mirrored by SLE as observed 
in health, with the exception of segment IGKV1-5. Statistical analysis was performed using 
analyses and adjusted by Bonferroni correction. (*) 
 
If the assumptions made regarding IGKV segment selection were correct, then the 
frequencies of non-productive IGK rearrangements from Ig- and Ig-expressing cells that 
have no biases should not only be equal to each other, but should also lie between the 
frequencies of productive rearrangements in Ig-expressing cells and the forbidden 





Consistent with this interpretation, where selection either for or against a particular IGKV 
gene segment was identified, the non-productive rearrangements were present at relative 
frequencies between those of productive repertoire from Ig-expressing cells and the 





Figure 3.6  Evidence for gene selection for and against IGKV segments in health and SLE. (A and 
B) Selection against segments IGKV5-2 and IGKV1-37 into the productive IGK repertoire. (C and 
D) Selection for segments IGKV1-39 and IGKV3-20 into the productive IGK mature naive 
repertoire. Relative frequencies of V segments in non-productive IGK rearrangements from genomic 
DNA of Ig- and Ig-expressing cells lie between the relative frequencies of productive 
rearrangements from Ig-expressing cells and productive forbidden productive IGK rearrangements 
from Ig-expressing cells using these specific IGKV segments  Statistical analyses  performed using 
analyses and adjusted by Bonferroni correction. (*) 
Selection for Selection against 
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3.2.1.3  Comparison of expressed IGK rearranged sequences from cDNA of Ig-
expressing cells with productive IGK rearrangements from the genomic DNA of 
IGK-expressing cells  
 
The IGKV segment repertoire of expressed sequences from the cDNA of Ig-expressing 
cells was analysed in health and SLE. The two most 3’ variable gene segments IGKV4-1 
(p=3.74x10-10), and IGKV5-2 (p=5.00x10-2) were significantly more frequently observed in 
the expressed repertoire of mature naive B cells from patients with SLE compared to 
controls (Figure 3.7 A) There was also a significantly lower frequency of rearrangements 
involving IGKV3-11 (p=5.99x10-4), and IGKV3-15 (p=7.42x10-3s) gene segments in the 
expressed repertoire in SLE compared to health. These biases were not observed in the 
productive rearrangements from genomic DNA from the same isolated cells from the same 












Figure 3.7 IGKV gene segment bias in mature naive B cells in SLE is apparent in the expressed but 
not the rearranged IGK repertoire. (A) Relative frequency of IGKV gene segment expression where 
IGKV4-1 and IGKV5-2 were significantly more frequently observed in the expressed repertoire in 
SLE compared to controls, and IGKV3-11 and IGKV3-15 significantly less frequently observed in 
SLE compared to health. (B) Relative frequency of IGKV gene segment usage in productive 
rearrangements of IGK amplified from DNA from FACS-sorted Ig-expressing B cells in controls 
(n=3) and SLE (n=3). These biases were not observed in the productive rearrangements from gDNA 
from the same isolated cells from the same individuals. Statistical analyses were performed using 
analyses and adjusted by Bonferroni correction (*).
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3.2.1.4  Comparison of the relative rearrangement frequencies of gene 
segments IGKV4-1 and IGKV5-2 in IGK sequences that were expressed, 
productively rearranged in the genomic DNA from Ig-expressers and 
forbidden productive rearrangements.  
 
Gene segments IGKV4-1 and IGKV5-2 were of particular interest because the bias observed 
was towards preferential expression in SLE compared to health. In addition, a bias towards 
IGKV4-1 expression in SLE was a consistent finding in previous studies (Andrews et al., 
2013). The segment IGKV5-2 was stringently selected against during development because 
the productive rearrangements in Ig-expressing cells were less frequent than forbidden 
productive rearrangements using IGKV5-2 in Ig-expressing cells in both health and SLE 
(p=1.52x10-15).  This segment was further selected against at the level of expression in 
health (p=6.19x10-5) but not in SLE (Figure 3.8 A). The IGKV4-1 segment was not selected 
against during development because the productive rearrangements in Ig-expressing cells 
were not significantly less frequent than in the forbidden productive rearrangements in Ig-
expressing cells in both health and SLE.  However, this segment was selected against at the 
level of expression compared to the productive rearrangements of IGK from Ig-expressing 
B cells (p=4.15x10-18) and the forbidden productive rearrangements from Ig-expressing 





Figure 3.8 Evidence to demonstrate the selection processes of IGK rearrangements involving 
individual IGKV gene segments. (A) Selection against IGKV5-2 at the DNA level and at the level 
of gene expression in both health (n=3) and SLE (n=3). (B) Lack of selection against IGKV4-1 at 
the DNA level in health and SLE, but selection against expression of IGKV4-1 in health. Failure to 
select against expression of IGKV4-1 in SLE compared to health. Statistical analyses were 
performed using analyses and adjusted by Bonferroni correction (*). 
 
These data provide evidence to suggest that Ig light chain expression could be regulated by 
more than one mechanism; at the molecular level during the initial Ig gene rearrangement 
process, as suggested by the usage of IGKV5-2 in both the healthy and SLE B cell 
repertoire, and also at the level of expression. Usage of IGKV4-1 appears to be selected 
against only at the level of expression of healthy subjects, where this is not observed in 
SLE. 
 
3.2.1.5   Analysis of IGKJ segment usage in genomic DNA 
 
It has been previously described that usage of more distal IGKJ gene segments may reflect 
receptor editing (Bräuninger et al., 2001). To further investigate the factors that shape the 
IGK expressed repertoire that may indicate receptor editing and whether this is the same in 
health and SLE, IGKJ gene segment rearrangement frequency was compared in IGK 
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sequences obtained from productively and non-productively rearranged genomic DNA in 
health and SLE. No selection for or against IGKJ segments was observed when the 
productive rearrangements of IGK from Ig-expressing cells were compared with the 
forbidden productive IGK rearrangements from Ig-expressing cells.  The only significant 
observation was a low frequency of non-productive rearrangements of IGKJ4 that was 
apparent in both health and SLE. No differences were found in the relative frequency of 
IGKJ segment involvement in health or SLE, and did not appear to be influenced by 




Figure 3.9 IGKJ gene segment rearrangement frequency in productive and non-productive 
rearrangements from both Ig- and Ig-expressing B cells in (A) controls and (B) SLE. No selection 
for or against IGKJ segments was observed when the productive rearrangements of IGK from Ig-
expressing cells were compared with the forbidden productive IGK rearrangements from Ig-
expressing cells, though Statistical analysis was performed using analyses and adjusted by 
Bonferroni correction (*). 
 
This section provides evidence for equivalent repertoire usage of the IGKJ gene segments 




3.2.2  Comparison of the features of the CDR3 by expressed IGK 
rearrangements from the cDNA of Ig-expressing cells with 




The hallmark of SLE is the production of antibodies specific for self-antigen, so it is of 
interest to study the components of the rearrangement that encodes a portion of the antigen 
binding site. The CDR3 region is associated antigen binding; it forms a portion of the 
antigen binding site in the folded receptor. Since the CDR3 regions tend to be the most 
hypervariable and therefore have the most influence over antigen specificity, the properties 
of IGK CDR3s that were expressed by Ig-producing B cells were analysed and compared 
to the CDR3s of forbidden productive IGK rearrangements from Ig-expressing cells in 
health and SLE. The CDR3s of Ig light chains range from approximately 8 to 11 amino 
acids in length so are significantly shorter than the CDR3s of the heavy chains, but it was 
considered important to investigate any variability in the light chain CDR3s since they too 
contribute to the antigen specificity of the antibody. The CDR3 properties analysed are 
stated below and the reasons for studying these parameters will be discussed as a prelude 
to each data section: 
 Analysis of CDR3 length 
 GRAVY index analysis of the CDR3 
 Analysis of the theoretical isoelectric point (pI) of the CDR3 
 Analysis of the aliphatic index of the CDR3 
 
Non-productively rearranged IGK sequences obtained from the genomic DNA of both Ig- 
and Ig-expressing cells were not considered as they are either out-of-frame or contain stop 
codons and are consequently not produced. 
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3.2.2.1  Analysis of CDR3 length 
 
Longer CDR3 lengths in Ig heavy chains have previously been associated with DNA-
binding antibodies (Aguilera et al., 2001; Crouzier et al., 1995; Radic and Weigert, 1995). 
Shorter CDR3 lengths are associated with antigenic selection after somatic hypermutation 
and are a feature of switched memory B cells (Wu et al., 2010).  
 
The CDR3 length of expressed IGK rearrangements from the cDNA of Ig-expressing cells 
in health and SLE was first investigated, and compared to forbidden productive IGK 
rearrangements from the genomic DNA from Ig-expressing cells. In the expressed IGK 
repertoire, a significantly higher proportion of IGK sequences in SLE (p=9.22x10-3) 
expressed Ig light chains with CDR3 regions 9 amino acid residues in length compared to 
health (Figure 3.10). Despite this however, there was a tendency to express rearranged IGK 
alleles with CDR3s 9 residues in length in both health and SLE (Figure 3.10). Forbidden 
productive rearranged IGK CDR3 regions from Ig-expressing B cells tended to be longer 
than those observed in the expressed naive repertoires in health and SLE. A significantly 
higher proportion of forbidden productive IGK rearrangements had CDR3s 10 residues 
long compared to those in the expressed repertoires in both health (p=2.01x10-7) and SLE 
(p=2.35x10-8).  There was also a significantly higher proportion of forbidden productive 
IGK rearrangements with CDR3 lengths outside the range of 8-11 residues in length than 






Figure 3.10 CDR3 length variability in productively rearranged IGK sequences that were expressed 
compared with those that were forbidden productive in healthy controls and SLE. Statistical analyses 
were performed by two-tailed  analyses and adjusted by Bonferroni correction.  
 
This section suggests that shorter CDR3 lengths are associated with the expressed IGK 
repertoire in health and SLE, compared to forbidden productive IGK rearrangements that 
have been selected against during B cell development for unknown reasons. A significantly 
larger proportion of expressed IGK sequences with shorter CDR3s (8-9 residues) were 
observed in SLE compared to health.  
 
3.2.2.2  GRAVY index analyses 
 
The grand average of hydropathicity (GRAVY) index is a score that can be used to identify 
the solubility of a protein based on its amino acid composition. It is calculated as the sum 
of individual amino acid hydropathy values divided by the number of residues in the total 
CDR3 (Kyte and Doolittle, 1982). A negative GRAVY index indicates a hydrophilic 
protein, whereas a positive score would be given to a hydrophobic protein. Due to the 
145 
 
varying lengths of CDR3 regions after IGK rearrangements and how this would influence 
the GRAVY score assigned, sequences were analysed according to their total CDR3 length 
of 8, 9, 10 or 11 amino acid residues.  
Differences in the hydropathicity of the CDR3 regions could be observed between IGK 
rearrangements in health that were expressed, compared to those that were productively 
rearranged but forbidden. All CDR3 regions of IGK rearranged light chains were 
hydrophilic, though there was a tendency for forbidden productive IGK rearrangements to 
have less negative GRAVY indices than those that are expressed in health. This was 
apparent in CDR3 regions consisting of all lengths (Figure 3.11 A-D). A similar trend is 
displayed by comparing the expressed and forbidden productive IGK rearranged sequences 
in SLE, where all CDR3 regions are hydrophilic, but forbidden productive IGK 
rearrangements tended to be less hydrophilic. This was significant in CDR3 regions of 9-
11 amino acid residues in length, but this was only observed as a trend in CDR3 regions 8 




Figure 3.11 GRAVY index analysis of CDR3 regions of expressed and forbidden productive IGK 
rearrangements of varying CDR3 length in (A-D) healthy controls (n=3) and (E-H) SLE patients 
(n=3). Statistical analysis was determined a two-tailed Student’s t-test assuming unequal variance. 
* p<0.05, **p<0.01, *** p<0.001. 
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GRAVY index scores among the expressed and forbidden productive IGK repertoires were 
then compared between health and SLE. CDR3 regions of 8, 10 and 11 amino acid residues 
in length did not differ in their hydropathicity in health or SLE (Figure 3.12 A, C and D 
respectively.) Expressed IGK light chains of 9 residues in length however not only appear 
to be the most frequently expressed CDR3 length, but those expressed in SLE tend to be 
less hydrophilic, with a less negative GRAVY score compared to healthy controls (Figure 
3.12 B.) Comparative analysis of the forbidden productive CDR3 regions within the control 
and SLE IGK repertoires revealed that regardless of whether CDR3 regions were 8, 9, 10 
or 11 amino acid residues in length, hydropathicity scores assigned were of a similar 





Figure 3.12 Analysis of GRAVY index scores assigned to CDR3 regions of varying amino acid 
length comparing productively rearranged IGK sequences in health (n=3) and SLE (n=3). (A-D) The 
expressed IGK repertoire and (E-H) the forbidden productive IGK repertoire. Statistical analysis 




This section demonstrates that in both health and SLE IGK light chain CDR3s are 
hydrophilic, but rearrangements of IGK that are expressed tend to be more hydrophilic than 
the forbidden productive repertoire of IGK rearrangements. This appears to be independent 
of total CDR3 length. Comparing the expressed IGK repertoires in health and SLE, CDR3s 
9 amino acid residues in length are less hydrophilic in SLE than those of the same length 
in health. No differences in hydropathicity were observed within the forbidden productive 
repertoire of any CDR3 length studied between health and SLE. 
 
3.2.2.3  Analysis of theoretical isoelectric points of IGK CDR3s in health and 
SLE 
 
The isoelectric point (pI) is the pH at which the net charge of a protein is zero. 
Immunoglobulins are highly diverse in their isoelectric points in that they can fall within a 
range of pH 4 to 9. A protein will carry a net positive charge if the pH of its environment 
is less than its pI, and a net negative charge at a pH above its isoelectric point. The 
theoretical pI of the CDR3 regions in expressed and forbidden productive IGK rearranged 
sequences was analysed in healthy controls. Analyses revealed that CDR3 regions from 
forbidden productive IGK rearrangements that were 10 and 11 amino acid residues in 
length tended to have significantly lower theoretical pI values that those IGK 
rearrangements that were expressed (Figure 3.13 C and D). No differences in pI were 
observed in CDR3 regions 8 and 9 residues long (Figure 3.13 A and B.) Similar trends in 
the pI of CDR3 regions were found in SLE through comparing IGK sequences that were 
either expressed or forbidden productive. Regardless of whether the IGK sequences were 
expressed or in the forbidden productive repertoire, rearrangements with CDR3 regions of 
8, 9 or 10 amino acids in length on average had similar pI scores (Figure 3.13 E, F and G). 
A significantly lower pI was found in the forbidden productive IGK sequences in SLE when 




Figure 3.13 Analysis of the theoretical isoelectric point (pI) of CDR3 regions of expressed and 
forbidden productive IGK rearrangements of varying CDR3 length in (A-D) healthy controls (n=3) 
and (E-H) patients with SLE (n=3). Statistical analysis was determined a two-tailed Student’s t-test 




Theoretical pI scores among the expressed and forbidden productive IGK repertoires were 
then compared between health and SLE. Comparing health with SLE, theoretical pI scores 
tended to be similar regardless of CDR3 length when studying the expressed IGK 
repertoire, though a significantly lower pI was observed when analysing expressed CDR3 






Figure 3.14 Analysis of the theoretical isoelectric point (pI) of CDR3 regions of expressed and 
forbidden productive in-frame IGK rearrangements of varying CDR3 length in (A-D) expressed 
IGK repertoire and (E-H) forbidden productive IGK repertoire in health and SLE. Statistical analysis 
was determined a two-tailed Student’s t-test assuming unequal variance. Error bars are SD.   * 
p<0.05, **p<0.01, *** p<0.001. 
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This section illustrates that forbidden productive rearranged IGK sequences with CDR3 
lengths of 10 or 11 amino acids in length tend to have a lower pI compared to those that 
were expressed in health. SLE CDR3s 11 residues long also had lower theoretical pIs in 
the forbidden productive IGK repertoire compared to the expressed. In addition, the pI of 
the expressed IGK repertoire 10 residues in length tended to be greater in health than SLE.  
 
3.2.2.4  Analysis of aliphatic indices of IGK CDR3s in health and SLE 
 
Further insight into the biochemical properties of rearranged IGK CDR3 regions can be 
gained by studying the aliphatic index of the CDR3, which relates to the hydrophobicity of 
a globular protein through determination of the relative volume occupied by aliphatic side 
chains (valine, alanine, isoleucine and leucine.) Higher aliphatic indices are considered to 
indicate globular proteins that are more thermostable and less polyspecific than those with 
lower aliphatic indices. These with lower aliphatic indices are associated with a higher 
tendency to exhibit polyspecificity. 
High-throughput sequence analysis revealed that productive rearrangements of IGK of 9, 
10 and 11 amino acid residues in length have a significantly lower aliphatic index if they 
are expressed, compared to those that are forbidden productive and not expressed by the 
cell. (Figure 3.15 A-D) This observation was the same when comparing the expressed and 
forbidden productive IGK repertoires in SLE, where forbidden productive sequences of 9, 
10 and 11 residues tended to have a significantly higher aliphatic index than those that were 
expressed. (Figure 3.15 E-H). No differences in aliphatic index were observed in CDR3 




Figure 3.15 High-throughput sequencing analysis to determine the aliphatic index of CDR3 regions 
of in-frame IGK expressed and forbidden productive rearrangements of increasing CDR3 length in 
(A-D) controls (n=3) and (E-H) SLE (n=3). Statistical analysis performed by student’s t-test. 
*p<0.05, **p<0.01, *** p<0.001. 
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Comparison of aliphatic indices in expressed IGK repertoires between health and SLE 
indicated that CDR3 regions 9 amino acid residues in length were significantly lower in 
SLE than health, though no differences were observed in IGK sequences of other CDR3 
lengths studied (Figure 3.16 A-D). Within the forbidden productive repertoires of IGK 







Figure 3.16 Analysis of the aliphatic index of CDR3 regions of varying amino acid length 
comparing in-frame IGK rearrangements in health (n=3) and SLE (n=3) within (A-D) the expressed 
IGK repertoire and (E-H) the forbidden productive IGK repertoire. Statistical analysis was 




This section shows that in both health and SLE, the aliphatic index of the IGK CDR3 is 
significantly lower in the expressed repertoire, compared to the inactivated repertoire in 
CDR3s of 9-11 amino acid long. Furthermore, expressed IGK CDR3s 9 residues long in 
SLE tended to have lower aliphatic indices than those IGK rearrangements expressed in 
health.  
 
3.2.2.5 Summary of experimental findings 
 
Below is a summary of findings and interpretations of the origins of IGK light chain biases 
with reference to IGKV and IGKJ gene segment frequency of rearrangement in the 
productive and non-productive groups of IGK rearranged sequences analysed from both 
the Ig- and Ig-expressing mature naive B cell repertoires in health and SLE after high-
throughput sequencing analysis. 
 Is there any difference between health and SLE in the imprint of the basic 
rearrangement mechanism? 
Outcome: The two data sets of non-productive sequences were virtually identical 
between Ig- and Ig-expressing cells as a source of the sequences in health and 
SLE, demonstrating no difference between the rearrangement processes in these 
groups.  
 
 Is there any difference between health and SLE in the relative frequencies of 
IGKV gene segments in the pool of productively rearranged IGK light chains 
in genomic DNA from Ig- and Ig-expressing cells? 
Outcome: Selection for and against individual gene segments was observed and 




 Is there evidence of differences between health and SLE in receptor editing? 
Outcome: No selection for or against IGKJ gene segments was observed in the 
productive IGK rearrangements from Ig- or Ig-expressing cells in health and 
SLE. Both health and SLE non-productive IGK sequences exhibited a low 
frequency of IGKJ4 rearrangement, potentially an imprint of receptor editing. 
 
 Is there any difference between health and SLE in the expression of IGK 
rearrangements using different gene segments? 
Outcome: The two most 3’ variable gene segments IGKV4-1 and IGKV5-2 were 
significantly more frequently observed in the expressed repertoire of mature naive 
B cells from SLE patients compared to health. 
 
 Is there any difference between health and SLE in the components of the 
CDR3 regions of Ig light chains that are expressed compared to those that 
are productive forbidden and not used? 
 
Outcome of CDR3 length analysis: Shorter CDR3 lengths were observed in the expressed 
IGK repertoire compared to those observed in the productive forbidden repertoire from Ig-
expressing cells in health and SLE. 
 
Outcome of GRAVY index analysis: More negative GRAVY indices were observed in 
the expressed IGK repertoire compared to productive forbidden IGK rearrangements in 
health and SLE. A significantly more negative GRAVY index was observed in the 




Outcome of the theoretical isoelectric point (pI) analysis: Significantly higher 
theoretical pIs were observed in the expressed IGK repertoire compared to the productive 
forbidden repertoire when CDR3 regions were 10 and 11 amino acids in length in health. 
This was true for SLE only when CDR3 regions contained 11 residues. Significantly higher 
theoretical pIs were observed in the expressed IGK repertoire with CDR3 regions 9 residues 
in length in health compared to SLE. 
 
Outcome of aliphatic index analysis: Significantly lower aliphatic indices were observed 
in the expressed IGK repertoire where CDR3 lengths were 8-10 amino acids in length 























The application of a high-throughput sequencing technique to PCR-amplified Ig 
rearrangements of human IGK light chains expressed by mature naive B cells allowed for 
investigation into gene segment rearrangement and selection processes during the 
development of the B cell light chain repertoire in health and SLE. These data suggest that 
the defect underlying the skewed Ig repertoire previously reported in SLE lies in regulation 
of light chain expression, rather than in selection and regulation of inherent VJ 
rearrangement events. 
 
The study of non-productive rearrangements of Ig gene segments allows investigation of 
an IGK repertoire that is not biased by selection because rearrangements cannot be 
expressed. They reflect the processes that are inherent to the development of a lymphocyte 
receptor and are governed by several factors; some random and some non-random.  The 
random element of V(D)J recombination involves stochastic processes that diversify the 
final product of rearrangement through the addition and removal of nucleotides at 
rearrangement junctions, mediated by TdT and exonuclease activity. As a result of these 
random events, two thirds of rearrangements are non-productive (out-of-frame) and result 
in no functional protein. The non-random factors are those that affect the rearrangement of 
different gene segments differently. V(D)J recombination is initiated by recognition of the 
recombination signal sequences (RSS) flanking each Ig gene segment by the enzymes 
catalysing the process; RAG-1 and -2 proteins that introduce double-stranded DNA breaks. 
RSSs at individual loci of the Ig gene family (IGH, IGK and IGL) have pre-determined 
orientations, and conserved composition such that rearrangement can only take place 
between gene segments with complementary sequences, thereby obeying the 12/23 rule 
(Bassing et al., 2000). Although they are largely conserved, some RSSs have minor 
differences that affect recombination frequency (Marie-Paule Lefranc, 2002). Additionally, 
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the existence of germline-encoded promoters and transcriptional enhancers embedded 
within antigen receptor loci regulate the accessibility of Ig gene segments and contribute 
to the rate of V and J gene segment recombination (Bassing et al., 2000; Fulton and Van 
Ness, 1993; Jung and Alt, 2004).  
 
The high-throughput sequencing data reported in this chapter first compared the IGKV 
rearrangement frequency in non-productive IGK rearrangements from the genomic DNA 
of Ig- and Ig-expressing mature naive B cells in both health and SLE. With the exception 
of infrequently rearranged segments IGKV3D-20 and IGKV2-24, which were seen at higher 
relative frequency in SLE compared to health, the same inherent biases in IGKV 
rearrangement frequency are apparent in both health and SLE. This may suggest that the 
skewed usage of IGKV rearrangements previously observed in SLE are not the result of a 
defect in the inherent mechanisms governing VJ recombination in IGK light chains.  
 
Forbidden productive sequences were considered to be of interest because they were 
rearranged productively yet cell fate decisions were made to not proceed with expression 
of Ig but to initiate rearrangement at the IGL loci. Forbidden sequences are present at 20-
25% in health and SLE as shown in this thesis. In mice, such productively rearranged but 
inactivated IGK light chain alleles have been shown to be present in 47% of IgM+ Ig-
expressing B cells (Retter and Nemazee, 1998). The relatively higher proportion of 
forbidden sequences in mice is expected since the percentage ratio of Ig:Ig light chain 
expression is 95:5.  
 
Comparison of forbidden rearrangements with those productively rearranged from Ig-
expressing B cells allowed for investigation into the processes governing selection for 
rearrangements involving specific IGKV gene segments. This analysis revealed that 
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selection both for and against individual segments was apparent. Selection against 
rearrangements of IGKV1-37 and IGKV3-7 is expected. IGKV1-37 is non-functional due to 
the replacement of a cysteine residue with glycine at position 104 in framework region 3 
(Marie-Paule Lefranc, 2002). IGKV3-7 has a mutation in an acceptor splice site.  
 
It was not clear what aspect of functionality was responsible for selection against the other 
segments; this could be based on ability of the new light chain to associate with heavy 
chain, or the production of an unwanted specificity. Little is known about mechanisms 
regulating VH:VL pairing, mainly due to the fact that any unsuccessful pairings would not 
be expressed by the cell. Only successful IGH:IGK/L pairs would subsequently be exposed 
to processes regulating antigenic selection at the cell surface since it is the six CDR loop 
regions contributed by both the heavy and light chains that determine the overall 
conformation and antigen interface of the binding site (Chailyan et al., 2011). It has been 
suggested that half of all productively rearranged Ig light chains can pair with IGH during 
development in the small pre-B II cell (Melchers et al., 2000).  
The equivalence of this process in health and SLE however demonstrates that the 
mechanisms involved in identifying that these segments have been rearranged at the pre-B 
stage and the subsequent cell-fate decision to move to rearrange at the IGL locus is the 
same in SLE and health with respect to segment selection. 
 
In contrast to the comparisons of genomic DNA that showed no differences between health 
and SLE, biases in the IGK repertoire in SLE were apparent by analysis of IGK gene 
expression in the cDNA of the same cells from which genomic DNA had been isolated. 
This suggests that the mechanisms regulating the expression of IGK rearrangements are 
responsible for the skewed light chain repertoire in reported SLE, and not the process of 
rearrangement and subsequent segment selection per se. This was not a consequence of 
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primer bias during PCR because the same set of IGKV segment primers was used to derive 
each set of sequences. These data are also consistent with Yurasov and Wardemann who 
identified a bias towards IGKV4-1 expression in single mature naïve B cells in SLE by 
analysis of gene expression.  This study did not include an analysis of genomic DNA and 
therefore would not have identified that the bias was only at the level of gene expression 
(Wardemann et al., 2003).  
Over-representation of IGKV4-1 has also been reported following analysis of rearranged 
IGK genes from the genomic DNA from single CD19+ B cells of an SLE patient (Dorner 
et al., 1998). This study also provided evidence for the clonal expansion and hypermutation 
of light chain rearrangements involving IGKV4-1 (Dörner et al., 1999). These data 
suggested that IGKV4-1 segments are indeed expressed and cells expressing this light chain 
may be readily activated. The IGKV4-1 segment has also been shown to be associated with 
F4+ B cell lines generated from 6 SLE patient. F4+ refers to the heavy chain idiotype of 
the antibody which are almost all IgG and bind dsDNA strongly. F4 expression is present 
predominantly in the serum of SLE patients at high titres (Manheimer-Lory et al., 1997).  
The gene segments IGKV4-1 and IGKV5-2 in health are both present with lower 
frequencies in the cDNA of Ig-expressing cells than expected expression when comparing 
to their frequencies in the pool of productive rearrangements in the genomic DNA from the 
same cells.  Regulation of IGK expression is dependent in part on the activity of the kappa 
deleting element (KDE), or RS in mice (Nemazee, 2000; Siminovitch et al., 1985; 
Siminovitch et al., 1987). The KDE is a non-coding, suppressive rearranging element that 
is located 25 kb downstream of IGKC and recombines to either a IGKV segment upstream 
of the unsuccessful rearrangement or to a non-canonical intronic recombination signal 
sequence (RSS) between the most downstream IGKJ segment and the constant region 
(Klobeck and Zachau, 1986).  This rearrangement event is V(D)J recombinase-dependent, 
and deletes the constant region and associated enhancers thus inactivating the allele 
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(Takeda et al., 1993). This would imply that the segments that are productively rearranged 
but not expressed in Ig-expressing cells have been KDE inactivated.  The KDE has been 
reported to have lower frequency of rearrangement in SLE compared to health. (Panigrahi 
et al., 2008). It is possible that the KDE fails to inactivate loci that have been selected 
against in Ig-expressing cells in SLE, permitting the ‘breakthrough’ expression of IGKV5-
2 and IGKV4-2.   
Data in this chapter also identified that IGKV5-2 is selected against during development at 
the point where cells make the fate decision to express Igprotein or to move on and 
rearrange IGL. In contrast, IGKV4-1 appears not to be selected against at this point, though 
both segments were selected against at the point of expression.  This suggests that multiple 
mechanisms are involved in identifying and regulating the IGK gene expression, 
presumably including those that initiate and regulate KDE activity. These may act at 
different times during B cell development. Their activity is essential because most B cells 
in the blood contain multiple light chain gene rearrangements, and each cell has the ability 
to produce two different light chains if rearrangements were productive; one encoded by 
each allele. Restriction to the expression of one light chain is known as isotypic exclusion, 
though active selection processes that govern this process are elusive.  Failure to effectively 
regulate can lead to aberrant expression, potentially allelic inclusion and a less stringently 
regulated light chain repertoire.  
Comparison of the CDR3 regions associated with productively rearranged IGK sequences 
in the expressed naive IGK repertoire with forbidden productive IGK rearrangements 
revealed some interesting differences regarding the components of the antigen binding sites 
that may influence selection for or against expression. Previous studies have predominantly 
focused on the CDR3 regions of Ig heavy chains as they form the physical centre of the 
combining site of the antibody. Longer IgH CDR3s have been associated with DNA-
binding antibodies, and shorter CDR3s have been associated with class-switched, memory 
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B cell populations (Crouzier et al., 1995; Radic and Weigert, 1995; Wu et al., 2010). 
Changes in length of the CDR3 therefore affects the potential for contacts in the site and 
overall conformation of the binding domain. Further studies have demonstrated that the 
IgH CDR3 may distinguish polyspecific from monospecific combining sites in natural and 
antigen-induced antibodies (Chen et al., 1991).  
 
Variations in these parameters have been described after analysis of the IgH CDR3 region 
in naive, IgM memory and switched memory B cell subsets. Naive B cells were associated 
with a downward trend in hydrophobicity and a decreased aliphatic index compared to 
memory B cell groups. In addition, the IGH CDR3 regions of IgM memory B cells 
exhibited lower aliphatic indices compared to those of switched memory B cells. The 
analyses of CDR3 characteristics illustrated in this chapter suggested that despite the 
relatively short length of Ig light chain CDR3 regions in comparison to CDR3 regions of 
IGH chains, subtle but significant differences are associated with the likelihood of a 
rearranged IGK light chain being expressed or not. CDR3s of the expressed IGK repertoire 
tended to be less hydrophilic in SLE compared to health, and CDR3s of the most commonly 
expressed length (9 amino acids) tended to hold lower theoretical pIs in SLE compared to 
health. These findings may suggest that the features of the CDR3 in the expressed SLE 
IGK repertoire may contribute to the skewed range of antigens targeted by SLE B cells. 
The caveat of the data generated by high-throughput sequencing was that different numbers 
of sequences were obtained from each individual and for each of three groups of sequences 
isolated from Ig-andIg-expressing populations of cells in both DNA and cDNA 
samples. Time and resources limited the study to one high-throughput sequence analysis, 
though if an experimental repeat was feasible, DNA and RNA would have been isolated 
from the same number of cells across all samples, rather than the same number of cells 




This chapter suggests that the skewed Ig repertoire observed in SLE is the result of the 
dysregulation of IGK gene expression at a genetic level. The following chapter will 
investigate a role for the KDE in regulating IGK gene rearrangements and will consider the 





































Chapter 4                                                                                 
Analysis of the rearranging activity of the kappa 
deleting element in populations of CD19+ B cells in 
























Following successful heavy chain rearrangement in the developing pro-B cell, the light 
chain genes generally rearrange in a sequential allelic order, occurring at the IGK locus 
before the IGL locus becomes available (Lewis et al., 1982). A consequence of sequential 
VJ rearrangements on one or both alleles at the IGK locus, and an additional one or two 
rearrangements at the IGL locus in some B cells, is that a circulating population of B cells 
may carry multiple Ig light chain rearrangements. These rearrangements are either 
expressed by the cell after successful pairing with a functional heavy chain, or they are not 
used due to functional inactivation of the unwanted allele. Alleles of IGK that become 
inactivated include those that have been selected against based on an aspect of their 
functionality and those not in the incorrect genetic reading frame. Mechanisms governing 
rearrangements at the light chain loci are therefore important to the maintenance of 
phenotypically silent light chain rearrangements (isotypic exclusion) and ultimately central 
B cell tolerance.  
 
The sequential order of light chain gene rearrangements in developing human B cells was 
first proposed from studies of transformed human B cell lines and leukemic lymphocytes. 
These early studies largely involved Southern blot analyses of Ig light chain rearrangements 
and identified that Ig+ pre-B cell lines or leukemic cells carried alleles of IGL in germline 
configuration, whereas Ig+ B cells all carried IGK alleles that had either undergone 
rearrangement or had been deleted by an unknown second mechanism governing 
hierarchical light chain rearrangements (Hieter et al., 1981; Korsmeyer et al., 1981; Lewis 
et al., 1982). This mechanism was later identified as rearrangement of the kappa deleting 
element (KDE), and it was demonstrated that 98.5 % of Ig+ human leukemic B cells 
carried IGK alleles that had undergone C deletion mediated by KDE rearrangement  
(Beishuizen et al., 1994; Klobeck and Zachau, 1986). These findings were supported by 
169 
 
analysis of VJ joints from amplified V gene rearrangements from the Ig+ and Ig+  
single cell FACS-sorted healthy human B cells (Bräuninger et al., 2001).  
 
The KDE is a recombining element located approximately 25 Kb downstream of the IGK 
constant (C) region and its rearrangement reflects functional inactivation of kappa light 
chains (Klobeck and Zachau, 1986). KDE rearrangements are considered a normal part of 
the developmental process in B cells and can take place before rearrangement at the IGL 
loci (Hieter et al., 1981; Korsmeyer et al., 1981).  Rearrangement of the KDE takes place 
to either an isolated, site-specific palindromic RSS (CACAGTG) located within the J-C 
intron located 917 base pairs 3’ to the last J segment, or to an upstream unrearranged V 
gene segment if available (Graninger et al., 1988; Klobeck and Zachau, 1986; Siminovitch 
et al., 1985). The former process results in the retention of VJ rearranged joints within 
the cell (Bräuninger et al., 2001), and is accompanied by deletion (or very rarely inversion) 
of IGKC and the intronic (iE) and 3’ (3’E) enhancers flanking this gene segment. The 
latter deletes the VJ joint. KDE rearrangements to these two sites takes place at 
frequencies of approximately 75% and 25% respectively (Beishuizen et al., 1994; Sakano 
et al., 1979).  
The KDE has a murine equivalent; the recombination sequence (RS) (Daitch et al., 1992; 
Durdik et al., 1984). Evidence detailing the mechanism of KDE rearrangements in both 
humans and mice strongly supports the notion that they are evolutionarily conserved events 
with an important functional role. Despite the marked differences in the ratio of Ig: Ig 
light chain expression between humans and mice (60:40% and 95:5% respectively), it has 
been demonstrated that the mouse RS sequence rearranges to an identical CACAGTG 
‘acceptor site’ sequence within the J-C intron, and that albeit relatively small, mouse 
Ig-producing B cells frequently carry deletions of C (Durdik et al., 1984).  
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Thus, KDE rearrangements prevent a series of activities that may take place at IGK loci. 
Firstly, KDE rearrangement prevents the expression of IGK gene segments that have been 
selected against. Secondly, KDE rearrangement prevents further rearrangement events 
from taking place on the same allele in developing B cells. Thirdly, KDE inactivation of 
IGK loci prevents somatic hypermutation of variable regions should the cell carrying the 
non-productive rearrangement subsequently become activated because this process is 
dependent upon the intronic enhancer iE. Additional studies demonstrated that both 
enhancers play a role in activating VJ rearrangement events, since double-mutant B cells 
exhibit no IGK rearrangement but can rearrange and express rearrangements of IGL (Inlay 
et al., 2002). 
It has previously been suggested that rearrangements of the KDE mirror the level of 
receptor editing taking place at the light chain loci, and it was proposed that  failure of KDE 
rearrangement, or the equivalent RS element in mice, may be associated with autoimmune 
disease states (Panigrahi et al., 2008). This group observed lower KDE rearrangement 
frequency in populations of B cells from patients with T1D and SLE compared to healthy 
controls. Data were interpreted as decreased levels of receptor editing taking place at the 
light chain loci in these autoimmune conditions, ultimately suggesting failure in central B 
cell tolerance.  
This chapter describes the use of a quantitative RT-PCR assay to quantify rearrangement 
events of the KDE on IGK alleles of human CD19+ Ig- and Ig-expressing B cells to 
investigate whether the KDE rearrangement process is inefficient in SLE, and whether it 
therefore may be implicated in the failure to inactivate expression of certain IGKV gene 





4.1.1 Experimental aims 
 
The aims of the analyses described in this chapter were to investigate the nature of the 
rearrangements of the human KDE in healthy and SLE B cells. The following questions 
were examined. 
 Is there any difference in the relative quantification of KDE rearrangements to the 
J-C intronic RSS in gDNA isolated from FACS-sorted populations of CD19+ 
Ig/Ig B cells isolated from healthy donors and SLE patients? 
 Does the KDE rearrange with equivalent frequency in health and SLE by its 
alternative rearrangement mechanism – to unrearranged, upstream V gene 
segments? 
 At the molecular level, are there differences in the nature of the KDE 
rearrangement junctions and breakpoints formed following rearrangement to the 

















4.2.1 Development and validation of a multiplex quantitative real-
time PCR assay to quantify KDE rearrangements. 
 
A quantitative real-time PCR assay was used to investigate the frequency of KDE 
rearrangement to the J-C intron (iRSS-KDE) in polyclonal populations of FACS-sorted 
B cells in health and SLE. This analysis used primers that have previously been applied in 
a similar quantitative real-time PCR to determine the relative rearrangement activity of the 
KDE in human subjects (Panigrahi et al., 2008). A schematic outlining the location of the 
primer binding sites on the IGK light chain is depicted in Figure 4.1 A. 
The initial experiment used the iRSS-KDE primers to verify that the genomic DNA of a 
Nalm-6 cell line could be used to efficiently quantify iRSS-KDE rearrangements over a 
range of concentrations. Nalm-6 gDNA is isolated from a pre-B cell line known to have 
KDE rearrangements on both IGK alleles so represents a positive control for iRSS-KDE 
quantification. This was performed in order to verify that these primers would be suitable 
for accurate detection of iRSS-KDE rearrangements from gDNA isolated from varying 
numbers of cells; the variable relating to the numbers of FACS-sorted B cells obtained for 
each sample. 
Amplification of the iRSS-KDE rearrangement was standardised relative to the expression 
of the endogenous reference gene RNaseP in a multiplex qRT-PCR reaction. RNaseP is 
known to be present in two copies in a diploid genome, so can therefore be used for relative 
quantitation of copy number targets of the iRSS-KDE rearrangement. Having the two 
primer sets in the same PCR reaction allowed for compensation for technical variability 
within each PCR reaction, such as pipetting errors. It also compensated for variabilities in 
starting DNA material since different cell numbers were sorted into each subset; a 
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reflection of the relative proportions of different subsets within individual CD19+ B cell 
populations.  
The amount of genomic DNA in each sample could be quantified by the relative Ct value 
obtained for iRSS-KDE rearrangement relative to the Ct values assigned for RNaseP within 
the same reaction. Serial dilutions of Nalm-6 genomic DNA were made and iRSS-KDE 
rearrangements were quantified relative to RNaseP. Quantification was always performed 
in triplicate at each concentration of serially diluted Nalm-6 DNA. Doubling dilutions of 
Nalm-6 DNA was reflected in one-cycle increments in cycle threshold (Ct) values obtained 
for iRSS-KDE rearrangement quantification. This was also mirrored by one-cycle 














Figure 4.1 Quantification of iRSS-KDE rearrangements. (A) Schematic outlining the rearrangement 
of the KDE to the recombination sequence located in the J-C intron and resulting deletion of 
Cand the enhancers iE and 3’E in green. Rearrangement of the KDE takes place if a non-
productive rearrangement is produced (NP) or if a productive rearrangement has been selected 
against and not used; forbidden productive (FP). The black lines represent the approximate location 
of the primer binding sites for quantification of iRSS-KDE rearrangements following alignment of 
their RSSs. (B) Quantification of iRSS-KDE rearrangements in serially diluted Nalm-6 genomic 
DNA relative to the housekeeping gene RNaseP in a multiplex quantitative real-time PCR reaction.  
 
Analysis of the real-time PCR data involved comparing the Ct values of the iRSS-KDE 
rearrangement with RNaseP, and then comparing with the Nalm-6 calibrator by the 




Log Starting Quantity 
Nalm-6 DNA (ng/ml) 
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This method for analysis of RT-PCR data is referred to as the 2–[][] Ct method, where: 
 Ct = []Ct of sample normalised to RNaseP   –  []Ct of Nalm-6 calibrator normalised to RNaseP 
The [][]Ct calculation was a valid analysis for this iRSS-KDE rearrangement 
quantification as the amplification efficiencies of the target and the endogenous reference 
RNaseP were approximately equal.  
Several quality control parameters were established prior to relative quantification of iRSS-
KDE rearrangements of genomic DNA. Previous data from Professor Spencer’s lab had 
determined that Ct scores greater than 35 cycles gave inaccurate quantification of the target 
gene, so only samples where Ct scores of less than 35 were obtained were considered for 
accurate iRSS-KDE quantification. Furthermore, where a Ct difference greater than one 
full cycle was observed among triplicates, the whole data point was excluded. Where a 0.3 
cycle difference in Ct score was obtained for two samples within a triplicate, the mean of 
these two values was taken, and the third score omitted, providing this Ct score was within 
the 1 cycle permitted for inclusion of the data point.  
The quality control data shown in Figure 4.1 confirm that the use of Nalm-6 is reliable as 
a sample calibrator for iRSS-KDE rearrangement quantification in the genomic DNA 
isolated from B cells. For the subsequent real-time PCR assays, genomic DNA from Nalm-
6 was used at a 1:100 dilution as a data calibrator. At this concentration,  all samples could 
be quantified in the exponential phase of amplification, thereby providing the most 





4.2.2  Relative quantification of the rearrangement frequency of the 
KDE to the J-C intronic RSS in CD19+ B cells of healthy controls and 
SLE patients. 
 
After optimisation, the previous assay used for quantification of KDE rearrangement to the 
iRSS was applied to genomic DNA isolated from FACS-sorted viable CD19+ Ig+ / Ig+ 
PBMCs of 10 buffy coats from anonymous healthy controls and 15 female SLE patients. 
As described in Chapter 3 (section 3.1.2.1), following cell surface immunostaining for Ig 
and Ig light chains, flow cytometry analysis revealed that in some SLE samples, varying 
proportions of CD19+ cells appeared to harbour both light chains. This observation is 
investigated in Chapter 5, though for the purpose of this iRSS-KDE quantification by RT-
PCR, all cells sorted were gated upon a high expression of Ig or Igand cells falling 
within intermediate expression levels of either light chains were excluded. An example of 
this is depicted in Figure 4.2 A. 
All SLE patients studied were serum ANA positive, though the population displayed a 
broad spectrum of clinical manifestations and had had different disease duration (Appendix 
2). The relative quantity of iRSS-KDE rearrangement joints will be expressed in terms of 
the delta delta CT (Ct) and will be referred to as a relative copy number (RCN), where 
the quantification of iRSS-KDE is standardised relative to RNaseP in the multiplex 
reactions, and then calibrated to the Ct for iRSS-KDE rearrangement status quantified 
from the positive Nalm-6 cell genomic DNA control which was always adjusted to ‘1’. 
This represents a 1:1 ratio between RNaseP and rearranged KDE since Nalm-6 carries two 
copies of iRSS-KDE rearrangement per genome. Quantification of iRSS-KDE 
rearrangements within CD19+ Ig+ B cells showed no difference between health and SLE 
(Figure 4.3 B). However, iRSS-KDE rearrangement frequency within populations of 
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CD19+Ig+ B cells isolated from SLE patients was significantly reduced compared to 
healthy controls (p = 0.0032). 
 
 
Figure 4.2 Relative quantification of the rearrangement frequency of the KDE in populations of 
CD19+ B cells from healthy controls or SLE patients.  (A) Outline of the FACS gating strategy used 
to sort viable CD19+ Ig-andIg-expressing B cells. (B) Relative quantification of the iRSS-KDE 
in CD19+ Ig+ B cells isolated from healthy controls and SLE patients. (C) Relative quantification 
of the iRSS-KDE in CD19+ Ig+ B cells isolated from healthy controls and SLE patients. Each dot 
relates to an individual healthy/patient sample. Statistical analyses were performed by Mann-







4.2.3 Relative quantification of the rearrangement frequency of the 
KDE to the J-C intron 5’ of the RSS in CD19+ PBMCs of healthy 
controls and SLE patients. 
 
The significantly lower iRSS-KDE rearrangement frequency observed in SLE CD19+Ig+  
B cell populations compared to equivalent CD19+ Ig+ B cell populations in health raised 
questions regarding the nature of the KDE rearrangement. As previously described, the 
KDE most frequently rearranges to the iRSS, but can rearrange to an unrearranged 
upstream V gene segment 5’ of the iRSS. To ask whether the reduced rearrangement 
activity of the KDE to the iRSS observed in SLE compared to health was due to more 
frequent KDE rearrangement to unrearranged V segments, RT-PCR primers were 
designed to target a portion of the J-C intron, 5’ of the iRSS in the same genomic DNA 
samples from which iRSS-KDE rearrangement frequency had been determined (Figure 4.3 
A). If quantification of this portion of the intronic sequence 5’ of the iRSS was also less 
frequent in SLE compared to health, it may suggest that this is the explanation for the 
reduced frequency of iRSS-KDE rearrangements observed. Quantification of KDE 
rearrangements to this intronic sequence 5’ of the iRSS was equivalent in both CD19+ Ig+ 






   
 
Figure 4.3 Quantitative RT-PCR for relative quantification of the rearrangement of the KDE to an 
upstream V gene segment. (A) Schematic representation of primers used to quantify a portion of 
the intron 5’ of the iRSS. (B) KDE rearrangement frequency quantified in FACS-sorted CD19+ Ig+ 
B cells in healthy controls and SLE. (C) KDE rearrangement frequency quantified in FACS-sorted 
CD19+ Ig+ B cells in healthy controls and SLE. Statistical analyses were performed by Mann-
Whitney tests assuming non-equal variance. 
 
This section provides evidence to suggest that the reduced frequency of iRSS-KDE 
rearrangements observed in SLE compared to health was not the result of the KDE 







4.2.4 Sequence analysis of the iRSS-KDE rearrangement junctions 
from PCR amplified and cloned genomic DNA isolated from CD19+ 
Ig+ PBMCs of healthy controls and SLE patients. 
 
It was considered possible that the reduced frequency of KDE rearrangements to the iRSS 
observed in SLE might be due to different sequences of the recombination sites involved 
in the rearrangement itself. Therefore, KDE rearranged junctions were sequenced and the 
possibility that there may be differences in the local sequence or breakpoint was 
investigated. Genomic DNA of CD19+ Ig+ B cells from 2 healthy controls and 2 SLE 
patients was PCR amplified using primers designed to amplify the iRSS-KDE 
rearrangement (Figure 4.4 A). The DNA from Ig-expressing B cells was studied because 
these will contain more iRSS-KDE rearranged junctions than those expressing Ig. PCR 
products were then cloned and sequenced. A total of 49 sequences from healthy controls 
and 63 sequences from SLE patients were obtained and analysed using Gene Jockey 
software. Each sequence was aligned with the germline J-C intron and germline KDE 
sequence to identify the breakpoint of rearrangement of the KDE to the intronic RSS. The 
final nucleotide at the junctional breakpoint was obtained for both the intron and KDE, and 
the percentage frequency of sequences that expressed this breakpoint was calculated. 
Examples are given in Figure 4.4 B. Similar trends were observed between health and SLE 
at both the intronic RSS and KDE breakpoint, with a highly diverse set of breakpoints at 







Figure 4.4 Sequence analysis of iRSS-KDE rearrangements. (A) Schematic to outline the 
experimental design. PCR amplification of iRSS-KDE rearrangements was performed using gDNA 
isolated from FACS sorted CD19+ B cells from two healthy controls and two SLE patients. 
Following PCR amplification and confirmation of the correct band size by gel electrophoresis PCR 
products were purified before cloning and subsequent sequencing (Beckman Coulter Genomics). 
Sequences obtained from these clones were analysed for junctional variability within the iRSS-KDE 
rearrangements amplified. (B) Representative example sequences of a rearranged iRSS-KDE 
junctions aligned with germline J-C intron and KDE sequences. The black arrows represent where 
the germline J-C intron ends and the germline KDE sequence begins. In this way the frequency 








Figure 4.5 iRSS-KDE rearrangement breakpoint analysis.  The percentage frequency of sequences 
that terminate at specific breakpoints after iRSS-KDE rearrangement. PCR products were cloned 
and sequenced from PCR-amplified genomic DNA isolated from CD19+ Ig+ populations of B cells 
in healthy controls (n=2) and SLE (n=2).  
 
Additional information regarding the nature and timing of the KDE rearrangement could 
be studied through analysis of N-nucleotide addition by TdT at the rearranged iRSS-KDE 
junction in the pooled control and SLE sequences. TdT varies in its activity during B cell 
development. Where the addition of P- and N- nucleotides were observed, total additions 
were pooled because in approximately 25% of cases, an N-nucleotide addition would be 
indistinguishable from a P-nucleotide. The trend in N-nucleotide addition at the junctions 
was similar in health and SLE, with approximately 35% of rearranged iRSS-KDE junctions 
having no N-nucleotide addition (Figure 4.6).  
 
Controls  (n=2) 
 SLE (n=2)  
(n}(n=2) 
n = 49 
 = 63 




Figure 4.6  N-nucleotide addition at the KDE-iRSS rearranged junction. The percentage frequency 
iRSS-KDE rearranged sequences from CD19+ Ig+ carrying varying N-nucleotide addition in health 
(HC n=2) and SLE (SLE n=2). Approximately thirty five percent of iRSS-KDE junctions studied 
lack N-nucleotide addition. 
 
4.2.5  Summary of experimental findings 
 Is there any difference in the relative quantification of KDE rearrangements 
to the J-C intronic RSS in gDNA isolated from FACS-sorted populations of 
CD19+ Ig/Ig B cells isolated from healthy donors and SLE patients? 
Outcome: Relative quantification of iRSS-KDE rearrangements demonstrated that 
the frequency of KDE rearrangement events to the iRSS is lower in CD19+Ig+ 






 Does the KDE rearrange with equivalent frequency in health and SLE by its 
alternative rearrangement mechanism – to unrearranged, upstream V gene 
segments? 
Outcome: Relative frequency of a conserved intronic sequence located in the J-
C intron but 5’ of the iRSS is similar in health and SLE, suggesting that the 
reduced frequency of iRSS-KDE rearrangements in SLE is not due to 
rearrangement of the KDE to an unrearranged upstream V segment. 
 
 At the molecular level, are there any differences in the nature of the KDE 
rearrangement junctions and breakpoints formed following rearrangement to 
the J-C intronic RSS between healthy and SLE B cells? 
Outcome: There was no difference in the features of the rearranged junction or 
















4.3  Discussion 
 
Rearrangements of the KDE serve to silence newly rearranged VJ joints that are in the 
incorrect genetic reading frame or have been selected against, and are thought to 
accompany ongoing rearrangement events associated with Ig light chains. As previously 
mentioned, Panigrahi et al., 2008 described the quantification of KDE rearrangement 
events to its most common site of rearrangement, the iRSS, in populations of B cells from 
mice and humans, observing lower KDE rearrangement frequencies in B cells from patients 
with SLE and T1D. They suggested that KDE rearrangements could serve as a biomarker 
for receptor editing at the light chain loci, and that their findings were reflective of 
decreased receptor editing by light chains in autoimmunity (Panigrahi et al., 2008).  
The first set of data presented in this chapter aimed to verify the observations of Panigrahi 
et al., 2008 through use of a similar quantitative real-time PCR assay to investigate the 
rearranging activity of the KDE to the iRSS in genomic DNA samples. The genomic DNA 
from populations of Ig-expressing B cells in SLE carried a significantly lower frequency 
of rearrangements of the KDE to the iRSS, confirming the previous observations (Panigrahi 
et al., 2008). In contrast to the data of this study however, no difference was observed in 
the frequency of iRSS-KDE rearrangements quantified in the genomic DNA from CD19+ 
Ig-expressing B cells between health and SLE. This may be due to the relatively small 
data set acquired compared to the previous study where double the number of SLE patients 
were studied. In addition, fewer iRSS-KDE rearrangements would be expected from Ig-
expressing cells than Ig-producers, so perhaps a comparatively larger sample size was 
required to detect subtleties in iRSS-KDE rearrangement frequency in these Ig cells in 
order to subsequently observe similar trends as those seen by Panigrahi and colleagues.  
These data presented in this chapter may provide an alternative interpretation of the lower 
KDE rearrangement frequency by SLE B cells to that of Panigrahi et al. 2008, who suggest 
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this reflects defective receptor editing in SLE. In addition, the high-throughput sequencing 
analysis of IGKV and IGKJ gene segment rearrangements did not identify any evidence of 
a defect in receptor editing in SLE. This is consistent with a study by Dorner and 
colleagues, who obtained single peripheral CD19+ B cells from a patient with untreated 
SLE and studied both IGKV and IGKJ gene segment usage in the productive and non-
productively rearranged IGK repertoire. They suggested that the increased usage of IGKV5 
compared to a control donor, alongside its over-representation with groups of productively 
rearranged sequences compared  with the non-productively rearranged sequences in the 
SLE patients, was reflective of intact and more apparent levels of receptor editing compared 
to health (Dorner et al., 1998). 
The potential of the KDE to rearrange to V-associated RSSs other than the iRSS meant 
that it was important to question whether the lower frequency of iRSS-KDE rearrangement 
events observed in SLE was due to an increase in KDE rearrangement events to previously 
unrearranged V gene segments. Additional studies have involved restriction map analyses 
of IGKV, J and C gene segments from different B cell lines including Nalm-6, pre-B cells 
from acute lymphoblastic leukemia cell lines and SU-DHL-6 cells from an IGH, Ig-
producing histiocytic cell line (Siminovitch et al., 1985).  These experiments showed that 
100% (20/20 cells studied) of C segments were lost from Ig-producing B cell precursors 
and that 5 of these cases exhibited deletion of all J segments, representing instances where 
the KDE rearranged to an upstream V segment (25% of KDE rearrangements) (Sakano et 
al., 1979). Quantification of a conserved portion of the J-C intron, 5’ of the iRSS, in both 
health and SLE aimed to question whether the KDE may have a tendency to rearrange more 
frequently to an upstream, unrearranged V gene segment in SLE. The equivalence in 
quantification of this portion of the intron suggests that this is not the case.  
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The cloning and sequening of iRSS-KDE rearranged junctions from the genomic DNA of 
Ig-expressing B cells from 2 SLE patients and 2 healthy controls allowed for comparison 
of the diversity in KDE rearrangement junctions, and to question the possibility that there 
may be differences in the local sequence or breakpoint between health and SLE, which may 
account for the lower frequency of KDE rearrangements observed. The composition of 
junctions generated by gene rearrangement is related to the activity of TdT that alters in 
expression during B cell development. TdT-deficient lymphocytes in mice bear no N 
nucleotides in their IGH variable region genes (Komori et al., 1993), and expression of this 
enzyme is largely restricted to early B cell differentiation in the pro-B cell stages when 
IGH rearrangement predominates (Li et al., 1993). This provides reason for the limited 
addition of N-nucleotides observed in VJ junctions analysed here, since light chain 
rearrangement only begins in the pre-B cell stage where only residual TdT would be 
present. The similarity in the DNA sequences involved in the iRSS-KDE rearrangement in 
SLE and health implies that they are acquired when relevant enzymatic activity is 
equivalent, and therefore at an equivalent stage in development. 
Although the inherent mechanism of a KDE rearrangement is fairly well documented, the 
signalling events that initiate the regulatory activity of the KDE remain elusive, largely due 
to the poor understanding of the signalling pathways involved in initiation of light chain 
rearrangements. One study described the requirement for transcription factors IRF-4 and 
IRF-8 in orchestrating the initiation of light chain rearrangements in pre-B cells, as the B 
cells of IRF4,8-/- mice arrest in the cycling pre-B cell stage (Lu et al., 2003). Five years 
later, it was suggested that light chain rearrangements are driven synergistically by 
convergent signalling pathways involving the transcription factor IRF4 and signalling 
through the IL-7R in the developing B cell, though debate lies in the requirement for 
acquired pre-BCR signalling or attenuated IL-7R signalling (Johnson et al., 2008).  
188 
 
The fact that the conserved CACAGTG heptamer sequence associated with the KDE is 
identical to the heptamer sequences that flank germline V and Jsegments (Sakano et al., 
1979) suggests that the recombinatorial enzymes, enhancers and promoters that mediate 
initial rearrangement activity at the IGK loci are also responsible for its functional 
inactivation by the KDE. It would therefore be of interest to study these enzymes, 
predominantly the RAG gene products and the signalling pathways upstream of them to 
investigate potential signalling pathways involved in KDE rearrangement initiation. 
The data presented in this chapter, alongside the conclusions drawn in Chapter 3 suggest 
that rearrangement of the KDE to functionally inactivate IGK alleles is inefficient in SLE 
compared to health, potentially allowing for the emergence of an SLE B cell repertoire 
expressing IGK light chains that are typically selected against in health. The following 
chapter will explore earlier observations involving the potential expression of both Ig and 
Ig light chains by some B cells in SLE (described in section 4.2.2) and consider the more 
























Chapter 5                                                                                           
Investigating immunoglobulin cell surface light chain 























Studies in Chapters 3 and 4 of this thesis required identification and isolation of B cells in 
SLE expressing Ig and Ig light chains as published previously by others (Panigrahi et 
al., 2008). However, as stated in Chapter 3 (section 3.1.2.1) and Chapter 4 (section 4.2.2), 
this was frequently more complex than initially considered. In this chapter, potential dual 
light chain expression by SLE CD19+ B cells is investigated.  
The monospecificity of B cells, mediated genetically by allelic exclusion of 
immunoglobulin heavy and light chain genes during V(D)J recombination, is regarded as 
one of the most evolutionary conserved features of the mammalian adaptive immune 
system. Allelic exclusion ensures that the expression of productively rearranged 
immunoglobulin alleles by a new B cell is limited to just one per cell (Vettermann and 
Schlissel, 2010), and historically is referred to as the ‘one B cell – one antibody’ paradigm 
(Nossal, 1958).   
Allelic and isotypic exclusion is established at the light chain loci through sequential 
rearrangement of alleles at the IGK loci which must be functionally inactivated by 
rearrangements of the KDE before the IGL loci undergoes rearrangement. This results in 
the expression of just one light chain isotype, Ig or Ig, and just one rearrangement at 
these loci if both rearrange productively. Isotypic exclusion limits the proportion of B cells 
expressing both Ig and Ig light chains to approximately 3% of B cells in fetal BM and 
spleen (Pauza et al., 1993). Interestingly, ordered Ig gene rearrangements are not per se 
required for allelic exclusion. Several studies have demonstrated that chickens, sharks and 
skates all display allelic exclusion despite rearranging their Ig genes simultaneously at 
various developmental stages (Hsu, 2009; Ratcliffe, 2006).  
191 
 
Exceptions to the ordered rearrangement of Ig light genes where rearrangement of alleles 
of IGL precede those of the IGK loci have also been reported. For example, mouse B cell 
lines have been shown to produce Ig light chain protein in the absence of IGK 
rearrangement (Berg et al., 1990; Felsher et al., 1991). In addition, the occasional 
rearrangement of IGL genes despite the maintenance of IGK alleles in germline states have 
been described in three human leukemic B cells in a total of seventeen studied (Tang et al., 
1991) and EBV-transformed human pre-B cells undergoing differentiation were shown to 
produce Ig in the absence of rearranged IGK alleles (Pauza et al., 1993).  
Several genetic models have been proposed that serve to explain the existence and 
maintenance of allelic exclusion of Ig genes. In the asynchronous recombination model, 
the mechanisms that mediate chromatin accessibility and access of RAG proteins to RSSs 
are proposed to result in the inability to simultaneously recombine two Ig alleles in one cell 
(Liang et al., 2004). This model in particular is thought to be relevant to the maintenance 
of isotypic exclusion exhibited by the Ig light chains, where differences in the activation 
status, RSS recombination efficiencies and the roles of the enhancers and promoters 
embedded at the IGK and IGL loci may limit synchronous recombination and ultimately 
light chain inclusion (Li et al., 2002b; Ramsden and Wu, 1991). Methylation status is also 
known to contribute to allelic exclusion at the IGK loci, since non-rearranged alleles remain 
methylated and those undergoing recombination are under-methylated (Mostoslavsky et 
al., 1998). 
The stochastic model proposes that allelic exclusion is the direct result of the low 
probability of generating a productive Ig gene rearrangement that additionally is a 
functionally pairing Ig chain. The resultant Ig:Ig cell surface expression ratio is therefore 
the result of the different recombination frequencies of IGK and IGL loci (Coleclough et 
al., 1981; Ramsden and Wu, 1991). In this way, allelic inclusion is minimised.   
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The feedback inhibition model proposed that intermediate products produced during V(D)J 
recombination serve to inherently inhibit the recombination process itself, where signalling 
through both the pre-BCR and BCR suppress further recombination (Alt et al., 1984). This 
model also supports the suggestion that second allele rearrangements take place following 
the generation of a non-productive or non-pairing heavy or light chain gene, as the lack of 
feedback inhibition signals allows for the continuation of recombination.  
The tendency of mammalian B cells to express just one rearranged light chain (Ig or Ig) 
despite having the genetic potential to express more than one simultaneously is dependent 
upon the mechanisms that preserve isotypic exclusion and prevent the expression of 
rearrangements that have been selected against. Defective rearrangement of the KDE and 
the subsequent failure to functionally inactivate rearranged alleles of IGK that have been 
selected against defies the laws of allelic exclusion and therefore may have dramatic 
consequences for the light chain repertoire of B cells. This chapter explores the features of 
the light chain repertoire in health and SLE to understand the features of light chain 












5.1.1   Experimental aims 
 
The aims of the analyses described in this chapter were to investigate the nature of cell 
surface immunoglobulin light chain expression by SLE B cells following the observations 
that several SLE patients appear to express both Ig and Ig light chains on their cell 
surface. These investigations were addressed by asking the following questions: 
 Is a tendency to express both Ig and Ig light chains by some B cells a rare or 
frequent observation in SLE? 
 Is this apparent dual Ig and Ig light chain expression a genuine feature of SLE 
CD19+ B cells, or is cytophilic binding of Igs, or Ig-ICs bound to the surface of 
SLE B cells responsible for interfering with immunostaining prior to flow 
cytometry analysis? 
 Is dual light chain cell surface expression stable? 
 Could VpreB surrogate light chain expression account for the apparent dual 
expression of light chains? 
 Can rearranged transcripts of IGK and IGL be detected in the cDNA isolated from 
single cells of a dual Ig+Ig+ SLE patient? 
 Is dual light chain expression a feature of one specific B cell subset? 
 Is there a correlation between dual light chain expression and KDE rearrangement 
activity in SLE? 








5.2  Results 
 
5.2.1  Investigation of cell surface light chain expression by 
healthy and SLE CD19+ B cells. 
 
Analysis of rearrangement of iRSS-KDE rearrangements in Ig- and Ig-expressing B cells 
described in Chapters 3 and 4 involved isolating genomic DNA from Ig- and Ig-
expressing B cells. It became apparent during the FACS sorting for these experiments that 
the profiles of cell surface light chain expression exhibited by some SLE PBMCs was 
highly variable in appearance, and in many instances, expression of solely Igor Ig light 
chains by populations of CD19+ B cells could not be identified in. This was overcome by 
avoiding cases that had unusual IgIg-expressing cell profiles (Chapter 3) or by isolating 
IgandIg-expressing cells independently of each other (Figure 4.2 A).  
To examine this observation more closely, PMBCs were isolated from the whole blood of 
58 SLE patients and 26 anonymous healthy controls and were then immunostained for the 
cell surface expression of CD19, Ig and Ig light chains prior to flow cytometry analysis. 
The variable nature of cell surface light chain expression by SLE B cells meant that strict 
gating rules were required in order to maintain a consistent determination of the degree of 
dual expression observed in each control and SLE sample analysed. Firstly, isotype control 
stains were performed for each sample which allowed for negative quadrant gates to be set 
according to these. The same quadrant was then applied to the equivalent stained sample, 
and adjusted to within 0.5 logs if necessary to control for background fluorescence and the 
potential for non-specific staining. If gating adjustments within this range were required, 
this was done through determination of the populations of CD19+ as observed in the contour 
setting, which could indicate the number of CD19+ populations present with respect to light 
chain expression. Furthermore, to exclude the possibility that SLE cases may differ in their 
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individual properties including for example rare background fluorescence, all SLE samples 
stained were accompanied by isotype controls and unstained cells as well as fluorescence 
minus one (FMO) controls. 
With the exception of one healthy individual, 95% of total CD19+ B cells from healthy 
controls expressed either an Ig or Ig light chain; a representative example of the light 
chain cell surface expression exhibited by a typical healthy control is shown in Figure 5.1 
A. In contrast, some SLE samples appeared to have three distinct populations of CD19+ B 
cells expressing varying degrees of Ig and Ig light chains; 58.15% of CD19+ B cells in 
SLE sample 1 and 19.03% in SLE sample 4 expressed both Ig and Ig on their cell surface. 
Other SLE samples appeared to have two fairly distinct populations of CD19+ B cells 
expressing either an Ig or Ig light chain, though cells within these populations seemed 
to drift into quadrants where cells within them seem express both light chain of their cell 
surface. This is illustrated by SLE example 3, where Ig+ B cell cells seem to drift into the 
range of Ig positivity. Some rare SLE patients appeared to express both light chains on 











Figure 5.1 Flow cytometry analysis of the cell surface expression of Ig and Ig light chains by 
CD19+ B cells compared to their isotype immunostained controls. (A) Typical light chain expression 
profile by a healthy donor with a ratio of approximately 60:40 Ig to Ig. (B) Both Ig and Igcell 












Comparison of light chain expression in all SLE samples with healthy controls stained by 
the same method revealed that a significantly higher proportion of CD19+ B cells in SLE 
exhibited a degree of dual light chain expression compared to the same B cell population 
in health, suggesting that this phenomenon may be associated with SLE (Figure 5.2). It was 
next addressed whether any clinical features of disease were associated with this apparent 
expression of both Ig and Ig light chains (clinical information on all SLE patients 
investigated in this study can be found in Appendix 2). Interestingly, a history of nephritis, 
including both active and non-active nephritis at the time of blood sample collection, was 
associated with a significantly higher expression of both Ig and Ig light chain by SLE 
CD19+ B cells compared to healthy control B cells (p<0.0001***). SLE patients with no 
history of nephritis however still harboured significantly higher frequencies of CD19+ B 
cells expressing both Ig and Ig light chains compared to healthy controls (p<0.0084**). 
CD19+ B cells from a disease control patient cohort with granulomatosis with polyangitis 
(GPA) were similarly stained for cell surface expression of both light chains and were 




Figure 5.2 Flow cytometry analysis of the proportion of CD19+ B cells expressing both Ig and Ig 
light chains in healthy controls (n=26), disease control GPA patients (n=21) and SLE patients with 
(n=29) or without (n=27) a history of lupus nephritis (total SLE patients n=56.) SLE patients with a 
history of nephritis (active or non-active at the time of blood collection) displayed significantly 
higher populations of CD19+ B cell expressing both Ig and Ig light chains on their cell surface 
compared to non-nephritis SLE patients, and both GPA and healthy control samples.  
 
It was also asked whether the presence of autoantibodies measured in SLE patient serum 
associated with the likelihood dual light chain expression by CD19+ B cells. The clinical 
information was retrieved from Lee Meng Choong at St Thomas’ Hospital, London, who 
was responsible for the collection of blood samples and storage of additional clinical 
information about the patients used in this study. The autoantibodies assessed included the 
following; anti-dsDNA, anti-ENA, anti-Ro, anti-La, anti-Sm, anti-RNP and anti-aPL. No 
differences were observed in the frequency of CD19+ B cells expressing both Ig and Ig 
light chains; patients exhibited dual light chain expression irrespective of their positivity 





Figure 5.3 Autoantibody titres measured from SLE patient serum and the frequency of SLE CD19+ 
B cells expressing both Ig and Ig light chains. There was no association between whether SLE 
patients harbour CD19+ B cells expressing both light chains and the presence of autoantibodies. 
 
5.2.2 Investigating the origin of dual light chain expression by SLE 
CD19+ B cells by flow cytometry analyses. 
 
The observation that B cells appeared to express both light chains to varying degrees in 
approximately half of all SLE patients studied meant that several areas had to be explored 
to determine if this observation was a genuine feature of SLE or an artefact. It was first 
considered, since the hallmark of SLE is the propagation of an autoimmune 
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immunoglobulin repertoire characterised by the presence of antibodies targeting dsDNA, 
that SLE B cells may be coated with immunoglobulin-dsDNA immune complexes. This 
could account for the presence of Ig and Ig light chains on the same cell. It is also 
believed that a contributing factor to the pathogenesis of SLE is the aberrant clearance of 
apoptotic cells and exposure to self-DNA and histones, leading to the subsequent immune 
response to autoantigen. Furthermore, lower serum levels of DNase I activity have been 
observed in active SLE patients compared to healthy donors (Chitrabamrung et al., 1981).   
 
DNase I treatment of PBMCs would remove any bound Ig/dsDNA complexes and sticky 
DNA molecules that may be present in the SLE samples and ensure they do not interfere 
with the staining of target cells for surface immunoglobulins. To test this, PBMCs from 
two SLE patients exhibiting highly distorted light chain flow cytometry profiles were 
washed prior to incubation with DNase I at a concentration of 0.1 mg/ml at room 
temperature for 30 minutes, according to manufacturer’s instructions. Cells were then 
washed and immunostained by the typical protocol. DNase I treatment did not alter the 
distorted light chain expression by the two SLE cases, where after DNase I incubation and 
subsequent immunostaining, similar proportions of CD19+ B cells expressed both Ig and 





Figure 5.4 Flow cytometry analysis of light chain expression by SLE B cells following incubation 
with DNase I (0.1 mg/ml) for 30 minutes at room temperature. The large proportions of dual light 
chain expressing B cell populations observed prior to DNase treatment, remained following DNase 
incubation. 
 
In order to eliminate the possibility that the detection of both light chains on single cells 
was a consequence of cytophilic binding or adsorption of serum immunoglobulin to the B 
cell surface, acidic wash buffers were used to treat the cells prior to immunostaining and 
flow cytometry analysis. Acid washed have previously been used to detach antibodies from 
antigen (Kameyama et al., 2007). PBMCs from the same SLE samples as in Figure 5.4 
were thawed and washed in 2% FCS. Cells were subsequently washed twice for 5 minutes 
in either 0.2M glycine 0.15M NaCl (pH 3.0) or RPMI-1640 media (pH 2.5) buffers. Acid 
washes were followed by two standard wash steps of 2% FCS in PBS. High frequencies of 
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Figure 5.5 Flow cytometry analysis of light chain expression by SLE CD19+ B cells following acid 
washing in a 0.2M glycine (pH3.0) and an RPMI-1640 media wash (pH2.5) for 5 minutes prior to 
immunostaining. Large dual-light chain expressing populations of cells were observed following 
acid washing two different buffers. 
 
To determine whether the expression of both light chains was a stable feature of SLE 
CD19+ B cells, dual-light chain producing CD19+ B cells from an SLE patient were FACS 
sorted and co-cultured with allogeneic CD3+CD4+ T cells isolated from a multidonor buffy 
coat obtained from the National Blood Service. Cells were stimulated with 50 ng/ml PMA 
for two days and cells were harvested and re-stained for the expression of CD19, Ig and 
Ig. Cells remained positive for the expression of both light chains after two days of 
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Figure 5.6 Investigating the stability of dual-light chain expression in an SLE patient. 
Immunoglobulin light chain expression by CD19+ B cells from an SLE patient after co-culture with 
allogeneic CD3+CD4+ T cells and stimulation with PMA for 2 days. Cells remained positive for both 
IgandIgcell surface expression 
 
The data illustrated in this section examined the possibility that the expression of both Ig 
and Ig light chains was due to artefact generated during the immunostaining process and 
treatment of SLE cells prior to analysis. Treatment of SLE PMBCs with DNase and acidic 
wash buffers did not alter the profile of light chain expression observed. Co-culturing the 
cells under stimulating conditions in attempts to induce recycling of the BCR and 
subsequent shedding of potential immunoglobulin-containing complexes to the cell surface 
also did not alter the light chain expressed observed.  
  Isotype    Rep #1 Rep #2 
  Isotype    SLE sort sample  
 Day 0 
 Sorting of 
Ig+Ig+ SLE 
CD19+ B cells 
  Day 2  following co-culture with CD3+CD4+ allogeneic T cells +  50ng/ml PMA  






Previous studies have identified an unconventional population of human B cells co-
expressing conventional light chains and the surrogate light chain VpreB (V-preB+L+). It 
was demonstrated that 68% of the antibodies expressed by V-preB+L+ cells were 
autoreactive; 50% were found to be genuine anti-nuclear antibodies which held additional 
binding complementarity to LPS, insulin and both ss- and dsDNA. In addition, these cells 
were found to express mRNA transcripts of RAG proteins and display skewed IGKJ gene 
usage, potentially an imprint of receptor editing (Meffre et al., 2000b; Meffre et al., 2004). 
V-preB+L+ B cell populations in peripheral blood are of very low frequency, but it was 
considered an important factor to eliminate in the context of the dual light chain expression 
profiles observed in SLE. 
 To investigate the possibility that expression of VpreB could contribute to possible cross- 
reaction of the antibody to Ig light chains, flow cytometry analysis was performed by 
immunostaining the PBMCs of 6 anonymous healthy donors and 8 SLE patients for the 
expression of CD19, IgIg and the surrogate light chain VpreB. No difference was 
observed in the cell surface expression of VpreB between healthy donors and SLE patients 
(Figure 5.7 A). These data however are not supported by a positive control sample, such as 
PBMCs isolated from fresh bone marrow, since at the time of immunostaining for VpreB 
such a sample was not available. 
To further investigate VpreB expression using a different method, VpreB was amplified by 
a semi-nested PCR reaction. The primers used to amplify VpreB span an intron so therefore 
allowed for amplification of both the DNA amplicon and RNA transcript.  If VpreB has 
been transcribed and expressed as protein, a smaller band of approximately 350bp would 
be observed since the intron will have been spliced out. The positive control used was 
cDNA isolated from BM cells, where detection of surrogate light chain is expected during 
human B cell development in the large pre-B cell. PCR amplification was performed on 
the cDNA of single (Ig- and Ig-expressing) FACS-sorted cells from the SLE patient 
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gated in Figure 5.6. VpreB transcript was only successfully amplified from the BM cDNA 
sample, where transcripts of this surrogate light chain would be expected (Figure 5.7 B). 
Bands the expected size of DNA VpreB amplicons were detected in two of the three SLE 
single cell cDNA samples (lanes 4 and 5) indicating the potential presence of a DNA 
contaminant in these samples. These data would require repeating using the correct 
experimental controls for the VpreB flow cytometry analysis and removal of the 








Figure 5.7 Investigating the expression of surrogate light chain VpreB by CD19+ B cells in healthy 
controls and SLE (A) Flow cytometry analysis of VpreB expression by CD19+ B cells. No 
differences were observed between healthy donors (n=6) and SLE patients (n=8). (B) Gel 
electrophoresis of PCR products after amplification of VpreB from total CD19+ DNA (lane 2), 
cDNA isolated from BM (lane 3), and in the cDNA isolated from single dual light chain expressing 
CD19+ cells from one SLE patient (lanes 4-6). VpreB transcript could only be detected from the BM 
cDNA sample. 



















   Lane #          1           2             3             4             5            6     
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5.2.3 cDNA analysis of single FACS-sorted SLE B cells  
 
The attempts to challenge the observation that SLE B cells may frequently express both 
IgandIg light chains have ultimately relied on flow cytometry analysis as a readout for 
determination of light chain production. In order to investigate dual light chain production 
using a different method, dual light chain expressing CD19+ B cells from a dual-expressing 
SLE patient (the same sample as gated in Figure 5.6) were single cell sorted into 96-well 
plates containing SLyRT buffer and the RNA reverse transcribed from individual cells. 
Single CD19+ B cells were sorted into 80 wells of each plate (rows A-H, columns 1-10) 
where column 11 contained 0 cells per well (negative control wells) and column 12 
contained 8 cells per well (positive control wells). The reverse transcribed product was then 
PCR amplified in two separate reactions, one containing primers to amplify VC (for IGK 
transcripts) and the second to amplify VC(for IGL transcripts). PCR primers were then 
used to further amplify the PCR products of round 1 in a second round. 
 As experimental controls, ten Ig-expressing CD19+ cells were sorted from a healthy 
individual into a 96-well plate containing SLyRT buffer and similarly RNA was reverse 
transcribed to cDNA prior to PCR amplification in two discrete reactions for the screening 
of IGK and IGL transcripts. The IGL PCR was performed on cDNA from Ig+ healthy B 
cells to serve as the negative control alongside a PCR H20 control. For analysis of light 
chain expression from the single cells, PCR for the expression of IGK transcripts was 
initially performed, and subsequent PCR amplification for IGL was only performed on the 
cDNA from wells that were positive for an IGK VC transcript. 
Ig-expressing cells from the healthy donor expressed IGK but not IGL message. IGK and 
IGL transcripts of the correct band size were both detected in the wells where 8 dual-
expressing SLE CD19+ cells had been sorted (Figure 5.8 A).  
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The efficiency of IGK light chain transcript detection from the single cells sorted from the 
SLE patient was 70%, and of these, 30% were also positive for IGL transcript. As a result, 
PCR amplicons of IGK and IGL from six single dual-expressing cells were cloned and 
sequenced and were found to be productive and unique after analysis on the IMGT database 
(Figure 5.8 B).  
 
 





Figure 5.8 cDNA analysis of SLE dual-expressing B cells. (A) Detection of both IGK andIGL 
transcripts in six single FACS-sorted SLE B cells following PCR amplification (B) IMGT 















5.2.4 Investigating the origin and nature of dual light chain 
expression in SLE 
 
Detection of both IGK and IGL rearranged transcripts within single cells of an SLE patient 
supported the hypothesis that the observed cell surface expression of both Ig and Ig light 
chains in some SLE patients may be a genuine feature of SLE B cells.  
 
5.2.4.1 Studying somatic hypermutation in SLE dual-expressing B cells 
 
Rearrangement of the KDE functionally silences unwanted rearrangements of IGK. This 
rearrangement removes IGKC and the intronic enhancers required for the accumulation of 
somatic hypermutations. Failure of KDE rearrangement could therefore result in somatic 
hypermutation of non-productive alleles of IGK that would normally have been inactivated 
and therefore would not undergo mutation. In order to examine the somatic mutation status 
of IGK rearrangements from dual light chain expressing SLE B cells, VJ rearrangements 
were PCR amplified from genomic DNA isolated from FACS sorted CD19+ cells from two 
SLE patients exhibiting 87% and 58% dual light chain expression. PCR products were then 
cloned and sequenced, and the VJrearrangements obtained were analysed using IMGT, 
where the productivity and mutation load could be assessed. 
SLE sequences were also compared to data obtained by a previous member of the lab, Dr. 
Su Wen, who examined the frequency of mutations within productively and non-
productively rearranged sequences from DNA of FACS sorted single lamina propria 
plasma cells. Studying the frequency of mutations within non-productive rearrangements 
reflect the cell’s capacity to silence unwanted rearrangements of IGK by KDE 
rearrangement, and any mutations observed in these sequences can be assumed to be 
nucleotide errors introduced from the use of Taq polymerase during the PCR reaction.  
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Studying the mutational frequency of rearranged IGK light chains isolated from the gDNA 
of FACS-sorted LP plasma cells serves as a good positive control since these cells represent 
a chronically activated population. Productive VJ rearrangements from these cells carry 
a high load of mutations, whereas in the non-productive rearrangements, 67% carry no 
mutations (31/46) and configure with the germline V and J gene segments (Figure 5.9). 
Remaining sequences only carried few numbers of mutations, assumed to be the 
consequence of the errors introduced by Taq polymerase during PCR-amplification. 
Strikingly, non-productive VJ rearrangements from the pooled SLE sequences carried 
similar levels of mutations to their productive equivalents, where just 47% of non-
productive IGK rearrangements carried no mutations (15/32) compared to 56% (24/43) 

















                           
    
Figure 5.9 Load of somatic mutations observed within productively and non-productively 
rearranged VJ sequences isolated from the genomic DNA of single LP plasma cells from a healthy 
individual compared with those isolated and amplified from CD19+ B cells from two SLE patients 
exhibiting aberrant light chain cell surface expression. The number of individual sequences analysed 
is in the centre of each pie chart.  **The mutational analysis from healthy intestinal LP plasma cells 
was performed by a former member of the Spencer Lab, Dr. Su Wen. 
 
5.2.4.2   Comparison of dual light chain expression by different B cell subsets 
in health and SLE 
 
In order to investigate the origin and nature of dual expression seen in SLE, it was first 
asked whether dual expression was a feature confined to a specific B cell subset. In order 
to examine this, PBMCs from 10 SLE patients and 7 healthy controls were stained and 
SLE CD19+ B cells 
Productive VJ 
rearrangements 
SLE CD19+ B cells 
Non-productive VJ 
rearrangements 
Control LP plasma cells 
Productive VJ rearrangements 
Control LP plasma cells 
Non-productive VJ rearrangements 
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analysed by flow cytometry. The following subsets were identified; early emigrant 
transitional B cells (CD19+ IgD+ CD27- CD10hi ), mature but antigen-naive B cells (CD19+ 
IgD+ CD27- CD10lo), memory B cells (CD19+ IgD- CD27+ CD10-) and activated 
plasmablasts, positive or negative for the production of IgA (CD19+ CD38+ CD27+ IgAhi/-
). Cells within each B cell subset were then further divided according to their cell surface 
light chain expression so that cells expressing both light chains could be identified. In 
health, a significantly higher frequency of IgA-producing plasmablasts appeared to express 
both Ig and Iglight chains compared to non-IgA-producing plasmablasts (p=0.0379*). 
However, the percent frequency of dual expression across all subsets analysed is much 
lower than the Ig+ Ig+ frequencies observed in SLE (Figures 5.10 A and B). Healthy 
controls typically harbour approximately 2-3% Ig+ Ig+ CD19+ B cells. In SLE however, 
if B cell samples exhibited dual expression of both light chains this was observed among 
all B cell subsets analysed and at a higher frequency than the healthy control subsets studied 



















Figure 5.10 Flow cytometry analysis of the frequency of dual light chain expressing B cells in 
different B cell subsets; transitional (TS) B cells (CD19+ IgD+ CD27- CD10hi ), mature naive (MN) 
B cells (CD19+ IgD+ CD27- CD10lo), memory (Mem) B cells (CD19+ IgD- CD27+ CD10- ) and 
activated non-IgA and IgA-producing plasmablasts (PB) (CD19+ CD38+ CD27+ IgA-/hi) in healthy 
(A) controls and (B) SLE. Note the difference in scales of both A and B. IgA plasmablast B cell 
populations express significantly higher levels of dual Ig and Ig light chain surface expression 
than that observed in the other B cell subsets investigated, though this expression is lower than the 
frequencies observed in SLE. Statistical analyses were performed by Mann-Whitney tests assuming 
non-parametric distributions. *p<0.05 
 
As a result of these data it was asked whether dual Ig and Ig light chain cell surface 
expression may be associated with a failure to rearrange the KDE, since Chapter 4 









to equivalent Ig-expressing B cell from healthy individuals. It was observed that a 
statistically significant negative correlation (p=0.0072) existed between the proportion of 
CD19+ Ig+Ig+ B cells and KDE rearrangement activity in SLE (Figure 5.11). This was 




Figure 5.11  Negative correlation between rearrangement status of the KDE and cell surface light 




5.2.6   Free light chains in SLE patient serum  
Quantification of free light chains in human serum is a frequently used immunoassay where 
increased detection of free light chains have been reported to be a useful biomarker in 
several autoimmune diseases. In order to ask whether dual light chain expression by SLE 
B cells may be associated with this phenomenon, serum samples from several SLE patients 
already analysed by flow cytometry were examined for the levels of free Ig and Ig light 
chains. This was a collaboration with The Binding Site Group Ltd, Birmingham. 




Ig and Ig light chains and the levels of free Ig or Ig light chains in the serum of the 





Figure 5.12 Correlation between the frequency of dual light chain expression by CD19+ SLE B cells 
and the concentration of (A) free Ig and (B) free Ig light chains in the serum of the same patients. 
SLE patients with higher quantities of both serum free Ig and Ig light chains tended to harbour 
larger populations of CD19+ peripheral B cells expressing both Ig and Ig light chains on the cell 
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5.2.7   Summary of experimental findings 
 
 Is a tendency to express both Ig and Ig light chains by some B cells a rare 
or frequent observation? 
Outcome: Flow cytometry analysis revealed that approximately half of all SLE 
patients examined in this study carried CD19+ B cells with clear dual-light chain 
expression populations. 
 Is apparent dual Ig and Ig light chain expression a genuine feature of SLE 
CD19+ B cells, or is cytophilic binding of Igs, or Ig-ICs bound to the surface 
of SLE B cells responsible for interfering with immunostaining prior to flow 
cytometry analysis? 
Outcome: The proportion of SLE CD19+ B cells expressing both Ig and Ig light 
chains does not differ following DNase treatment or acidic washing prior to 
immunostaining. 
 Is dual light chain cell surface expression stable? 
Outcome: Dual-light chain expressing CD19+ B cells FACS sorted from an SLE 
patient maintained expression of both light chains following a 2 day co-culture 
with allogeneic CD3+CD4+ T cells under stimulatory conditions. 
 Could VpreB surrogate light chain expression account for the apparent dual 
expression of light chains? 
Outcome: VpreB transcript could not be detected by flow cytometry analysis of 







 Can rearranged transcripts of IGK and IGL be detected in the cDNA isolated 
from single cells of a dual Ig+Ig+ SLE patient? 
Outcome: Unique and productively rearranged IGK and IGL sequences (V-C) 
were obtained following the cloning of PCR products amplified from the cDNA of 
single FACS-sorted CD19+Ig+ Ig+  B cells from an SLE patient. 
 Is dual light chain expression a feature of one specific B cell subset? 
Outcome: Flow cytometry analysis of different B cell subsets revealed that when 
dual IgandIgexpression was a feature of an individual SLE patient, it was not 
confined to a specific B cell subset.  
 Is there a correlation between dual light chain expression and KDE 
rearrangement activity in SLE? 
Outcome: A significant negative correlation was observed between the frequency 
of B cells expressing IgandIglight chains, and the frequency of KDE 
rearrangements in the gDNA of Ig–expressing SLE B cells. 
 Are serum free light chains associated with dual light chain expression by SLE 
B cells? 
Outcome: There was a positive correlation between the levels of free light chains 
in the serum of SLE patients and the proportion of B cells expressing both 











5.3   Discussion 
 
The observation that KDE rearrangements are inefficient in SLE compared to health in the 
previous chapter could suggest that a failure to silence rearranged but unwanted alleles of 
IGK may allow for their cell surface expression by some B cells. The global consequence 
of a failure to rearrange the KDE in populations of B cells could therefore result in a failure 
to obey isotypic exclusion, and could be accompanied by the observation of dual light chain 
expression by single B cells. Failure of light chain isotypic exclusion in the context of a 
failure to rearrange the KDE could include the expression of two different Ig light chains 
simultaneously by an Ig-producing B cell, or the expression of one or more Ig light 
chains and an Ig light chain by Ig-producing B cells.  
For the expression of more than one light chain to be biologically plausible, the rearranged 
alleles of IGK unsilenced by KDE rearrangement would have to be in the correct genetic 
reading frame in order to be transcribed and expressed on the cell surface. As described in 
Chapter 3, analysis of the productive forbidden rearranged IGK light chain sequences 
obtained from the high-throughput sequencing analysis from the genomic DNA of Ig-
expressing B cells revealed that over 20% of these IGK rearrangements in both healthy 
individuals and SLE patients were productively rearranged (Figure 3.3 B). If these 
forbidden productive rearrangements of IGK do not carry rearrangements of the KDE, the 
expression of these Ig light chains that were previously selected against could be 
conceivable. These data suggest that failure to KDE-inactivate rearrangements of IGK light 
chains that are unwanted may subsequently allow for their transcription, translation and 
subsequent cell surface expression by SLE B cells. 
 
Several methods were used to challenge the dual expression and apparent allelic inclusion 
initially observed during flow cytometry analysis of SLE PBMCs. Treatment of the pre-
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immunostained PBMCs with DNase I, washing the pre-immunostained PBMCs with acidic 
wash buffers, or co-culturing sorted Ig+ Ig+ cells short-term with PMA did not alter the 
profile of light chain expression exhibited by specific SLE samples after immunostaining. 
SLE PBMCs were also shown to express similar levels of cell surface VpreB expression as 
healthy controls, however a caveat of these data is that no positive control was available 
for use at the time of the immunostaining this surrogate light chain. A sample known to 
express cell surface VpreB, such as PBMCs isolated from fresh bone marrow, would be 
required if this experiment were to be repeated.  
Unique IGK and IGL (VL-CL) rearranged sequences were obtained from the cDNA of single 
dual-expressing B cells from an SLE patient, suggesting genuine expression and production 
of two light chains is a feature of this SLE CD19+ B cells. A caveat of these data lies in the 
lack of a control for testing the IGL primers; the primers used for amplification of IGK and 
IGL transcripts were tested using cDNA isolated from 10 Ig- producing B cells from a 
healthy donor (the IGL primers were used on this cDNA to test for specificity to IGK). If 
this experiment were to be repeated, 10 Ig+ cells should be sorted from the same healthy 
individual to demonstrate that the primers detecting IGL transcripts are also just specific 
for IGL amplification and not IGK. Nevertheless, detection of IGL transcripts was achieved 
from the SLE single sorted B cells following sequence analysis using IMGT. 
The hypothesis that allelic exclusion is not intact in a large proportion of the SLE patients 
used in this study is supported with reference to the quantification of KDE rearrangement 
frequencies in SLE compared to health described in Chapter 4. Populations of Ig-
expressing B cells in SLE exhibited significantly lower frequencies of KDE rearrangements 
compared to controls. As shown in Figure 5.11 of this chapter, there is significant 
correlation between SLE CD19+ B cells with the lowest levels of KDE rearrangement 
activity to appear to express both Ig and Ig light chains on the cell surface. Dual 
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expression of both light chains by SLE B cells appears to not be confined to one specific B 
cell subset, which could suggest that failure to allelically exclude light chains is a 
phenotype that is not lost during B cell maturation since it is genetically determined during 
early B cell development.  
In further agreement within a defective KDE rearrangement status in SLE, somatic 
mutations were observed with the non-productive B cell repertoire of two SLE patients at 
equivalent frequencies to those observed in the productive VJ sequences from the same 
patients; alleles which should have lost their intronic enhancers following KDE 
rearrangement. A caveat of this sequence analysis is that a more relevant controls could 
have been used. VJ rearrangements could have been amplified from gDNA isolated from 
CD19+ healthy control B cells and also from the gDNA isolated from CD19+ SLE B cells 
from a patient that did not exhibit dual expression of both light chains. However, the 
equivalent frequencies of mutations observed in the productive and non-productive IGK 
rearranged sequences from CD19+ populations of B cells from two SLE patients support 
the hypothesis that failure to rearrange the KDE is a feature of SLE.  
 
Failure to isotypically exclude light chains has been reported in healthy individuals and 
mice. An early study described the generation of a human pre-B cell line by EBV 
transformation, named 30.30, which co-expressed both Ig and Ig light chains on 49% of 
all cells during flow cytometry analysis (Pauza et al., 1993). These cells carried two 
rearrangements of IGK, unsilenced by the KDE, and single rearrangements of IGL and 
IGH. The phenotype of this dual light chain expressing population after FACS sorting was 
not stable, as after several weeks in culture cells became a heterogeneous pool of both Ig+ 
Ig+ and single Ig+ cells (Pauza et al., 1993).  
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B cell Ig light chain allelic inclusion has previously been observed, and experiments 
involving the introduction of a human IGKC region gene to be expressed alongside mouse 
IGKC  genes have demonstrated that B cells harbouring both Ig light chains were found 
to be responsive to BCR stimulation with anti-IgM in vitro and BCR aggregation in vivo 
(Velez et al., 2007). Several groups have observed a genuine population of B cells 
expressing two different light chains and a tendency to exhibit autoreactivity in both mice 
and humans (Fournier et al., 2012; Giachino et al.,1995; Pauza et al., 1993). In addition, a 
small population of Ig- and Ig- producing CD19+ B cells following FACS and EBV-
immortalisation were characterised from five dual-light chain expressing B cell clones. It 
was revealed that these cells expressed both Ig and Ig chains on the same Ig molecule, 
expressed IgM and three of the five clones carried modest numbers of somatic mutations 
in V-J, suggesting that they were isolated from an antigen-selected B cell population 
(Giachino et al., 1995).  
A recent study crossed IGKh mice that carry gene targeted human IGKC allele within a 
wild-type Ig repertoire with lupus-prone MRL-faslpr/lpr mice to allow for study of in the 
context of a self-intolerant autoimmune disease state (Fournier et al., 2012). These mice 
exhibit defective receptor editing and reduced tolerance induction (Li et al., 2002a; 
Panigrahi et al., 2008). The dual Ig-producing B cells from these mice exhibited 
autoreactivity and their frequency increased with age and disease severity. They were also 
found to be contained within the plasmablast memory B cell pool and were capable of 
secreting autoantibodies (Fournier et al., 2012). More recent work has demonstrated that 
usage of both IGK and IGL light chain gene segments by B cells has a profound effect on 
the maintenance and breakage of B cell tolerance in animal models of autoimmunity 
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The high-throughput sequencing analysis of Chapter 3 studied the profile of IGK 
rearrangements in the DNA and cDNA of mature naïve B cells isolated from the peripheral 
blood of three healthy donors and three SLE patients. The profile of IGK rearrangements 
in the genomic DNA of mature naïve B cells bears the hallmarks of IGKV segment selection 
during B cell development and this is equivalent in health and SLE. Selection both for and 
against individual segments was apparent and consistent with an earlier analysis of genomic 
DNA from single IgM-expressing B cells. It is unclear what aspect of functionality is 
selected for, but the equivalence of this process in health and SLE however demonstrates 
that the mechanisms that identify these segments have occurred at the pre-B stage and the 
subsequent cell-fate decision to either continue to mature or move to rearrange at the IGL 
locus is the same in SLE and health with respect to segment selection.  
The biases in the IGK repertoire in SLE were apparent by analysis of IGK gene expression 
at the cDNA level. This suggests that the mechanisms regulating the expression of IGK 
rearrangements are responsible for the biased light chain repertoire in SLE and not the 
segment selection process per se. This study identified that IGKV5-2 is selected against 
during development at the point where cells make the fate decision to express IGK or to 
move on and rearrange IGL.  In contrast, IGKV4-1 appears not to be selected against at this 
point, though both segments have decreased representation in the expressed repertoire in 
health.  This suggests that multiple mechanisms are involved in identifying and regulating 
the IGK gene expression, presumably including those that initiate and regulate KDE 
activity. These may act at different times during B cell development. Their activity is 
essential because most B cells in the blood contain multiple light chain gene 
rearrangements. Failure to effectively regulate can lead to aberrant expression, potentially 
also allelic inclusion and a less stringently regulated light chain repertoire. The caveat of 
these data described in Chapter 3 lies in the unequal numbers of sequences obtained from 
each B cell subset and across all individual samples, though time and funding did not permit 
223 
 
the repeat of such experiments, which could have ensured equal numbers of cells sorted 
from each individual. Nevertheless, these data have contributed to the identification of a 
potential origin of the light chain biases observed in SLE.  
Chapter 4 explored the rearrangement activity of the kappa deleting element, which in part 
plays a role in regulating IGK expression through the silencing of IGK rearranged but 
unwanted alleles. The data in this chapter demonstrated that populations of SLE CD19+ B 
cells carried reduced rearrangement frequencies of the KDE compared to healthy controls, 
which could account for the emergence of IGK rearrangements involving IGKV4-1 and 
IGKV5-2 in the expressed repertoire in SLE where they are rarely observed in the expressed 
repertoire in health, as observed in Chapter 3. Support for the observation of reduced KDE 
rearrangement activity by SLE CD19+ B cells was demonstrated by sequence analysis of 
somatic mutations within non-productively rearranged IGK alleles of CD19+ B cells from 
2 SLE patients. The equivalent frequencies of mutations observed in both the non-
productive and productive groups of sequences indicates that the IGKC gene segment and 
enhancers flanking it may not have been removed in some instances. This would permit the 
acquisition of mutations by some IGK rearrangements that theoretically should have been 
destined for KDE inactivation. 
Chapter 5 investigated the potential for populations of B cells in some SLE patients to 
exhibit altered light chain cell surface expression profiles, as observed in previous chapters. 
Approximately half of all SLE patients studied in this investigation appeared to harbour 
populations of CD19+ B cells expressing both Ig and Ig light chains on their cell surface 
following flow cytometry analysis. Experiments to challenge the validity of these 
observations did not disprove the flow cytometry data. Productive transcripts of both IGK 
and IGL were detected in an individual SLE patient that appeared to exhibit dual Ig and 
Ig cell surface expression on approximately 90% of their peripheral B cells. Perhaps most 
interestingly, the frequency of dual light chain-expressing B cell populations in SLE 
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negatively correlated with the frequency of KDE rearrangements quantified in Ig-
expressing B cell gDNA. Dual expression of both Ig and Iglight chains also appeared 
to positively correlate with levels of serum free Ig and Ig light chains, a marker typically 
associated with autoimmune disease states in humans.  These findings may suggest that 
KDE rearrangement activity alongside analysis of cell surface light chain expression would 
be a useful tool in predicting SLE disease. A key point to note is that a history of nephritis, 
both active and non-active at the time the SLE blood was taken is significantly associated 
with the expression of both Ig and Ig light chains, the latter of which negatively 
correlates with KDE rearrangement frequency in population of SLE B cells. What would 
be fundamental to next address would be identification of the signalling pathway or 
pathways that initiate rearrangement of the KDE, and potential proteins that may interact 
and bind the KDE. These questions could be investigated using a ChIP approach. If this 
could be achieved any differences in the protein machinery governing KDE rearrangement 
could be investigated. 
The work presented in this thesis proposes that defective regulation of light chain gene 
expression in SLE, which in part may be mediated by a failure to rearrange the KDE, is 
relevant to SLE pathogenesis by aberrantly permitting the ‘breakthrough’ expression of 
segments that have been counter-selected. Individual B cells that allelically include Ig light 
chains may be capable of recognising and responding to more than one foreign antigen via 
their BCRs. The presence of these cells in the peripheral setting of an SLE autoimmune T 
cell repertoire could serve to propagate and amplify autoimmunity. These findings may 
also contribute to understanding the origin of the self-reactive and hyper-responsive nature 









































CD19+IgD+CD27-            
Ig+  Ig+ 
Healthy 
donors 
H01 54,000 54,000 
H02 100,000 100,000 
H03 115,000 115,000 
SLE 
patients 
SLE 1 42,750 42,750 
SLE 2 15,000 15,000 
SLE 3 180,000 180,000 
 
Ig- and Ig-expressing sorted B cell populations were divided into two so 
approximately half of each total population was used for DNA isolation and RNA 
isolation. 
 
Sequence frequencies following high-throughput sequencing analysis 
Healthy controls (n=3)          
            
CD19+IgD+







HC 1 HC 2 HC 3 TOTAL HC 1 HC 2 HC 3 TOTAL 
Ig+ cDNA V-C Used 144 295 707 1146 NA NA NA 0 
Ig+ gDNA V-J All rearr. 173 542 451 1166 103 460 305 868 
Ig+ gDNA V-J Not used 295 308 10 613 955 961 27 1943 
          Total  5736 
            
            
SLE patients (n=3)           
            
CD19+IgD+



















Ig+ cDNA V-C Used 175 1219 499 1893 NA NA NA 0 
Ig+ gDNA V-J All rearr. 113 296 340 749 45 262 287 594 
Ig+ gDNA V-J Not used 234 70 6 310 878 254 20 1152 




Appendix 2    SLE patient clinical information 






Lu-009 F 48 AfC 7 0.26 MTX, HCQ, Pred 
Lu-011 F 42 Cauc 22 0.13 MTX, HCQ, Pred 
Lu-014 F 57 Cauc 10 0.64 MMF, Pred 
Lu-015 F 23 Cauc 8 20.02 HCQ 
Lu-016 F 49 AfC 17 18.23 HCQ 
Lu-017 F 45 Cauc 16 26.06 MMF, HCQ, Mepacrine 
Lu-018 F 65 Cauc 8 1.45 none 
Lu-022 F 73 Cauc 25 27.67 HCQ 
Lu-023 F 45 Cauc 15 2.71 HCQ 
Lu-024 F 45 Af 6 37.32 HCQ, Pred 
Lu-025 F 40 Cauc 14 87.06 HCQ, Pred 
Lu-026 F 53 Cauc 18 1.18 none 
Lu-031 F 21 AfC 3 58.15 AZA, HCQ 
Lu-039 F 40 Asian 16 50.8 AZA, HCQ, Pred 
Lu-040 F 35 Orien 13 25.97 AZA, Pred 
Lu-041 F 51 Cauc 9 2.31 MMF, HCQ, Pred 
Lu-042 F 63 Cauc 20 0.82 AZA, Pred 
Lu-043 F 46 Af 5 90.73 MMF, HCQ, Pred 
Lu-044 F 54 Af 4 4.53 HCQ, Pred 
Lu-045 F 40 Af 12 14.85 MMF, HCQ, Pred 
Lu-046 F 23 Cauc 2 1.18 MMF, HCQ, Pred 
Lu-047 F 59 Cauc 4 1.48 Leflunomide, HCQ 
Lu-048 F 32 Cauc 3 2.68 HCQ, Pred 
Lu-049 F 51 Cauc 4 0.31 none 
Lu-056 F 58 Cauc 39 29.6 none 
Lu-061 F 31 Af 5 2.7 RTX 2008 2009 2011 2012 HCQ, Thalidomide, Pred 
Lu-066 F 44 Cauc 18 3.71 MMF, HCQ, Pred 
Lu-067 F 52 AfC 16 27.3 RTX 2012  HCQ, Pred 
Lu-069 F 47 Af 20 27.5 CYC IV HCQ Pred 
Lu-070 M 62 Cauc 20 25 HCQ, Pred 
Lu-071 F 67 AfC 1 1.8 RTX 2012 HCQ, Pred 
Lu-073 F 33 Af 9 7.84 HCQ, Pred 
Lu-075 F 56 Cauc 12 7.6 RTX 2009 2012 AZA HCQ Pred 
Lu-076 F 34 Af 5 6.8 RTX 2010 2012  
Lu-077 F 51 Cauc 21 26 HCQ, Pred 
Lu-078 F 23 Oriental 1 2.2 HCQ, Pred 
Lu-079 F 54 Asian 40 17.3 HCQ, Pred 
Lu-080 F 57 Cauc 14 7.3 HCQ 
Lu-081 F 36 Cauc 14 2 RTX 2012  MMF HCQ Pred 
Lu-086 F 60 Cauc 12 1.5 RTX 2012  MTX HCQ Pred 
Lu-092 F 17 Af 10 6 RTX 2010 2012  Pred 
Lu-095 F 32 Af 5 2.4 RTX 2012  MMF HCQ Pred 
Lu-104 F 40 Cauc 20 9.62 RTX 2009 2012 AZA HCQ Pred 
Lu-108 F 26 Af 7 26.3 RTX 2012 MMF HCQ Pred 
LCLu-008 F 55 Cauc Unknown 0.26 Statins 
LCLu-118 F 62 Oriental 13 22.15 MMF, lisinopril, aspirin, SIM, calcichew 
LCLu-119 F 47 AfC 13 22.07 Pred, AZA, LOS, RAN, Plaqenil 
LCLu-120 F 38 Cauc 16 22.17 AZA, Pred, warfarin, aspirin, adalat, HCQ, rabeprazole, co-
codamol           
LCLu-121 F 41 Cauc 7 10.68 CAN, HCQ, MTX, aspirin, NTP, TRA, OMP, calcichew, 
alendronate acid, AML, co-dydrmol           
LCLu-122 F 37 Asian 12 21.84 not listed 
LCLu-124 F 25 Asian 13 40.7 
Pred, myfortic,warfarin, VAL, ranitidine, HCQ, vitamin d, 
calcium 
LCLu-125 F 24 Oriental 5 22.49 Pred, AZA, HCQ, famotidine, SIM, enalapril 
LCLu-126 F 46 AfC 21 0.78 not listed 
LCLu-127 F 41 AfC 18 1.22 not listed 
LCLu-128 F 56 AfC 3 1.71 Pred, HCQ, adcal-3-calcium, ramipril, MMF, alendronic acid 















CNS CVS/RS Haem 
Lu-009 Y Y Y N N Y Y N N 0.71 0.13 N Y Y N Y Y LN III+V N N Y 
Lu-011 N Y Y Y Y N N N Y 1.41 0.23 Y Y Y N Y Y N N Y N 
Lu-014 Y Y Y Y N N N N N 1.35 0.16 N Y Y N Y Y LN IV+V N N Y 
Lu-015 Y Y Y Y N N Y N Y 1.05 0.24 Y Y Y Y Y Y N N N Y 
Lu-016 N Y Y Y N N Y N N 1.04 0.22 N Y Y N Y Y N N N N 
Lu-017 N Y Y Y N Y N N Y 0.81 0.18 N Y Y N Y Y LN V N N Y 
Lu-018 N Y Y Y N Y Y N N 0.97 0.19 Y Y N N Y Y N N N Y 
Lu-022 Y Y Y Y N N N N N 1.09 0.15 Y Y N N Y Y N N N Y 
Lu-023 Y Y Y Y Y N N N Y 0.93 0.15 Y Y N N Y Y N N N Y 
Lu-024 Y Y N Y Y N N N N 0.77 0.12 N N N N Y Y LN III+V N N Y 
Lu-025 Y Y Y Y N N N N Y 1.22 0.14 Y Y N N N Y N N N Y 
Lu-026 Y Y Y Y Y N N N N 1.36 0.14 Y Y N N N Y N N N Y 
Lu-031 Y Y Y Y N N N N N 0.75 0.08 Y Y Y N Y Y LN IV+V N N Y 
Lu-039 Y Y N N N N N N N 0.91 0.06 N N N N Y N LN V N Y Y 
Lu-040 N Y N Y Y N N N N 0.67 0.1 Y Y N N N N LN IV  N N N 
Lu-041 Y Y N Y N Y Y N N 0.65 0.06 Y N N N N N N Y N N 
Lu-042 N Y N N N N N N N 1.49 0.35 Y Y N N Y N N N N N 
Lu-043 Y Y N Y N Y Y N N 1.65 0.19 N N N N Y N LN III N N N 
Lu-044 N Y N N N N Y N N     N N N N Y N N N Y Y 
Lu-045 N Y N N N N N N Y 1.08 0.45 N N N N N N LN II+IV N N N 
Lu-046 Y Y N Y Y N N N N 1.02 0.21 N N N N N N LN III N N N 
Lu-047 N Y N N N N N N N 1.49 0.3 N N N N Y Y N N N N 
Lu-048 N Y N N N N N N N 0.86 0.16 N N N N Y N N N N Y 
Lu-049 N Y N Y N N N N N 0.94 0.22 N Y Y N N Y N N N N 
Lu-056 N Y N N N N N N Y 1.05 0.2 N Y N N Y Y N Y N N 
Lu-061 Y Y N N N N N N N 0.88 0.14 N Y N Y Y Y N N N N 
Lu-066 Y Y Y N N N Y N N 0.76 0.14 Y Y Y N Y N LN II Y Y Y 
Lu-067 Y Y Y N N N N Y N 1.22 0.32 N N N N Y Y LN III+V N N Y 
Lu-069 Y Y Y Y N Y Y Y N 0.72 0.07 N N N Y Y Y LN IV+V N N Y 

















CNS CVS/RS Haem 
Lu-071 N Y Y N N Y Y N N 1.08 0.36 N Y N N Y Y N N Y Y 
Lu-073 N Y Y Y N Y N N N 1.5 0.45 N N N N Y Y N N N Y 
Lu-075 N N N N N N N N N 1.38 0.23 N Y N N Y Y N Y Y N 
Lu-076 Y Y Y N N Y Y Y N 0.55 0.06 N Y N Y Y Y N Y N Y 
Lu-077 Y Y N N N N N N Y 0.58 0.13 Y Y Y N Y N N N N Y 
Lu-078 Y Y Y Y N N N N N 1.09 0.2 Y Y N N Y Y N N N Y 
Lu-079 N Y N N N N N N Y 1.23 0.24 N N N N N N LN II N N N 
Lu-080 N Y N N N N N N Y 1.37 0.23 Y Y N N Y Y LN V N N Y 
Lu-081 N Y Y Y N Y Y N N 1.14 0.16 Y Y N N Y Y N Y Y Y 
Lu-086 N Y Y Y Y N N N N 1.33 0.24 Y Y N N Y Y N N N Y 
Lu-092 Y Y Y N N Y Y N N 0.48 0.05 Y Y N N Y Y LN III+V N N Y 
Lu-095 Y Y Y Y N Y Y N Y 1.01 0.44 Y Y N N Y Y LN IV+V N N N 
Lu-104 Y Y N N N N N N N 0.91 0.16 Y Y N N Y Y LN V N Y N 
Lu-108 Y Y Y N N N N N N 1.11 0.44 N N N N Y Y LN III+V N N Y 
LCLu-008 N N   N N N N           N     Y Y N N N   
LCLu-118 N Y   Y N N N           N     Y Y Y N RAY   
LCLu-119 Y Y   N N Y Y           Y     Y Y Y Y RAY   
LCLu-120 N       N               N     Y N Y Y RAY   
LCLu-121 Y Y   Y N Y Y           Y     N Y Y N N   
LCLu-122 N Y   Y N N N           N     Y Y Y Y N   
LCLu-124 N     N N N N           N     Y Y Y N RAY   
LCLu-125 Y Y   Y N Y Y           Y     Y Y Y Y RAY   
LCLu-126 N Y   N N N Y           Y     Y Y Y Y RAY   
LCLu-127 Y Y   N Y N N           N     Y Y N N RAY   
LCLu-128 Y     Y N Y Y           Y     N N Y Y RAY   
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